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Areas of hypoxia caused by poor perfusion are a common occurrence in breast 
cancer. Hypoxia-inducible factors-1 and 2 (HIF1/2) drive the cellular response to hypoxia in 
such areas, resulting in the upregulation of genes which facilitate the survival of cancer cells 
and promote growth, invasion, metastasis and angiogenesis, generally leading to more 
aggressive tumour characteristics. Previous research has demonstrated that growth factor 
signalling, such as the ligand-mediated activation of HER receptors, can promote the action 
of HIFs in normoxia, and correlation between HER2 expression and HIFα proteins has been 
demonstrated in clinical samples of breast cancer. Despite this, little research has been 
conducted on how the growth factor-driven regulation of HIFα subunits might modify the 
cellular response to hypoxia. In this thesis, the role of HER2 overexpression in HIFα 
modulation was assessed in breast cancer cell lines and publically available clinical datasets 
for breast cancer with the aim of further understanding the implications of hypoxia and HIFα 
expression in the context of HER2-positive breast cancer. 
  The upregulation of HIF1α and HIF2α by hypoxia was observed across breast cancer 
cell lines, and the role of HER2 in this process was assessed using an isogenic MCF7 cell line 
model overexpressing HER2. This demonstrated an increased hypoxic upregulation of HIF2α 
but not HIF1α when HER2 was overexpressed. The increased upregulation was shown to be 
facilitated by an increase in normoxic HIF2α, which is driven by a higher transcriptional rate 
of the EPAS1 (HIF2) gene as a direct result of HER2 overexpression. HER2 overexpression 
also resulted in the increased hypoxic upregulation of known hypoxia response genes in 2D 
and 3D culture models. This demonstrates a novel mechanism for growth-factor mediated 
HIFα regulation in the context of HER2 overexpression, with an important role for HIF2α.  
 Microarray analysis of MCF7 and MCF7-HER2 cells was used to compare the global 
transcriptional response to acute (24 hrs) and chronic (>10 weeks) hypoxia (0.5% O2) and 
demonstrated a broadly increased upregulation of hypoxic response genes in the HER2 
overexpressing cell line when compared to wild-type MCF7. This included an increase in 
previously described HIF1 and HIF2 target genes. MCF7-HER2 also illustrated an increased 
expression of hypoxia response genes in normoxia, and an analysis of the genes involved 
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showed the promotion of a number of pathological processes including proliferation, 
invasion, angiogenesis and epithelial to mesenchymal transition.  
 Large-scale, publically available expression datasets for breast cancer cell lines and 
clinical patient data were used to investigate the expression of HIF2α and hypoxia response 
genes in relation to HER2 expression. A set of pathologically important genes which were 
primed for hypoxia in MCF7-HER2 were also demonstrated to correlate with HER2 across 
breast cancer cell lines, suggesting that HER2 may more broadly promote a readiness to 
respond to hypoxia in breast cancer cells. Assessment of HIF2α in clinical samples has shown 
its increased expression in the HER2-positive subtype, and HIF2α was shown to be associated 
with worse disease-specific survival in the context of HER2-positive samples only. To 
investigate whether HIF2α is a potential target in HER2 overexpressing breast cancer, the 
effect of HIF2α inhibition through siRNA or HIF2-specific chemical inhibitors was assessed in 
cell lines with high or low HER2 expression, and this demonstrated an increased sensitivity of 
HER2 overexpressing cell lines to HIF2α inhibition. 
 This work highlighted HER2 as an important modulator of the cellular response to 
hypoxia in breast cancer, demonstrating a previously overlooked role for HIF2α in this 
process. HIF2α expression can be directly driven by HER2 and this differs mechanistically 
from that previously reported for HIF1α. Finally, further work into the potential for HIF2α as 
a target for anti-cancer therapy is suggested, as an increased sensitivity of HER2-positive cell 
lines to anti-HIF2α agents was shown, as well as a HER2-specific relationship between HIF2α 
expression and worse prognosis. More generally, this work has shown an important interplay 
between growth factor receptor expression and the cellular response to hypoxia, suggesting 
that HER2 may promote a stronger response to hypoxia in breast cancer, which may 






 Uncontrolled cellular growth and abnormal blood vessel formation in breast cancer 
often leads to areas where oxygen levels are reduced (hypoxia). The hypoxia-inducible 
factors HIF1 and HIF2 are the main cellular machinery for dealing with hypoxia; their levels 
are directly regulated by oxygen, and when oxygen levels are limiting they activate the 
production of a number of other proteins which facilitate cell survival under these conditions. 
In cancer this not only provides the cells with a coping mechanism but also encourages other 
processes associated with worse prognosis, such as metastasis, the ability for cancer cells to 
migrate through the blood vessels and for tumours to develop in new locations. In addition 
to responding to hypoxia, HIF1 levels have been shown to be increased by growth factor 
signalling; this occurs even in normal oxygen conditions through the stabilisation of its alpha-
subunit. This provides a mechanism which allows the harmful actions of HIF activity to occur 
regardless of oxygen levels, especially when growth factor signalling is high, such as in HER2-
positive breast cancers, which represent approximately 20% of breast cancers and are 
characterised by their high expression of the HER2 growth factor receptor. Despite this, we 
still have relatively little understanding of the full implications of HER2-HIF interactions. 
Further research into such interactions will provide a fuller understanding of how HIFs 
contribute to tumour pathology and help to identify circumstances where direct targeting of 
hypoxia or growth factor signalling may be more effective.  
 In this thesis I investigated the relationship between HER2 overexpression and HIF 
activity by asking how HER2 might affect the normal cellular response to hypoxia. This has 
been investigated in terms of HIF proteins and known downstream effectors of HIF biology 
in both 2D and 3D cell line models of breast cancer. In addition, a large scale gene expression 
experiment was used to investigate how thousands of genes are regulated in response to 
hypoxia in both short and long term experiments, and this was compared with and without 
HER2 overexpression, providing a comprehensive overview of the gene expression changes 
in response to hypoxia in these two contexts. In doing this, I was able to demonstrate that 
the cellular response to hypoxia was exacerbated in the HER2-positive breast cancer cell line 
and that HER2 overexpression places cells in a primed state ready for hypoxia.  
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This increased hypoxic response included an increase in the level of the HIF2 
protein. I was able to show that HIF2α is expressed at higher levels when HER2 is 
overexpressed, and this leads to a stronger upregulation of HIF2α in response to hypoxia. For 
the first time this demonstrates an important role for HIF2α as part of the growth factor-
modulated response to hypoxia. I have shown that the increase in HIF2α caused by HER2 
occurs through a different mechanism to that previously described for HIF1α, suggesting that 
both HIF factors may be regulated by growth factors in different signalling contexts.  
Experiments were then conducted to assess whether inhibiting HIF2 activity could 
reduce cell growth in breast cancer cell lines. Generally, cell lines expressing higher levels of 
the HER2 receptor had an increased sensitivity to HIF2 inhibition. Large scale datasets of 
publically available clinical data were then used to investigate the relationship between HER2 
and HIF2α expression in breast cancer patients and revealed that HIF2α expression was 
commonly higher in cases of high HER2 expression. Finally, survival rates for patients with 
HER2-positive breast cancer were shown to be reduced in cases of high HIF2α expression. 
This effect was not detectable in HER2-negative cases or when HER2-positive and negative 
cases were combined. This demonstrates that HIF2α may be an important determinant of 
patient survival, but only in the context of HER2-overexpression. 
This work has highlighted an important role for HER2-HIF2 interaction in terms of the 
cellular response to hypoxia. It has provided initial evidence that this interaction may 
promote poorer patient outcome, whilst demonstrating a potential sensitivity of HER2-
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Chapter 1: Introduction 
 
1.1 Cancer and breast cancer epidemiology 
The term ‘cancer’ represents a large, heterogeneous group of diseases characterised 
by the uncontrolled replication of cells which go on to invade healthy tissue and metastasise 
to other organs. Different cancers can vary enormously depending on the tissue and cell-type 
of origin as well as the specific genetic defects and molecular abnormalities driving the 
initiation and progression of the disease. Thus, cancer is a multifaceted disease which is 
difficult to define both concisely and accurately. However, in 2000, Hanahan and Weinberg 
first described the six ‘hallmarks of cancer’ in their seminal paper, providing a framework for 
describing and understanding the disease. These hallmarks were proposed as the 
fundamental capabilities acquired by cells in the multi-step process of human tumorigenesis 
and include the abilities to sustain proliferative signalling, resist cell death, evade growth 
suppressors, enable replicative immortality, activate invasion and metastasis, and induce 
angiogenesis. These ideas were more recently updated in 2011 to include two new 
‘hallmarks’ reflecting our latest understanding of the interplay involved in cancer emergence 
and progression: deregulating cellular energetics and avoiding immune destruction, as well 
as two ‘enabling characteristics’ of cancer: genome instability/mutation, and tumour-
promoting inflammation [1, 2]. These hallmarks are shown in Figure 1.1. 
Recent global statistics from the GLOBOCAN project estimated over 14 million new 
cases of cancer and 8.2 million cancer-related deaths worldwide in 2012 [3]. Breast cancer 
was named as the most common cancer in women, with an estimated 1,676,000 new 
patients and 521,900 deaths worldwide that year [3]. In 2014 the UK saw an estimated 
356,860 cancer cases with 163,444 cancer-related deaths, and 55,222 new breast cancer 
patients alongside 11,433 breast cancer-related deaths [4]. As such, breast cancer is the third 
most common cause of cancer deaths in the UK and the second most common in women, 
accounting for 7% of all cancer deaths. Despite this, the last decade has seen a 17% reduction 
in breast cancer mortality in the UK and likelihood of 10-year survival between 2010 and 2011 
in England and Wales was at 78% [4].  




Figure 1.1: The Hallmarks of cancer 
The hallmarks of cancer as defined by Hanahan and Weinberg in 2011. The 10 hallmarks are 
shown as sectors of the circle each contributing to cancer formation. These include 8 hallmarks: 
evading growth suppressors, avoiding immune destruction, enabling replicative immortality, 
activating invasion and metastasis, inducing angiogenesis, resisting cell death, deregulating 
cellular energetic and sustaining proliferative signalling, as well as 2 enabling characteristics: 
genome instability and mutation and tumour promoting inflammation. The methods which can 
be used to target each of these hallmarks are shown on the outside of the circle. (Figure taken 
from Hanahan and Weinberg 2011 [1]). 
17 
 
1.2 Breast cancer 
1.2.1 Anatomy of the breast 
The breast is composed of the mammary gland surrounded by adipose tissue and 
supported by a framework of connective tissue. The mammary gland is a network of ducts, 
consisting of a layer of epithelial cells surrounded by a layer of contractile myoepithelial cells 
and with approximately 15 to 20 lobes leading towards the nipple [5, 6]. It is highly 
proliferative and undergoes repeated tissue restructuring under hormonal control; during 
the menstrual cycle it goes through repetitive cycles of rapid growth and involution and 
during pregnancy high levels of prolactin, oestrogen and progesterone stimulate the 
branching and growth of ductal tissues [7]. As gestation progresses, high progesterone levels 
lead to further branching and the formation of milk producing alveoli through the 
differentiation of epithelial cells at the end of each duct [8, 9]. These structures develop to 
perform the breast’s primary function of milk production for the nourishment of the new 
born infant and, after weaning, regress through controlled apoptosis, returning to a pre-
pregnancy state [10]. A diagram describing normal breast and alveolar physiology can be 
seen in Figure 1.2. 
 
1.2.2 Histological classification of breast cancers 
Breast cancers are commonly categorised and characterised in a number of ways to 
facilitate prognosis and the development of a treatment strategy. This includes histological 
classification, which places invasive cancers and pre-invasive cancers into groups based on 
the histological origin of the disease; grading and staging, which scores cancers broadly based 
on tissue differentiation and extent of disease, and molecular subtyping, which separates 
cancers based on the expression of key molecular determinants, helping to indicate which 
targeted therapeutics may be effective.  
The histological classification of breast cancers initially divides neoplasms into 
invasive carcinomas and carcinomas in situ (or pre-invasive cancers) based on the integrity 
of the basement membrane which is traversed by invasive disease. The carcinomas in situ 
can be further divided into ductal carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS), 





Figure 1.2: Normal anatomy and physiology of the breast  
A) The anatomy of a healthy breast; the mammary gland is made up of approximately 15-25 
glandular units, each made up of a terminal ductal lobular units (TDLU) with collecting ducts all 
leading towards the nipple opening. The gland is surrounded by stromal and adipose tissue and 
supported by cooper’s ligaments. (Image adapted from radiologykey.com) B) A schematic 
representation of mammary gland differentiation during pregnancy, showing the highly 
proliferative terminal end bud (TEB) of the mammary duct in its pre-pregnancy state (i), and the 
ductal branching that occurs during pregnancy (ii). (Image adapted from Gajewska et al. 2013 
[9]). C) A schematic of how hormonal signalling contribute to side branching of mammary ducts 
during development, puberty and pregnancy. This includes the formation of alveolar structures 






Figure 1.3: Histological and molecular classifications of breast cancer  
A) Histological classification of breast lesions into invasive and non-invasive breast cancer 
subcategories. The majority of breast cancers are invasive ductal carcinomas. B) The 
stratification of invasive breast cancer based on intrinsic molecular markers. The percentage of 
cancers in each group are shown in brackets and defining gene expression characteristics are 





Whilst LCIS shows generally low histological variation, DCIS is comparably heterogeneous and 
is therefore further categorised into five well-recognised subtypes based on architectural 
features of the neoplasm (Comedo, Cribiform, Micropapillary, Papillary and Solid) [13].  
Invasive tumours can also be further stratified into the following groups: infiltrating 
ductal carcinoma (IDC), invasive lobular carcinoma (ILC), ductal/lobular, tubular, mucinous 
(colloid), medullary and papillary, with IDC accounting for 70 – 80% of these invasive breast 
tumours [14]. Rarer breast cancers include inflammatory breast cancer and Paget’s disease. 
A summary of these histological subtypes can be seen in Figure 1.3. 
 
1.2.3 Breast cancer grading and staging 
Even within histological categories, the growth rate and other characteristics of 
breast cancers can vary enormously. Therefore, universally recognised grading and staging 
procedures for invasive breast cancer have been developed to allow clinicians to consistently 
describe the progression and malignancy of the disease, and thereby reliably assign individual 
tumours to discrete categories based on general severity [15-17].   
The TNM system is used for staging a variety of cancer types. It was developed in 
1947 by the Union International Cancer Centre (UICC) and was adapted for use in breast 
cancer in 1960 [18-21]. Staging is designed to give an indication of how far a tumour has 
progressed by taking a number of features into account. Tumours are grouped into five 
stages (with pre-invasive cancers denoted as stage 0 and invasive cancers given a stage of I–
IV). This is achieved by first scoring tumours based on tumour size (T), whether tumour cells 
have accessed the lymph nodes (N) and the presence or absence of distant metastases (M). 
The stage is then designated based on a combination of these factors [22, 23]. How T, N and 
M values are determined and how this corresponds to the assigned stage is shown in tables 
1.1 and 1.2. 
Histological grading of breast cancers is used to score tumours based on expected 
malignancy. Grades are assigned 1-3, with higher grades being associated with more 
aggressive disease and therefore a worse prognosis. Grading is achieved by a combined 
scoring of three individual attributes of the tumour. Firstly, tumours are scored 1-3 for tubule 
formation. A high number of regularly formed tubules are indicative of well differentiated 
healthy tissue (scoring 1), whilst poorly differentiated tissue is associated with a loss of   
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Table 1.1 Staging of breast cancers using the TNM system 
Tumour size 
(T) 
TX Tumour size cannot be assessed 
T0 No primary tumour 
Tis Ductal carcinoma in situ (DCIS) 
T1 
Mi Less than 0.1 cm across 
A 0.1 – 0.5 cm across 
B 0.5 – 1 cm across 
C 1 – 2 cm across 
T2 2 – 5 cm across 
T3 Greater than 5 cm across 
T4 
A Tumour has spread into the chest wall 
B Tumour has spread into the skin 
C Tumour has spread into the skin and chest wall 
D Inflammatory breast cancer 
Node status 
(N) 
NX Lymph nodes cannot be assessed 
N0 No lymph node involvement 
N1 
N1 
Cancer cells in the lymph nodes in the armpit, but lymph 
nodes are not stuck in surrounding tissue 
pN1mi 
One or more lymph node contains micrometastases (less 
than 0.2 mm) 
pN1a 
Cancer has spread to 1 – 3 lymph nodes with at least one 
larger than 2 mm  
pN1b 
Cancer cells have spread into internal mammary nodes but 
are not palpable 
pN1c 
Cancer has spread to 1 -3 lymph nodes in the armpit and to 
internal mammary nodes, but are not palpable 
N2 
N2a 
Cancer cells in the lymph nodes of the armpit, with nodes 
sticking to each other and other structures 
N2b 
Cancer cells in internal mammary nodes (not the armpit), 
which are palpable or visible on a scan 
N3 
N3a Cancer cells in the lymph nodes below the collar bone 
N3b Cancer cells in the internal mammary nodes and the armpit 
N3c Cancer cells in lymph nodes above the collar bone 
Metastasis 
(M) 
M0 No sign of metastasis 
cMo(i+) 
No sign of metastasis in physical examinations, but cancer 
cells are present in blood, bone marrow or distant lymph 
nodes according to laboratory tests. 
M1 Cancer has metastasised to a distant site 
  
Table 1.1: Staging of breast cancers according to the TNM system 
Tumours are graded based on size (T), node status (N) and whether there is any sign of 
metastasis (M). The various assignments for T, N and M are shown with details of what 




Table 1.2: Staging of breast cancers 
Stage Description Associated TNM 
scores 
Classification 
Stage 0 No spread of abnormal cells into 
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Tumour larger than 5 cm in size 
and small clusters of breast 
cancer cells in the lymph nodes 
A 
Tumour is larger than 5 cm in 
size and has spread to 1-3 lymph 
nodes in the armpit or near the 
breast bone 
B 
The tumour has spread into the 
skin or breast wall and may have 
spread into up to 9 lymph nodes 





Tumour of any size which has 
spread into the skin or breast 
wall along with any of the 
following: reached 10 or more 
lymph nodes in the armpit, 
reached lymph nodes above or 
below the collar bone, reached 
lymph nodes both in the armpit 
and by the breast bone. 
T(0-4)N3M0 
Stage IV 
Tumour of any size with or 
without lymph node 
involvement, but cancer has 






Table 1.2: Staging of breast cancers 
A table showing how stages I, II or III are assigned based on characteristics of the tumour 
and TNM score [23]. 
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regular tubules (scoring 2-3). Secondly, tissue is scored 1-3 for nuclear pleomorphism, a high 
number of aberrant vesicular nuclei scoring highly. Finally, the tissue is scored 1-3 for mitotic 
index. These three scores are added to give an overall score which is indicative of the tumour 
grade:  less than 3 = non-tumour; 3-5 = grade 1; 6-7 = grade 2; 8-9 = grade 3 [15-17].    
Tumour grading and staging provide a valuable tool for taking tumour heterogeneity 
into account when considering prognosis and appropriate treatment strategies. Whilst the 
broad groupings provide relatively little information about the precise nature of the 
individual tumour, the power of this classification comes from its widespread and 
reproducible clinical implementation. This means that consistency in clinical practice can be 
obtained, a requirement if such classification is to be used as a tool for retrospective research 
to understand factors determining differences in tumour aggressiveness and the benefits of 
treatment regimens in different clinical contexts. 
 
1.3 Current treatment strategies 
The molecular and histological classification of breast cancer provides clinicians with 
information on the specific tumour, which can be used to determine prognosis and to 
develop a treatment strategy. A number of approaches are available for treating the disease 
and in most instances more than one of these are used in combination whilst clinicians 
constantly keep measure of therapeutic responses and reassess the ongoing stratagem. 
Below I will briefly describe how various therapeutic approaches are applied to breast cancer 
and indicate some of the challenges that remain in tackling the disease.   
 
1.3.1 Surgery 
In the majority of cases, surgery is still the best option for the treatment of breast 
cancer. Depending on the size, severity and location of the tumour, breast resection will be 
performed to various degrees. In the event of small, localised tumours, a lumpectomy can be 
undertaken, removing just the cancerous tissue and a small area around it [24]. Additionally, 
in some cases a partial section of the breast is removed (quadrantectomy) leaving a large 
proportion still intact. These are referred to as breast-conserving surgeries and are typically 
considered appropriate for women with stage I or II breast cancer [24-27]. In more advanced 
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cases, a mastectomy (removal of the entire breast) or radical mastectomy (removal of the 
breast, axillary lymph nodes and some underlying chest muscle) may be performed in the 
case of highly disseminated tumours to reduce the risk of recurrence, or to remove a large 
or highly disseminated tumour. In some cases, people at high risk of developing breast 
cancers in their lifetimes (such as those with identified BRCA 1/2 mutations) can receive a 
prophylactic mastectomy [28-30].  
Whilst surgery is the most effective intervention for breast cancer, in most instances 
it is used in combination with radiotherapy, chemotherapy, endocrine therapy, HER2 therapy 
or novel therapies. This allows for the application of breast-conserving surgery instead of 
radical or non-radical mastectomies when used to shrink the tumour before surgery 
(neoadjuvant setting), or can be used to reduce the risk of recurrence and increase overall 
survival when used post-surgery (adjuvant setting).  
 
1.3.2 Radiotherapy 
 Radiotherapy is widely used for the management of breast cancer typically in the 
adjuvant setting after lumpectomy or mastectomy [31, 32]. This may be used alone, with 
chemotherapy [33-35] or with endocrine therapy [36]. The most common method for the 
delivery of radiotherapy is through external beam radiation. This uses a linear accelerator to 
direct irradiation at the breast and is typically performed 5 days a week for 5–7 weeks post-
surgery, with a higher level radiation boost often given for the last week [37, 38]. Beyond 
external beam radiation, radiotherapy can also be given either internally or intraoperatively. 
Internal radiotherapy, often called brachytherapy, involves small pieces of radioactive 
material or ‘seeds’ being placed inside the breast next to the site of the removed tumour. 
Radiation sources can be inserted/removed through small tubes and are typically given either 
in 10-minute doses twice a day for 5 days, or as a single treatment left in for 3 days 
(depending on whether high-dose or low-dose radiation sources are being used). 
Intraoperative radiotherapy uses a single high dose of irradiation to treat the underlying 
breast tissue during surgery. This is usually achieved using a linear accelerator to deliver a 
short-range electron beam to the affected tissue before finishing surgery. Internal and 
intraoperative radiotherapy are beneficial in that they can target the area of the tumour 
more directly, therefore allowing higher doses of radiation with reduced risk to the 
surrounding tissue. This comes with the added benefit of reduced treatment times, meaning 
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therapy can be completed over the course of a single week, or even in a single dose during 
surgery, compared to the 5-7 weeks required for external beam radiotherapy. Despite this, 
external beam radiotherapy is currently standard procedure as the benefits in relation to 
recurrence and mortality are better established [39].  
 Radiotherapy used in the adjuvant setting after either lumpectomy or mastectomy 
of early stage breast cancer has been shown to reduce the risk of recurrence and mortality 
in a number of trials [40, 41].  The use of radiotherapy after lumpectomy or other breast-
conserving surgery has been shown to reduce the risk of recurrence to equate with that of 
radical mastectomy, meaning the use of adjuvant radiotherapy permits the use of less 
disfiguring surgical techniques with little or no added risk [41-45].  
 
1.3.3 Chemotherapy 
Chemotherapy involves the treatment of cancer by the systemic administration of 
one or more cytotoxic agents. Chemotherapy agents generally work by inhibiting the process 
of DNA synthesis or cell division, meaning highly proliferative cancer cells are particularly 
sensitive. Unfortunately, the lack of specificity for cancer cells mean these agents can also 
affect other highly proliferative cells in the body. This includes those of the blood, intestinal 
tract and hair follicles, often resulting in the side-effects commonly associated with 
chemotherapy, such as fatigue, nausea, myelosuppression and alopecia [46, 47]. The 
majority of chemotherapeutic agents target cell division in this way, but can do this through 
a number of mechanisms; anthracylines such as epirubicin and doxorubicin inhibit DNA 
synthesis by intercalating between DNA bases and impeding the progress of the DNA 
replication machinery [48, 49], alkylating agents such as cyclophosphamide, carboplatin and 
cisplatin cause irreversible DNA crosslinking (once again preventing effective DNA 
replication) [50, 51], antimetabolites such as fluorouracil block the production of metabolites 
such as thymidine which are required for DNA synthesis [52], and a number of agents, such 
as the taxanes docetaxel and paclitaxel, prevent the separation of chromosomes during 
metaphase by perturbing microtubule assembly dynamics [53].  
Chemotherapy is usually used in the adjuvant setting to reduce the risk of recurrence 
after surgery, often in combination with endocrine or radiotherapy. In early breast cancer 
this has been shown to improve overall survival by 10% [54], whilst a meta-analysis of 194 
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trials, reported in 2005, demonstrated that a multiple agent chemotherapy approach such as 
FAC or FEC (combination treatments of either fluorouracil, doxorubicin and 
cyclophosphamide (FAC) or fluorouracil, epirubicin and cyclophosphamide (FEC)) resulted in 
a significant reduction in recurrence and mortality, independent of a number of tumour 
variables [55, 56]. Additionally, chemotherapy can be used in the neoadjuvant setting in the 
case of locally advanced, primarily inoperable and inflammatory breast cancer to reduce 
tumour size before surgery [57]. 
Whilst there are clear benefits of chemotherapy and radiotherapy for breast cancer 
in the neoadjuvant and adjuvant settings, the extent to which both of these treatment 
modalities can be employed is limited by harmful side-effects elicited by their impact on 
normal, healthy tissue. The benefits of radiotherapy must be weighed against the risk of 
overexposure to irradiation and cardiac toxicity [58-63], whilst chemotherapy doses must be 
constantly reassessed and often moderated to avoid the short and long-term detrimental 
side-effects ranging from cardiac disease to cognitive dysfunction or leukaemia [46, 64, 65]. 
It is these inherent limitations which have driven research into therapies better designed to 
target just cancer cells and leave healthy tissue relatively untouched, this being the goal of 
endocrine and targeted therapies.  
 
1.3.4 Endocrine therapy 
Endocrine therapy refers to the treatment of hormone-dependent breast cancers 
through the disruption of specific hormonal signalling pathways. In breast cancer this is most 
often through the inhibition of oestrogenic signalling. The effective disruption of oestrogenic 
signalling can be achieved through direct inhibition of the oestrogen receptor with selective 
oestrogen receptor modifiers (SERMs) or selective oestrogen receptor down-regulators 
(SERDs) [66], by the inhibition of oestrogen biosynthesis using aromatase inhibitors [67, 68], 
or by inhibiting oestrogen production in the ovaries. The above can be done either 
pharmaceutically using GnRH agonists [69, 70] or surgically through oophorectomy [71, 72]. 
SERMs such as tamoxifen inhibit the cellular activity of the oestrogen receptor by binding in 
place of oestrogen, reducing its ability to drive the transcription of oestrogen-regulated 
genes, whilst SERDs such as fulvestrant similarly bind the oestrogen receptor but result in its 
degradation [73]. Tamoxifen has been the gold-standard for the treatment of endocrine-
responsive breast cancer [66, 74] and can be used in both pre and postmenopausal women. 
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An overview of randomised trials published in 2005 demonstrated that tamoxifen, used in 
the adjuvant setting for 5 years, reduced recurrence risk by 41% and mortality by 33% [55], 
and the results of longer term studies have shown that the benefits of 5-year tamoxifen in 
terms of recurrence and survival are still present up to 15 years after diagnosis [75, 76].   
 Aromatase inhibitors (AIs) work by inhibiting the final step of oestrogen biosynthesis; 
the conversion of androgen precursors into oestrone or oestradiol, which is catalysed by the 
enzyme aromatase [67, 68, 77]. The use of AIs such as letrozole, anastrazole and exemestane 
in the treatment of breast cancer is mostly limited to postmenopausal women, as their use 
in premenopausal women results in a feedback mechanism through the hypothalamus and 
pituitary gland, leading to an increased stimulation of oestrogen production in the ovaries 
[74, 78]. Their use in postmenopausal women has proven very effective; individual clinical 
trials for letrozole, anastrazole and exemestane have all shown clinical benefits when used 
as a second-line treatment in tamoxifen-resistant disease [79-82], and results from clinical 
trials of AIs as a front-line therapy for advanced or metastatic breast cancer have 
demonstrated a better response when compared to tamoxifen in terms of clinical response 
rates and time to progression [83-86].  
        In premenopausal women, the majority of circulating oestrogen is produced in 
the ovaries, and inhibiting ovarian oestrogen production has proven an effective means of 
inhibiting breast cancer growth. This can be achieved through ablation of the ovaries through 
surgery or irradiation, or through treatment with GnRH agonists [69-71, 74]. Ovarian ablation 
has been shown to reduce recurrence and mortality rates by 25% in a combination of 12 
randomised trials with women under 50 years of age [87], whilst in 2000 an overview by the 
Early Breast Cancer Trialists’ collaborative group (EBCTCG) confirmed a clinical benefit for 
ovarian ablation through GnRH agonists [40, 74]. 
 In general, targeting oestrogen signalling has proven an effective tactic in the 
treatment of oestrogen or progesterone receptor positive breast cancers, predominantly in 
the adjuvant setting [88]. The current challenges are to determine how these therapies may 
be best combined with each other and with chemotherapy to provide the optimum clinical 
response, and to understand how resistance to endocrine therapies arises and how it may 





1.3.5 HER2-directed and other targeted therapies  
 Targeted therapies, like endocrine therapy, function by inhibiting known pathways 
or molecules which may drive breast cancer progression. The use and choice of targeted 
therapy depends on the specific characteristics of the tumour. The use of inhibitors targeting 
the human epidermal growth factor receptor 2 (HER2) is an exemplar for the potential of 
targeted therapies in breast cancer. The HER2 receptor is overexpressed in around 20% of 
breast cancers [92, 93], so HER2 inhibition has become a therapeutic option for a large 
proportion of breast cancers. Many HER2-positive tumours are hormone receptor-negative, 
while HER2 may also be up-regulated in endocrine-resistant disease, hence this molecule is 
an attractive target for therapy. Current HER2 targeted therapies include monoclonal 
antibodies such as trastuzumab (Herceptin) and pertuzumab (Perjeta) as well as small 
molecular inhibitors such as lapatinib (Tykerb), and antibody-chemotherapy conjugates such 
as trastuzumab-emtansine (Kadcyla).  
 Trastuzumab is a humanised monoclonal antibody which binds to the extracellular 
domain of the HER2 receptor. This antibody predominantly works by inhibiting receptor 
dimerization and stopping the activation of the receptor which normally occurs through 
transphosphorylation of the intracellular domain [94]. However, other mechanisms are also 
believed to contribute to its cytotoxic effect; binding of the antibody reduces HER2 activation 
by driving receptor endocytosis, inhibits receptor cleavage leading to the active ligand-
independent p95 isoform and also drives cell-mediated cytotoxicity through the recruitment 
of immune effector cells [95-97]. These mechanisms all contribute to the efficacy of 
trastuzumab seen clinically. Following a number of successful clinical trials [96, 98-102] 
trastuzumab has been approved for use alongside chemotherapy in the adjuvant setting. The 
efficacy of trastuzumab in this setting was summarised by a meta-analysis in 2012 of 8 such 
studies looking into the efficacy of trastuzumab plus chemotherapy versus chemotherapy 
alone [103]. This analysis favoured trastuzumab containing regimens, with significant 
improvements in overall and disease-free survival [103]. Additionally, trastuzumab has been 
shown to be beneficial in the neoadjuvant setting for HER2-positive breast cancer, doubling 
the likelihood of patients achieving pathological complete response when used alongside 
chemotherapy [104].  
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 Ado-trastuzumab emtansine (T-DM1 or Kadcyla) consists of the trastuzumab 
monoclonal antibody conjugated to emtansine, a chemotherapy agent that inhibits 
microtubule assembly [105, 106]. T-DM1 allows the targeted delivery of chemotherapy to 
the site of HER2-positive cancers and has become a standard second-line therapy for HER2-
positive disease [96]. In the phase III EMELIA trial [107], the effectiveness of T-DM1 was 
compared to lapatinib with capecitabine in women with advanced HER2-positive breast 
cancer who were previously treated with trastuzumab and taxane chemotherapy. The results 
of this trial demonstrated that T-DM1 treatment led to an increase in overall and progression-
free survival. T-DM1 has also been shown to provide benefits in patients with progressive 
disease (TH3RESA trial) [108]. Here improvements to progression-free survival were seen in 
the T-DM1 arm, when compared to the “physician’s choice” arm, including when the 
physician’s choice included trastuzumab treatment. Despite this, comparisons of T-DM1 with 
trastuzumab as a first-line treatment in HER2-positive advanced disease have shown mixed 
results, demonstrating a reduced risk of disease progression when compared to trastuzumab 
and docetaxel in a phase II trial [109], whilst a more recent phase III trial (MARIANNE) 
demonstrated no significant difference in progression-free survival between T-DM1-treated 
patients and those on trastuzumab and taxanes as a combination therapy (also this trial 
showed no increased efficacy of T-DM1 with the addition of pertuzumab) [110, 111].    
 Pertuzumab (Perjeta) is another humanised monoclonal antibody that targets the 
HER2 receptor [112]. It differs from trastuzumab in that it targets the dimerization domain 
of the receptor (extracellular domain II, compared to trastuzumab which targets extracellular 
domain IV) and is an inhibitor of receptor heterodimerisation, allowing more effective 
inhibition of HER2/HER3 heterodimerisation in the presence of a ligand [112-114]. For this 
reason it is considered complimentary to the effects of trastuzumab [96]. The use of 
pertuzumab in certain contexts has been shown to provide clinical benefit, predominantly 
when given with trastuzumab and chemotherapy. This combination has been demonstrated 
to improve invasive disease-free survival as a first line adjuvant treatment for aggressive, 
early, HER2-positive breast cancer in the phase III APHINITY trial [115, 116]. In the 
neoadjuvant setting, pertuzumab has similarly been shown to provide added benefit in terms 
of pathological complete response rate in two separate clinical trials comparing trastuzumab 
and chemotherapy with and without the addition of pertuzumab [117, 118]. Together this 
has led to pertuzumab being FDA-approved for use with trastuzumab and docetaxel as a first-
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line adjuvant therapy in HER2-positive metastatic breast cancer and in the neoadjuvant 
setting for HER2-positive, locally-advanced, inflammatory or early stage breast cancer [119].  
 Lapatinib is a small molecular inhibitor of both HER1 (EGFR) and HER2 activity. By 
occupying the ATP-binding site in the intracellular domain of either receptor, lapatinib is able 
to prevent ATP-dependent tyrosine kinase activity of the receptors and thereby prevents 
their activation despite ligand binding and dimerization [96, 120-122]. In the adjuvant setting 
lapatinib has shown poor efficacy in clinical trials when used alone (TEACH) [123] or in 
combination with trastuzumab (ALTTO) [124]. In the neoadjuvant setting lapatinib treatment 
has been shown to be less effective than trastuzumab, but can offer some benefit when 
combined with trastuzumab and chemotherapy [125-127]. Lapatinib can also provide some 
benefit in the treatment of locally advanced or metastatic HER2-positive breast cancer, 
where it can be used in combination with trastuzumab and provides improved overall and 
progression-free survival [128]. 
 Whilst HER2 targeted therapies have made a large contribution to improved 
prognosis in individuals with HER2-positive breast cancers, they are inherently limited by 
their applicability to only 20% of tumours. As such, a number of targeted therapies have been 
developed or are under development which may be beneficial in the treatment of breast 
cancers with otherwise limited options. Those which have been made available clinically 
include, CDK4/6 inhibitors such as palbociclib (Ibrance) and ribociclib (Kisqali), as well as the 
mTOR inhibitor everolimus (Afinitor) [129].  
 Palbociclib and ribociclib are inhibitors of cyclin dependent kinases 4 and 6 (CDK4/6). 
These have been shown to be particularly effective in aggressive ER-positive breast cancers. 
Both palbociclib [130-132] and ribociclib [133, 134] have recently been approved for clinical 
use in combination with letrozole for advanced and metastatic hormone receptor-positive 
breast cancers.  
 Everolimus is an inhibitor of the mammalian target of rapamycin (mTOR) a regulator 
of cellular growth, metabolism and proliferation. As with CDK4/6 inhibition, inhibition of the 
pathways regulating cellular proliferation are particularly effective in ER-positive breast 
cancers, and as such Everolimus has been approved for use in cases of advanced hormone 
receptor-positive, HER2-negative breast cancers in conjunction with exemestane. It has been 
also been shown in the BOLERO-2 trial to improve overall survival [135].  
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 Besides these approved targeted therapies a large number of compounds are 
currently in early development as possible treatments for selected breast cancers. These 
inhibitors target a number of pathways in cancer and include but are not limited to; growth 
signalling pathways including PI3K/AKT/mTOR and MEK inhibitors, alternative growth factor 
receptors such as IGFR, MET, FGFR and EGFR/HER3, epigenetic regulators such as histone 
deacetylases (HDAC) inhibitors and DNA methyltransferases (DNMT), cancer stem cell 
signalling pathways such as notch and β-catenin, and regulators of the hypoxic tumour 
microenvironment such as HIF1 [136]. The wide range of targetable pathways common to 
cancer provides future possibilities for fighting this disease. 
Whilst this approach seems to be a good counter for the problem of breast cancer 
heterogeneity and the poor response rates of broad-range treatments, more work is still 
needed to be done in order to understand when particular targeted therapies are the best 
option. The tumours in which these inhibitors work best require identification and their 
potential impact on normal cells and associated toxicities need to be understood. Targeted 
therapies have the potential to provide improved treatment modalities for all types of breast 
cancer, but this requires further work both in the laboratory where we can gain an 
understanding of the targetable pathways that define and drive breast cancer, and clinically, 
where trials can provide a better understanding of the efficacy of targeted treatments alone 
or in combination.          
 
1.4 Gene expression profiling and the molecular subtypes of 
breast cancer 
 The advent of gene expression and microarray technologies has increased interest in 
the molecular basis of the heterogeneity seen in breast cancer. Seminal studies by Perou 
[137] and Sorlie [138] in 2000, were the first to show that gene expression patterns derived 
from microarray experiments could be used to stratify breast cancers into at least 5 
subclasses, with significant differences in clinical outcome. These were termed the ‘intrinsic 
subtypes’ of breast cancer and consisted of Luminal A (ER+ subtype with low HER2), Luminal 
B (an ER+ subtype often with increased HER2 expression), HER2-positive (generally ER- with 
high HER2 expression), Basal (generally triple negative (ER-/PR-/HER2-) with expression of 
basal cytokeratins and EGFR) and Normal-like (with a similar genetic signature to adipose 
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tissue of the breast) groups. These classifications were later extended by the addition of 
claudin-low as a subset of the basal group (characterised by low expression of claudins 3, 4 
and 7 as well as by an epithelial to mesenchymal transition (EMT) phenotype) [139, 140]. In 
2012 research published by The Cancer Genome Atlas Network [141] defined these subtypes 
more comprehensively using an integrated analysis of genetic, epigenetic, transcriptome and 
protein array data. With this approach they were able to demonstrate that breast cancers 
can be separated into the four phenotypically distinct classes: Luminal A, Luminal B, HER2-
enriched and Basal-like. This study showed that these molecular subtypes exhibit different 
frequencies of specific driver mutations and differences in dominant signalling pathways 
[141].  
The intrinsic subtypes consolidated the idea that breast cancer is best defined as, not 
one disease, but a group of diseases, and has formed the basis of the molecular taxonomy of 
breast cancer. However, the clinical application of subtype stratification has been slow, as 
assigning intrinsic subtype to samples is only possible retrospectively using large patient 
cohorts, and so is not particularly amenable to single patient stratification [142-144]. As such, 
recent years have focussed on the identification of single sample predictors, gene sets which 
can provide prognostic or predictive information about a patient through the gene 
expression profile of that patient alone [145]. These were designed to stratify patients into 
risk categories to aid treatment decisions independently of subtype (however some do 
provide indication of intrinsic subtype (PAM50)) [146]. A number of such multigene 
predictors have been established and are used frequently in the clinic; brief descriptions of 
gene signatures used clinically can be seen in Table 1.3 [147-150]. Despite the utility of such 
gene expression signatures in helping to predict response to therapy, they have only proven 
useful predictors in ER+ breast cancers, and have not been able to replace clinical 
pathological features such as tumour size, grade, node status and expression of ER/PR/HER2 
as prognostic indicators and generally must be used alongside such observations in cases of 
intermediate risk, to decide if additional chemotherapy is necessary [147]. Additionally, 
simple immunohistochemical tests such as IHC4+C , a 4 protein IHC test which takes clinical 
features into account, and measures ER, PgR, HER2 and Ki67, may be equally effective in 
predicting response to therapy whilst being much cheaper and easier to apply universally in 
the clinic [151, 152].  
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Thus, the stratification of breast cancer using multigene signatures has been shown 
to be useful in aiding treatment decisions in the clinic, but is currently limited in its uses. At 
present, these are only informative in ER-positive breast cancers, often placing the vast 
majority of ER-negative tumours in the high risk category and so providing no stratification 
in these cases [153]. Current efforts are focussed on devising better prognostic and predictive 
tests for other types of breast cancer, as well as developing tests capable of predicting 
outcome from specific chemotherapy drugs or regimens [143, 146, 154]. Finally, whilst the 
use of molecular stratification into intrinsic subtypes has itself changed little in the clinic, 
using such categorisation has provided researchers with a way to divide breast cancers into 
distinct categories allowing a more targeted approach to understanding the molecular 
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Table 1.3: Prognostic and predictive gene signatures for breast cancer 
A table showing various gene signatures which can be used as prognostic or predictive 
indicators for breast cancer, along with a description the various characteristics of each 
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1.5 Tumour microenvironment  
Atmospheric oxygen concentration (approximately 21%, 160 mmHg), frequently 
referred to as ‘normoxia’, is not representative of the oxygen concentrations to which cells 
are routinely exposed when in their natural setting. True physiological oxygen concentrations 
(‘physoxia’) are known to be highly variable and tissue specific ranging from approximately 
14.5% (110 mmHg) in the alveolar tissue of the lung, to around 4% in certain peripheral 
tissues [159]. Oxygen levels are further reduced in most solid tumours, falling below 2% in 
most cases [159]. The situation in breast tissue is no different; the median oxygen 
concentrations in healthy breast tissue has been shown to be approximately 6.8% (52 mmHg) 
[160-162], compared to a median of 1.3% (10 mmHg) in breast cancers, which exhibit oxygen 
concentrations below 0.33% (2.5 mmHg) in more than 60% of cases [160]. 
Hypoxia in tumours develops as the growing mass outstrips its blood supply. As the 
tumour outgrows its vasculature, cells distant from oxygen rich blood vessels become limited 
in their oxygen supply. This is often countered by an increase in angiogenic signalling in breast 
cancers [163], which promotes the formation of new blood vessels. However, new tumour 
vasculature tends to be poorly formed [164, 165]. Blood vessels in tumours are highly 
disorganised and contain a large number of morphological abnormalities including loss of 
vascular hierarchy, aberrant branching, and the formation of blind endings. In addition, 
vascular permeability increasingly results in ‘leaky’ vessels. In general, blood flow is poorly 
regulated through these vessels resulting in weak and unreliable blood perfusion. This means 
that low oxygen levels persist within the tumour [164, 165].  
There is a well-established link between areas of hypoxia and poor outcome in breast 
cancer [162, 164, 166-169]. A contributing factor is the negative impact that hypoxia has on 
response to both radiotherapy and chemotherapy. Tumour hypoxia reduces the 
effectiveness of radiotherapy, as molecular oxygen and the generation of reactive oxygen 
species (ROS) are required for radiotherapy-induced DNA damage [170, 171], thus 
radiotherapy leads to fewer DNA double-strand breaks in hypoxic regions [171]. The lowered 
proliferative rate of cells in hypoxia also makes them less sensitive to accumulated DNA 
damage from both radiotherapy and DNA damage-inducing chemotherapeutic agents [171]. 
Furthermore, poor tumour perfusion as a result of malformed vasculature prevents the 
action of systemic chemotherapy agents which are unable to be delivered properly to the 
tumour area as a result of ineffective blood supply and high interstitial pressure [165]. In 
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addition to resistance to therapy, poor outcome has also been attributed to an increase in 
angiogenic and migratory phenotypes in hypoxia, resulting in increased invasion and 
metastasis [162].  Hypoxia is also thought to contribute to an increase in stem cell 
characteristics resulting in a larger stem cell population [172]. Many of these characteristics 
are thought to be driven predominantly through hypoxia-inducible factor (HIF) transcription 
factors [172, 173] and the role of HIFs in hypoxic breast cancers will be discussed below.  
 
1.6 Hypoxia-inducible factors (HIFs) 
1.6.1 HIF family and structure 
The cellular response to hypoxia is predominantly mediated by a family of 
transcription factors called hypoxia-inducible factors (HIFs). Active HIF transcription factors 
are heterodimers which consist of a HIFα subunit bound to a HIFβ subunit [174]. There are 
three different HIFα proteins (HIF1α, HIF2α and HIF3α), all of which are quickly degraded in 
the presence of oxygen and only allowed to accumulate when oxygen is limited [175-179]. 
This oxygen-dependent degradation of HIFα forms the mechanistic basis for how the 
transcriptional response to hypoxia is regulated [180].  
HIF proteins show a high level of homology and are characterised by the presence of 
a number of important functional protein domains (a comparison of HIF family protein 
domain structures is shown in Figure 1.4). Starting at their N-terminal ends all HIF proteins 
contain a basic helix-loop-helix domain (bHLH) followed by two PAS domains (PAS-A and PAS-
B). These domains are required for HIF dimerization and are thus highly conserved between 
factors [176, 181]. HIFα subunits also contain an oxygen-dependent degradation domain 
(ODDD), required for the oxygen-mediated regulation of these factors, and transactivation 
domains important in regulating gene transcription. In HIF1α and HIF2α there are two 
transactivation domains, an N-terminal transactivation domain (N-TAD) nestled within the 
ODDD, and a C-terminal transactivation domain (C-TAD) near the C-terminus of the protein 
[180-182]. HIF3α is a truncated HIFα protein and thus only the N-TAD is present, with the C-






The general functions of HIF proteins are reflected in their structures, HIF1α and 
HIF2α, which share the largest degree of homology, are together considered the 
predominant mediators of the cellular response to hypoxia, and drive a largely overlapping 
transcriptional programme [184]. HIF3α, which is truncated at its C-terminal end and 
therefore differs from HIF1α and HIF2α, has been understood to be a dominant-negative 
inhibitor of the other two HIFα proteins, acting as a form of negative feedback [183, 185-
187]. This role of HIF3α has recently been challenged by the demonstration that HIF3α is also 
able to drive the transcription of a largely unique set of genes in response to hypoxia, and so 
Figure 1.4: Hypoxia-inducible factor family domain structures  
Basic structure of HIFα and HIF1β proteins showing the layout of functional domains. Important 
phosphorylation sites for oxygen dependent regulation are shown. Percentages show amino acid 
similarity between HIF1α and HIF2α for each domain. Amino acid length of each protein is shown 
on the right hand side. Each member of the family contains two Per-Arnt-Sim (PAS) domains, 
which allow the formation of alpha-beta dimers, and a basic helix-loop-helix domain which 
facilitates DNA binding. The HIFα proteins all contain an oxygen-dependent degradation domain 
(ODDD). HIF1α and HIF2α contain an N-terminal and C-terminal transactivation domain (N-
TAD/C-TAD), whilst HIF3α has a truncated C-terminus containing a Leucine zipper (LZ) domain 
but lacking a C-TAD. . 
38 
 
its contribution to the cellular response to hypoxia may be more complex than originally 
thought [185, 188]. The HIFβ subunits, otherwise known as aryl hydrocarbon nuclear 
translocator (ARNT) include two HIFα-binding  proteins: HIF1β (ARNT/ARNT1) and HIF2β 
(ARNT2) [189]. HIFβ subunits are not regulated by oxygen concentration as they lack an 
ODDD, and instead are constitutively expressed even in normoxic conditions. In healthy 
adults, HIF1β is expressed in the vast majority of cell types, whilst HIF2β expression is strictly 
limited to renal and neural tissues. In breast cancer, HIF1β is therefore the typical binding 
partner for HIFα subunits [190, 191].  
 
1.6.2 Canonical oxygen-dependent HIFα regulation 
 As mentioned above, the oxygen-dependent regulation of HIFα subunits is critical for 
their role as responders to hypoxia. Thus the molecular mechanisms involved in this 
regulation have been thoroughly investigated and are generally well understood. A 
schematic for this process is shown in Figure 1.5. In the presence of molecular oxygen, HIFα 
subunits are constantly degraded, denying them the chance to accumulate [192]. The 
degradation is mediated by the PHD (prolyl hydroxylase domain) family of prolyl 
hydroxylases, which use molecular oxygen and 2-oxoglutarate as co-substrates and 
ascorbate and iron as co-factors to attach a hydroxyl group to proline residues (P402 and 
P564 in HIF1α, P405 and P531 in HIF2α or P490 in HIF3α) in the ODDD [193-196]. 
Hydroxylation at these sites allows recognition by the VHL E3 ubiquitin ligase complex, which 
targets the HIFα proteins for proteasomal degradation by the attachment of multiple 
ubiquitin molecules [197-199]. In hypoxia oxygen is limited as a substrate and generally 
unavailable for the hydroxylation of HIFα by PHDs. The resulting failure of HIFα to be targeted 
for degradation leads to an accumulation of the protein, which at sufficient levels is able to 
dimerise with the constitutively present HIFβ subunit and relocate to the nucleus. In the 
nucleus, HIF dimers recognise a consensus sequence called a hypoxia-response element 
(HRE) and with the help of co-activator p300 are able to recruit the basal transcriptional 
machinery and drive gene transcription [200].      
 In addition to the PHD-mediated hydroxylation of proline residues in the ODDD, HIFα 
activity is also regulated by asparagine hydroxylation (N803 in HIF1α and N851 in HIF2α) in 
the C-TAD [201]. This process is catalysed by the factor-inhibiting HIF protein (FIH). 
Hydroxylation of asparagine at these residues can occur at lower oxygen concentrations than 
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PHD-mediated proline hydroxylation and so hydroxylation can still occur when oxygen levels 
are moderate. Asparagine hydroxylation in the C-TAD without proline hydroxylation does not 
result in protein degradation, but instead limits the transcriptional activity of the C-TAD, 
modifying HIF target gene transcription [181, 195]. The general role of PHD and FIH 






Figure 1.5: Canonical/oxygen-dependent regulation of HIFα proteins 
 A schematic of how HIFα proteins are regulated by oxygen concentration. Under high oxygen 
concentrations (red arrows), HIFα is hydroxylated both by FIH-1, which disrupts binding of co-
activators CBP/P300 and inhibits transcriptional activity, and by PHD enzymes which promote 
binding and ubiquitination by the VHL E3-ligase complex, leading to the proteasomal 
degradation of HIFα. When oxygen is limited (green arrows), hydroxylation by FIH and PHDs is 
inhibited and HIFα is permitted to accumulate and bind co-activators, leading to the recruitment 
of the transcription initiation complex (TIC) and the initiation of the transcription of HIF target 






Figure 1.6: FIH and PHD-mediated regulation of HIFα proteins 
A) PHD and FIH1 enzymes hydroxylate proline and asparagine residues on HIFα 
respectively. This reaction requires molecular oxygen and 2-oxoglutarate as co-
substrates. 2-oxoglutarate is converted to succinate in this process. Ascorbate and 
Fe (II) are required as cofactors for the reaction. B) Differential oxygen requirements 
for prolyl and asparagyl hydroxylation by PHDs and FIH1 respectively allows 
regulation of HIFα over a gradient of oxygen concentration. Whilst complete 
hydroxylation at low oxygen inhibits HIFα, moderate oxygen allows only FIH-




1.6.3 Non-canonical regulation of HIFα 
Whilst the canonical oxygen-dependent regulation of HIFα proteins is considered the 
main HIF regulatory system, there are a number of non-canonical mechanisms which can also 
modulate HIFα levels in the cell. These include pathways affecting the stability and 
degradation of HIF1α protein, as well as pathways which modulate the translational and 
transcriptional rate. 
Modulation of VHL-regulated HIFα protein stability 
 The rate of VHL-dependent degradation of HIFα subunits is influenced by a number 
of factors, some of which have been shown to contribute to HIFα dysregulation in cancers. 
Proteins osteosarcoma-9 (OS-9), spermidine/spermine-N-acetyltransferase 2 (SSAT2) and 
the pVHL-interacting de-ubiquitylating enzyme (VDU2) can all modify the rate of HIF1α 
ubiquitination and subsequent proteasomal degradation through various mechanisms. OS-9 
has been shown to bind directly to HIF1α and PHD enzymes 2 or 3 to increase stability of the 
complex. This increases the rate of HIF1α proline hydroxylation thereby increasing the rate 
of recognition and binding by VHL [202]. Similarly to OS-9, SSAT2 is able to increase the rate 
of HIF1α degradation by stabilising HIF1α binding to the degradation machinery. In this case 
SSAT2 mediates the interaction between HIF1α, VHL and elongin C, promoting the 
ubiquitination of HIF1α through VHL [203]. VDU2 is currently the only known protein to de-
ubiquitinate HIF1α [204]; in doing so it is able to rescue HIF1α from proteasomal degradation 
by removal of ubiquitin [205]. These studies demonstrate the complexity of regulation 
involved in the VHL-dependent degradation of HIFα subunits. Unfortunately, due to a lack of 
research into HIF2α at the time, none of these studies investigated whether these 
interactions were specific to different HIFα proteins or more generally applicable. Whilst 
these studies were effective in discerning some of the cellular mechanisms involved in HIFα 
regulation, they were performed in cell lines most amenable to HIF research, predominantly 
renal cancer cell lines, and so it is still unclear what role these mechanisms may play in breast 
cancer.  
 One VHL-modulating pathway which has been shown to be applicable to a number 
of cancers including breast cancer is the ubiquitin carrier protein (UCP). UCP has been shown 
to increase the levels of HIF1α by ubiquitinating VHL, leading to its proteasomal degradation 
[206]. UCP was therefore found to correlate inversely with pVHL in cancer cell lines, and was 
detected coincidentally with HIF1α in primary liver, colon and breast tumours [206]. Whilst 
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HIF2α was once again not included in this investigation, VHL downregulation would be 
presumed to cause an upregulation of all HIFα proteins, and so the importance of this 
regulatory mechanism in breast cancer may involve roles for both HIF1α and HIF2α.  
VHL-independent regulation of HIFα protein stability 
 In addition to VHL-mediated degradation, studies have also shown that VHL-
independent mechanisms exist to control the degradation rate of HIFα. One of these 
pathways involves the proteins 90 kDa heat shock protein (HSP90) and receptor of activated 
protein kinase C (RACK1), which are in competition with one another to bind HIF1α. RACK1 
is also able to recruit components of the E3 ligase complex to HIF1α and promote its 
ubiquitination and proteasomal degradation without the requirement for PHD hydroxylation 
or VHL [207]. The competitive binding of RACK1 and HSP90 is the basis for HSP90 inhibitors 
as a therapeutic tool to inhibit HIF1. By inhibiting HSP90, RACK1-mediated degradation is 
allowed to proceed unhindered and HIF1α levels are reduced [207]. RACK1 activity can be 
inhibited through phosphorylation mediated by the calcium-dependent protein calcineurin 
A, thus providing a mechanism by which cellular calcium signalling can modulate HIF1α levels 
[208].  
 In addition to RACK1, the proteins glycogen synthase kinase 3β (GSK3β) and forkhead 
box-O-4 (FOXO4) have been shown to drive the degradation of HIF1α through VHL and 
oxygen-independent ubiquitination [209, 210]. Both of these factors are negatively regulated 
by AKT signalling, suggesting that growth factor signalling which has been shown to mediate 
HIF activity [211, 212] may act by inhibiting non-canonical degradation pathways. This may 
occur in concert with the effects that these signalling pathways have on HIF1α translation 
(discussed below).  
Regulation of HIFα at the translational level 
 In addition to post-translational regulation of HIFα levels, it has been demonstrated 
that cells can control the level of HIFα by altering the rate of its translation. In general, cells 
appear to reduce protein synthesis in response to both acute and chronic hypoxia [213, 214]. 
Despite this, it has been noted that HIF1α translation can be increased under hypoxic 
conditions. Whilst the mechanisms controlling this are still subject to debate [204], work by 
Braunstein et al 2007 [215] demonstrated that the overexpression of 4E-BP1 and eIF4G in 
breast cancer can help mediate the increase in HIF1α and VEGF translation seen in hypoxia, 
44 
 
leading to increased expression of these proteins in breast cancer cell lines and increased 
angiogenesis in a mouse xenograft model of breast cancer. 
 In addition to increased translation in hypoxia, it has been demonstrated that HIF1α 
translation can also be induced by growth factor signalling. A large number of cytokines and 
hormones have been shown to regulate HIF1α in various ways [216]. These include insulin 
and interleukin-1β in a hepatoma cell line [212], insulin-like growth factor 1 in colon cancer 
cell lines [217], EGF in prostate cancer cell lines [218], and PTEN inactivation in glioblastoma 
cell lines [211], all of which have been shown to increase HIF1α levels through increased 
translation via MAPK or PI3K/AKT signalling pathways [219]. In breast cancer, it has been 
shown that treatment with HER3 growth factor ligand neuregulin-1β can also increase the 
translation of HIF1α in MCF7 cells in a PI3K, AKT and mTOR-dependent manner [220].    
Regulation of HIFα at the transcriptional level 
Despite the large amount of research into post-transcriptional regulation of HIFα 
proteins, surprisingly little is known about how they are transcriptionally regulated. HIF1A 
gene transcription has been shown to increase in response to hypoxia in a number of 
contexts, however this is considered to play a minor role in HIF1α regulation when compared 
to the canonical post-translational mechanisms described above [221]. In normoxia a number 
of factors have also been shown to drive HIF1A gene transcription; mechanical stress, 
reactive oxygen species (ROS), and vascular agonists such as angiotensin-II, thrombin and 
VEGF are all able to induce HIF1α in endothelial or smooth muscle cells [222-224]. In the 
context of cancer certain cytokines have been shown to regulate HIF1A expression, this 
includes IL-8 in melanoma and hepatocyte growth factor (HGF) in both liver and certain 
breast cancer cell lines [225]. Additionally, the ability of NF-κB signalling to drive HIF1A gene 
expression has been well established [225-227].    
 Research into the non-canonical regulation of HIFα has focussed almost exclusively 
on HIF1α, and it is still unclear in most instances whether the same or equivalent mechanisms 
regulate HIF2α levels. Additionally, whilst our knowledge of HIF1α regulation has vastly 
improved, our understanding of how these factors interact to modulate HIF1α in breast 
cancer is still not clear. One recurring theme, seen at the transcriptional, translational and 
post-translational levels of regulation, is the involvement of cytokine and growth factor 
signalling, predominantly through PI3K/AKT or MAPK signalling pathways, which indicates 
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that perturbations to these pathways which are often seen in cancer, can have an effect on 
the non-canonical regulation of HIFα subunits.  
 
1.6.4 Differential roles of HIF1 and HIF2 
 Due to lack of research, our understanding of HIF2α regulation is limited in 
comparison to HIF1α. However, now that the differences between HIF proteins are being 
increasingly recognised, more research is being published on how these factors differ in 
terms of their roles and their regulation.  
Differences between HIF1α and HIF2α have been noted in a number of functional 
knock-out studies which assessed the effects of reducing the expression of individual HIFs on 
development and tumorigenesis. Such studies were able to demonstrate specific roles in 
embryogenesis [228], haematopoiesis [229], vascular remodelling [230], stem cell 
maintenance [231], and roles in tumour growth [232-235] for different HIFα proteins. To 
understand these functional differences, especially in terms of tumorigenesis, a number of 
studies have assessed the differences in cellular roles of HIF1 and HIF2 transcription factors 
and have successfully demonstrated that HIF1 and HIF2 drive the transcription of unique 
targets with differing roles in cancer pathogenesis. HIF1 has been shown to uniquely regulate 
cellular metabolism in response to hypoxia through the upregulation of a number of 
glycolysis genes (e.g. PGK1, LDHA and PKM). Whilst HIF2 does not drive the upregulation of 
these genes, it has been shown to uniquely upregulate genes such as CCND1, TGFA, EPO and 
OCT4 [231, 235-238]. In breast cancer, the targets of HIF1 and HIF2 transcriptional activity 
have been investigated in studies by Mole et al. 2009 [239] and Schödel et al 2011 [240], who 
were able to use genome-wide chromatin immunoprecipitation of HIF1α and HIF2α in MCF7 
cells to identify HIFα binding sites. This research was able to demonstrate a non-redundant 
role for these factors in this cell line, showing an increased role for HIF1 in driving genes 
involved in glycolysis and carbohydrate metabolism and a specific role for HIF2 in driving 
Oct4-regulated pluripotency genes in concordance with previous findings in other cell types 
[239, 240]. Despite differences in target selection by HIF1 and HIF2, high-resolution genome-
wide mapping of HIF binding sites by Schödel et al. [240] was also able to demonstrate that 
both HIF1 and HIF2 bind to the core HRE RCGTG motif, with no discernible consensus 
sequences specific to either factor. This suggests that differential target selection by these 
factors is not mediated by differences in direct DNA binding sites. Instead target specificity is 
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thought to be controlled, at least in part, by differences in the N-TAD (but not the C-TAD) 
[241, 242] and differential co-factor association with HIF1α and HIF2α [242, 243]. 
In addition to differences in target gene transcription, HIF1α and HIF2α have been 
shown to have different, even opposing, interactions with important mediators of cancer 
pathogenesis such as Myc, P53 and mTOR signalling. Myc controls cellular proliferation by 
regulating G1/S phase transition and is commonly overexpressed or otherwise upregulated 
in various cancers. HIF1α is able to facilitate cell cycle arrest by inhibiting MYC transcriptional 
activity under hypoxic conditions [244]. This inhibitory role is seen in both acute hypoxia, 
where HIF1α can rapidly disrupt the association of MYC with its transcription factor binding 
partner MAX [245], and in chronic hypoxia, where HIF1α drives the expression of MAX 
interactor 1 (MXI1) to displace MAX from MYC and also directly promotes the degradation of 
MYC itself [246, 247]. In contrast HIF2α has been shown to increase MYC promoter 
occupancy and transcriptional activity, promoting cell cycle progression in hypoxic cells. This 
is believed to be mediated by direct interactions between HIF2α and MAX which stabilises 
MYC-MAX binding [248, 249]. 
 P53 is a tumour suppressor gene commonly mutated in cancers and an important 
driver of genes involved in DNA repair and the maintenance of genome integrity under 
cellular stress [250, 251]. HIF1α and HIF2α have also been demonstrated to have opposite 
effects on its stabilisation and activity in response to hypoxia. HIF1α has been shown to 
stabilise p53 in response to hypoxic stress by binding to the p53-targeting ubiquitin ligase 
MDM2. This inhibits p53 ubiquitination and thereby protects it from the proteasome 
degradation pathway [252, 253]. In contrast HIF2α has been shown to both reduce p53 
stability and transactivation and to increase the expression of MDM2 through HIF2 target 
genes TGFα and PDGF (demonstrated in RCC cells [254, 255]).  
Finally, mTOR signalling, which regulates protein synthesis in response to nutrient 
and growth factor availability, can be differentially regulated by different HIFα proteins. 
HIF1α has been shown to drive the expression of DDIT4 and BNIP3, which inhibit mTORC1 
activity through different mechanisms [256, 257], but HIF2α promotes mTORC1 activity 
through the HIF2 target gene RB1CC1, which inhibits the TSC1-TSC2 mTORC inhibitory 
complex [258]. Whilst research into these roles of HIFs in regulating such pathways has 
focussed on their roles in RCC, the general applicability of defects in Myc, p53 and mTOR 
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signalling to numerous if not all cancer types suggests that these interactions are important 
when considering the roles of HIF1α and HIF2α in the context of breast cancer. 
1.6.5 Differential regulation of HIF1α and HIF2α 
  The emerging differences in the roles of HIF1α and HIF2α, especially in cancer, has 
led to an increase in research aiming to understanding how these two proteins may be 
differentially regulated. Whilst our understanding is far from complete, a number of 
regulatory mechanisms have been identified which can equip cells with the tools to 
individually regulate different HIFα proteins activity. 
Temporal control of HIF1α and HIF2α by HAF 
 Whilst the canonical, oxygen-dependent regulation of HIF1α and HIF2α has generally 
been shown to work through the same pathway [259, 260], it has been observed that HIF2α 
is stabilised in more moderate oxygen concentrations (2-5%) when compared to HIF1α (0-
2%), and in a number of different cell types HIF2α upregulation is maintained over a longer 
time period than HIF1α [249, 261]. These differences are believed to reflect the varying roles 
which these two factors play, with HIF1α mediating an immediate hypoxic response and 
HIF2α helping cells to survive in long term hypoxia. Differences in the oxygen tensions 
required for the activation of HIF1α and HIF2α are thought, at least in certain contexts, to be 
mediated by a slight preference of FIH towards HIF1α asparagine hydroxylation [262]; the 
less stringent hydroxylation of HIF2α allows it to become transcriptionally active at higher 
oxygen tensions. These differences are also mediated by regulators of degradation; HIF-
associated factor (HAF) is a protein with E3-ubiquitin ligase activity which has been shown to 
mediate ubiquitination and subsequent proteasomal degradation of HIF1α independent of 
HIF1α prolyl hydroxylation [263]. The ubiquitin ligase activity of HAF has been shown to be 
specific to HIF1α, as it is unable to ubiquitinate HIF2α. However, HAF has been shown to bind 
to the carboxy-terminal end of HIF2α and promote its transcriptional activity [264]. HAF 
expression has been shown to decrease in acute hypoxia but increase with prolonged 
exposure, suggesting that HAF may act to switch cells from a HIF1α-governed acute hypoxic 
response into a HIF2α-governed response to chronic hypoxia [265]. Similarly, the Int6 gene 
is an E3 ubiquitin ligase found to have specific activity for HIF2α, driving VHL and oxygen-
independent degradation in a similar way to HAF. Int6 was originally discovered as an 
insertion site for the mouse mammary tumour virus, suggesting that Int6 loss-of-function 
may drive breast cancer tumorigenesis, potentially through HIF2α stabilisation [266-269]. 
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The precise role of Int6 in HIFα regulation is unknown and more research is required. 
However, it seems likely that the HIF2α specific activity will allow Int6 to act in opposition to 
HAF, and it may function to inhibit early upregulation of HIF2α in response to acute hypoxia.  
Differential regulation by PHD enzymes 
As mentioned above, the PHD enzymes are the oxygen-dependent hydroxylases 
responsible for canonical HIFα regulation. The PHD family of prolyl hydroxylases includes 3 
members: PHD1, PHD2 and PHD3 (also known as EGLN2, EGLN1 and EGLN3 respectively). It 
has been shown that PHD family members can differ in their activity towards HIF1α or HIF2α, 
providing an important level of regulation that can be applied individually to different HIFα 
proteins. 
 It has been previously described that PHD2 plays the central role in the normoxic 
regulation of HIF1α [270], and by using siRNA specific to PHD1, 2 or 3 to assess the 
subsequent upregulation of HIF1α and HIF2α in MCF7 cells, Appelhoff et al. [196] 
demonstrated that HIF1α is most strongly induced by the reduction of PHD2 compared to 
PHD1 or PHD3, confirming this result. In addition, they were able to show that PHD2 
inhibition had a smaller effect on HIF2α, whereas PHD1 or PHD3 knockdown was more 
effective in the upregulation of HIF2α over HIF1α. Under hypoxic conditions (48 hrs, 1.5% 
O2), they demonstrated a lone capability of PHD3 knockdown to further upregulate HIFα 
subunits. This effect was predominantly on HIF2α, suggesting a specific role for PHD3 in 
keeping HIF2α regulated even under hypoxia.  
As well as being important regulators of HIFα level, it is now known that PHD proteins 
can themselves be induced by hypoxia, allowing a form of negative feedback. In general PHD1 
is considered non-hypoxia inducible [196, 271], whereas PHD2 and PHD3 are both 
upregulated. Interestingly, the level by which PHD2 and PHD3 are induced by hypoxia 
appears cell line dependent, and even between breast cancer cell lines there appears to be 
a distinction between lines which strongly upregulate PHD2 and those which more highly 
upregulate PHD3 in response to hypoxia [196]. Aprelikova et al. [271] examined the HIF-
mediated regulation of these 2 PHD enzymes in hypoxia and demonstrated differential roles 
for HIF1 and HIF2. Upregulation of PHD3 was inhibited by the knockdown of either HIF1α or 
HIF2α by siRNA. On the other hand, PHD2 upregulation was affected only by HIF1α 
knockdown, not HIF2α, and was only reduced at longer hypoxic time points. This suggested 
the hypoxia-induced increase in PHD2 noted at the earlier time point may be both HIF1α and 
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HIF2α independent but that HIF1α may play a role in the longer term induction of PHD2. It 
has also been shown that the overexpression of stable forms of HIF1α and HIF2α (mutated 
at proline 564 and 531 respectively) in HEP3B cells was enough to upregulate PHD3 
transcription, with HIF2α having a more prominent effect than HIF1α. In addition to this, it 
was shown in the 786-0 renal cell line, which does not express HIF1α, that PHD3 was 
downregulated by the expression of active VHL (but not an inactive form) and could also be 
upregulated in hypoxia, suggesting that in this cell line at least, PHD3 upregulation by both 
mechanisms is mediated by HIF2α. Whilst not performed in breast cancer cell lines, these 
experiments demonstrate that the regulation of HIFα subunits and PHD proteins is 
bidirectional and the hypoxic regulation of PHDs probably works to ensure a quick turnover 
of HIFα subunits upon reoxygenation. Interestingly an affiliation seems to exist between 
specific HIF and PHD proteins in both directions, and such specific regulation probably works 
to balance the relative activities of HIF1 and HIF2 in response to hypoxia in different cellular 
contexts.    
Investigation into different PHD proteins in vivo has shown that expression can have 
implications for prognosis. PHDs 1, 2 and 3 have all been shown to be overexpressed in breast 
cancer [272-274]. However, the specific functional and pathological roles of individual PHDs 
is still not particularly well understood, and whilst PHD2 expression and nuclear localisation 
have both been associated with tumour aggressiveness and poor clinical parameters [275, 
276], little has been reported on the pathological consequences of PHD1 or 3 expression 
[272]. 
Research suggests that the relative expression of PHDs can vary in breast cancer and 
is highly dependent on cellular context. Analysis of Affymetrix microarray data alongside 
immunohistochemical analysis of 129 breast cancer samples shows an interesting 
relationship between ER and HER2 levels with PHD expression. PHD1 is more highly 
expressed in ER-positive samples (agreeing with previous findings that PHD1 is oestrogen-
inducible [277]), PHD2 is more highly expressed in ER-negative/ HER2-negative samples and 
PHD3 is higher in the ER-negative, HER2-positive samples [278, 279]. This shows that intrinsic 
subtypes may correlate to specific PHD expression but it still remains to be seen whether this 
has direct implications for the activity of HIF1 and HIF2 in breast cancer subtypes. 
PHD enzymes and HIF activity act to regulate one another and form a feedback loop 
which ensures a suitable response to hypoxia. However, non-redundancy between PHD 
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proteins and their preferential regulation of HIF1α or HIF2α means that the expression of 
these enzymes may determine not only the basal level of either HIF1α or HIF2α in normoxia 
but also their specific regulation under hypoxia. Such differential expression has been shown 
to exist in breast cancer, and correlation with important drivers such as ER and HER2 suggests 
that molecular subtype may play an important role in this. 
Differential regulation of translation 
 Another important difference between the regulatory mechanisms of HIFα proteins 
comes in the form of differential translational control. It has been shown that HIF2α mRNA, 
but not HIF1α, contains an iron response element (IRE) in the 5’ untranslated region of the 
transcript, and that IRE binding protein 1 (IREBP1) is able to bind the IRE and inhibit the 
translation of HIF2α mRNA. IREBP1 is unable to bind HIF1α mRNA and thus confers a specific 
mechanism of regulation onto HIF2α. IREBP binds IREs in mRNA transcripts when iron levels 
are low, and it is suggested that this mechanism may underpin the specific role of HIF2α in 
the regulation of erythropoiesis and cellular iron metabolism [249, 280-282]. The role of 
IREBP1 in HIF2α-specific inhibition is the basis for the action of HIF2α targeting compound 
C76 discussed below (in Section 1.7.3) [283].  
   
1.6.6 Expression of HIF1α and HIF2α and their roles in breast cancer 
HIF1α 
 With the role of hypoxia in driving breast cancer being well-recognised (Section 1.5), 
a number of studies have aimed to assess the levels of HIFα expression in breast cancer, as 
well as its association with survival, metastasis and the expression of other known drivers of 
the disease. As with the majority of HIF research in breast cancer, this has been focussed on 
HIF1α. The levels of HIF1α expression seen in breast cancer vary from study to study, as a 
result of differences in methodology and sample selection. In a large retrospective analysis 
of 745 patients performed by Dales et al. in 2005 [284] HIF1α expression was observed in all 
samples, but was found to be highly variable between tumours, with a larger degree of spatial 
heterogeneity within tumour samples; a median value HIF1α expression was seen in 16.32% 
of cells [284]. In line with the role of hypoxia, HIF1α expression has been shown to correlate 
with poor survival in a number of studies. This includes association with overall survival [284-
286], recurrence/disease-free survival [285-290] and distant-metastasis-free survival [287, 
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290]. HIF1α has also been associated with tumour size, grade [289, 291], treatment 
resistance [288] and the expression of Ki67 [285, 289, 291], cyclin D1 [289] and known 
hypoxic cancer drivers including VEGF [285, 291], GLUT1 [292] and CAIX [290, 292]. 
Interestingly, HIF1α has also been shown to correlate with HER2 expression in a number of 
breast cancer studies [285, 289, 291, 293]. The relationship of HIFs and HER2 will be discussed 
in more detail in Section 1.9.  
 Mechanistically, HIF1α has been shown to play multiple roles in breast cancer 
pathogenesis, acting to drive angiogenesis [294], metastasis [295], stem cell characteristics 
[296] and resistance to both endocrine and chemotherapy [297, 298].  
Hypoxia is understood to be a key regulator of angiogenesis. This is thought to be 
mediated predominantly through HIF1α-driven VEGF expression [294] and as such HIF1α 
expression has been correlated with both VEGF expression and increased microvessel density 
in breast cancer [299].  
In terms of metastasis, a number of mechanisms have been discovered which allow 
HIF1α to drive this process in breast cancer. This would clearly have an impact on breast 
cancer pathogenesis as over 90% of breast cancer deaths are attributable to metastasis [295]. 
Epithelial-to-mesenchymal transition (EMT) can be regarded as an initial step of metastasis 
[300, 301]. During EMT, cells lose cell-cell contacts by reducing their expression of E-cadherin 
and claudins, resulting in changes to cell morphology and increased motility as well as a 
propensity to detach from the tumour mass [295]. HIF1 activity has been shown to drive EMT 
through the upregulation of EMT transcription factors SNAIL, ZEB1, TWIST and TCF3 [302, 
303]. With regards to breast cancer it has been shown that exposure to hypoxia can cause an 
EMT phenotype in MDA-MB-468 cells through ZEB1 expression [304], but this was not 
directly attributed to HIF1 activity. The process of metastasis also involves cells acquiring the 
capability to invade locally, move into blood vessels (intravasation), exit blood vessels at a 
new site (extravasation) and settle successfully in the metastatic location. Interestingly, HIF1 
driven gene expression has been shown to promote each of these processes in breast cancer. 
HIF1 has been shown to drive extra cellular matrix (ECM) remodelling through the expression 
of matrix metallo-proteinases MMP-2 and MMP-9 [302, 305] and collagen biosynthesis 
enzymes P4HA1 and P4HA2. MMPs degrade components of the ECM, facilitating local cancer 
invasion, and have been correlated with increased rates of metastasis in breast cancer [306-
308], whilst pro-collagen prolyl hydroxylases P4HA1 and P4HA2 are required for collagen 
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deposition and metastasis in breast cancer [309]. Extravasation in breast cancer has also 
been shown to be enhanced by HIF1 [310], and is mediated through the increased expression 
of angiopoietin-like 4 (ANGPLT4), a secreted factor known to increase vascular permeability, 
and its expression has been associated with increased lung metastasis in breast cancer [311]. 
Finally, HIF1 supports metastasis in breast cancer by driving the expression of lysyl oxidases 
LOX, LOXL2 and LOXL4. LOX enzymes have been shown to remodel the ECM, not only at the 
primary tumour site, but additionally at distant sites. These secreted factors contribute to 
the formation of a breast cancer premetastatic niche and have been associated with hypoxic 
regions and metastasis in breast cancer [312-315].     
In addition to the direct role of hypoxia in resistance to cancer therapies discussed 
above, HIF1 has been shown to mediate resistance to treatment in breast cancer. Using a 
mouse mammary tumour model, Moeller et al. [316] were able to demonstrate that HIF1 is 
upregulated by reactive oxygen species during tumour reoxygenation after radiotherapy. In 
this context, HIF1 drives the expression of VEGF which contributes to cell radioresistance. 
HIF1 has also been shown to mediate hypoxia-induced resistance to chemotherapeutic 
agents in MDA-MB-231 triple-negative breast cancer cells by protecting cells against drug-
induced senescence [317]. In addition, Samanta et al. [297] were able to show that treatment 
of triple-negative breast cancer cells with paclitaxel or gemcitabine lead to an increase in HIF 
expression and activity, promoting stem cell characteristics which contribute to therapy 
resistance.  
Finally, HIF1 activity promotes breast cancer pathogenesis by promoting a stem cell 
phenotype. Breast cancer stem cells possess the capacity for continuous self-renewal and 
ability to form secondary tumours [296]. Hypoxia has been shown to induce a breast cancer 
stem cell (BCSC) phenotype in breast cancer cells, mediated by HIF1, and which drives the 
expression and activity of TAZ, a transcriptional co-activator which promotes the BCSC 
phenotype. HIF1 drives TAZ both directly through increased transcriptional activity and 
indirectly through the expression of SIAH1, which promotes the degradation of TAZ 
inactivating kinase LATS2 [318].   
HIF2α 
 In contrast to HIF1α, the roles of HIF2α in breast cancer pathogenesis have not been 
extensively studied. Whilst subject to far fewer studies, HIF2α, like HIF1α, has been shown to 
correlate with pathological variables in IHC analysis of patient breast cancer samples. An early 
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study which compared HIF1α and HIF2α expression in a series of cancer types, including 
breast cancer, was able to demonstrate important differences between the two proteins 
[319]. HIF1α and HIF2α were both found to be highly expressed in breast cancer, with higher 
staining seen at peri-necrotic regions where oxygen levels are likely to be low. However, 
HIF1α and HIF2α were not expressed in matching regions, with HIF2α less restricted to peri-
necrotic zones. In addition, this study demonstrated the increased expression of HIF2α but 
not HIF1α in tumour associated macrophages (TAMs), which was later shown to be 
associated with tumour vascularisation and grade [319, 320]. This led to subsequent studies 
which focussed on the role of HIF2α expression in breast cancer survival. In 2006, a study by 
Giatromanolaki et al. [321] found strong expression of HIF2α protein in 35.9% of samples 
(n=62) and demonstrated that HIF2α expression was associated with increased vascular 
density and nodal status, suggesting that HIF2α expression is a driver of angiogenesis and 
metastasis in breast cancer. This pathological role for HIF2α was supported by a study by 
Helczynska et al. in 2008 [261], which used a tissue microarray containing 512 patient 
samples to correlate HIF1α, HIF2α and VEGF expression to clinical parameters. They 
demonstrated that whilst overlap between HIF1α and HIF2α was not significant, both were 
individually associated with increased VEGF expression. Despite this, only HIF2α 
demonstrated an association with survival, being an independent prognostic factor for 
recurrence-free and breast cancer-specific survival.  
 Mechanistically, less is understood about how HIF2α drives breast cancer 
pathogenesis. However, a number of genes known to be drivers of breast cancer progression 
have been shown to be HIF2α targets in other cell types. Like HIF1, HIF2 is also known to 
drive VEGF expression, which, in line with the clinical studies discussed above, provides a 
mechanism by which angiogenesis can be driven by either factor [322]. HIF2 has also been 
shown to increase the expression of key drivers of metastasis including TWIST1, LOX and 
CXCR4 [312, 322-324], and work by Aprelikova in 2006 [243] was able to demonstrate a HIF2α 
specific role in amplifying the expression of a number of important genes in MCF7 cells. This 
includes IGFBP3, EFNA1, LOXL2 and HEY1, which have been shown to increase 
premenopausal cancer risk, tumour growth, invasion, and EMT in breast cancer respectively 
[325-328]. The HIF2α driven expression of these genes was shown to depend on ETS-1 as a 
co-activator, implicating a role for ETS family transcription factors in HIF target selection in 
breast cancer [243, 329]. Finally, HIF2α is understood to have an important role in promoting 
stem cell characteristics, such as the increased expression of pluripotency regulator Oct4 
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[231, 330]. Hypoxia has been shown to promote a dedifferentiated state and stem cell 
characteristics, and roles for both HIF1 and HIF2 in this process have been demonstrated in 
breast cancer [331, 332]. In a 3D cell line model of glioblastoma a switch from HIF1 to HIF2 
signalling mediated by HAF has been associated with the enrichment of the stem cell 
population, suggesting that this phenotype may be favoured by HIF2 [264].  
 
1.7 Targeting hypoxia-inducible factors for cancer therapy 
Given the role of both HIFs and the hypoxic microenvironment in driving both breast 
cancer pathogenesis and resistance to therapy, targeting these mechanisms offers a 
promising approach for cancer therapy. Generally, this has been approached in two ways; 
targeting cells in hypoxia using hypoxia-activated prodrugs, and targeting hypoxia-inducible 
factor activity [333].  
 
1.7.1 Hypoxia-activated prodrugs   
Hypoxia-activated prodrugs are inactive (or relatively low toxicity) compounds which 
are converted to cytotoxic agents only in hypoxic tissues [334]. This can be achieved, for 
example, as prodrugs are constantly reduced by cellular reductases to produce a molecular 
intermediate, which in the presence of molecular oxygen is oxidized back into its prodrug 
form. When oxygen is limited, the intermediate is not oxidized and instead is converted into 
its active cytotoxic form, producing a build-up of this compound selectively in hypoxic tissues 
[333-335]. A number of hypoxia-activated prodrugs have been assessed in clinical trials for a 
several cancer types [333]. Whilst trials with some compounds have produced disappointing 
results [336, 337], these have resulted in the development of second generation molecules 
with improved activity [338], or in the case of apaziquone treatment (EO9) in bladder cancer, 
adjustment of treatment delivery to promote improved activity [333]. Another hypoxia-
activated prodrug, evofosfamide (TH-302), has shown more success in clinical trials, 
demonstrating efficacy when used in combination with gemcitabine in pancreatic cancer or 
with doxorubicin in soft tissue sarcoma in phase II clinical trials [339, 340]. In both cases 
phase III trials have been completed and are awaiting the publication of results 
(NCT01440088 and NCT01746979). TH-302 has been tested in preclinical models of breast 
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cancer, where it was shown in vivo to reduce mammary tumour growth in combination with 
paclitaxel [341]. 
 
1.7.2 HIF inhibitory compounds  
 Whilst targeting hypoxia with prodrugs is an attractive strategy, many research 
studies have assessed the potential of inhibiting HIF signalling directly. As discussed above, 
HIF is a key regulator of hypoxic cell survival and cancer pathogenesis, and so direct inhibition 
of HIF activity offers a means to target cancer cell survival in the hypoxic microenvironment 
and also reduce invasion and angiogenesis driven by HIFs in hypoxia. Early experiments into 
the effects of HIF1 inhibition using dominant negative constructs were able to demonstrate 
that reduction in HIF1 activity could reduce tumour growth in pancreatic, colon and breast 
cancer xenograft models [342-344]. This led to screens for HIF1 targeting compounds and 
the further development of a large number of molecules shown to perturb HIF1 activity [344, 
345], and resulted in clinical and preclinical investigations into a diverse set of HIF1 inhibiting 
compounds, most of which have an indirect effect on HIF1, and some of whose mechanism 
of action is still unknown.  
HSP90 inhibitors 
 As discussed in Section1.6.3, inhibition of HSP90 can lead to degradation of HIF1α 
through RACK1-mediated ubiquitination [207]. As such, compounds which inhibit HSP90 can 
also be used to target HIF1α for cancer therapy. The first generation HSP90 inhibitors were 
developed from the natural compounds Geldamycin (GD) (isolated from Streptomyces 
hygroscopicus), or Radicicol (RD) (isolated from Monocillium nordinii and Monosporium 
bonorden) [346]. GD and its derivatives 17-AAG and 17-DMAG have demonstrated promising 
anticancer activity in phase I, II and III trials [346]. Most notably for breast cancer, 17-AAG 
was shown to have good tolerability and antitumour activity in combination with 
trastuzumab in HER2-positive breast cancer refractory to trastuzumab alone [347].  Despite 
this, these compounds have not been developed further [346]. RD derivatives KF55823 and 
KF25706 were also well-tolerated and demonstrated anti-tumour efficacy in xenograft 
models of human breast and colon cancer [348], but have not yet reached clinical trials. The 
development of second generation HSP90 inhibitors now aims to develop similar compounds 
without the solubility and toxicity issues associated with compounds of this class [346]. One 
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particularly promising second generation HSP90 inhibitor for the inhibition of HIF1α is EC154. 
Initial in vitro experiments demonstrated the ability of EC154 to inhibit HIF1 and HIF2 activity 
at concentrations 10-fold lower than 17-AAG [349]. Whilst the further development of such 
inhibitors seems a promising option for cancer therapy, the mechanisms of action are still 
not entirely clear. As a chaperone protein, HSP90 has a number of client proteins, many of 
which will be affected by this class of inhibitor. Thus understanding in more detail the cellular 
effects of HSP90 inhibition may help elucidate which patients could benefit from their use. 
Histone deacetylase (HDAC) inhibitors 
A number of histone deacetylase inhibitors exist and have already been FDA 
approved for the treatment of various cancers where they have been shown to generally lead 
to inhibition of tumour growth and apoptosis [350]. In breast cancer a number of HDAC 
inhibitors such as SAHA (vorinostat, Zolinza), trichostatin A and etinostat have been shown 
to be effective in preclinical models of breast cancer, and are able to reduce proliferation, 
induce apoptosis and inhibit EMT in breast cancer models [350]. Whilst in a phase II study in 
metastatic breast cancer, SAHA showed only modest effects [351], etinostat has shown 
significantly improved recurrence-free survival in metastatic ER-positive breast cancer 
resistant to aromatase inhibition when used in combination with exemestane [352]. HDAC 
inhibitors have been shown to inhibit HIF1α translation and promote degradation [353], but 
it is still unclear whether their HIF inhibitory actions are responsible for their efficacy in breast 
cancer.  
Topoisomerase I inhibitors 
 FDA-approved topoisomerase I inhibitors irinotecan and topotecan have been shown 
to possess HIF inhibitory activity. Topotecan is an inhibitor of HIF1α translation [354-356], 
and has been shown clinically to reduce HIF1α expression as well as VEGF and GLUT-1 levels 
in a small pilot study of matched tumour samples [357]. PEG-SN38, a solubilised metabolite 
of irinotecan, has been shown to effectively reduce the expression of both HIF1α and HIF2α 
in a neuroblastoma model [358] and demonstrated low toxicity in a phase I trial in 
neuroblastoma [359]. Whilst limited work on the efficacy of topoisomerase I inhibitors has 
been conducted in breast cancer, their efficacy in other tumour models and their ability to 
inhibit HIF1α and HIF2α suggests that they could be a useful tool in targeting HIF-driven 




 Cardiac glycosides are a family of drugs including the well characterised compounds 
digoxin and digitoxin, commonly used for the treatment of cardiac congestion and 
arrhythmias [360]. A role for cardiac glycosides has been demonstrated in breast cancer 
where digitalis has been shown to improve patient survival and reduce malignant 
characteristics in studies undertaken as far back as the 1970s [361-363]. In 2008 Zhang et al. 
[364] were able to demonstrate that a number of cardiac glycosides, including digoxin, 
ouabain and proscillaridin were able to inhibit HIF1 gene transcription in Hep3B cells. In 
addition, they demonstrated that ouabain and proscillaridin were able to reduce both HIF1α 
and HIF2α protein levels, while digoxin inhibited tumour growth in vivo, an effect which was 
inhibited by the enforced expression of HIF1α. Whilst the mechanisms by which cardiac 
glycosides inhibit HIF proteins is still unknown, their effect on HIFs offers a novel mechanism 
for their anticancer activity. A phase II trial to investigate the effects of digoxin treatment on 
HIF1α expression in breast cancer prior to surgery is currently underway (NCT01763931) 
[333].       
2ME2 and analogues 
 Potentially one of the more promising sets of HIF inhibitors are 2-methoxyestradiol 
(2ME2, Panzem) and its analogues. 2ME2 is an oestrogen metabolite which both targets 
microtubules, promoting mitotic arrest, and inhibits the translation of HIF1α [333, 365]. This 
inhibition of HIF1α resulted in the downregulation of VEGF in prostate and breast cancer cells 
and a reduction in tumour growth and angiogenesis in an orthotopic breast cancer model 
[365]. 2ME2 has also been shown to reduce HIF2α levels in hepatocellular carcinoma, while 
overcoming resistance to the TKI inhibitor sorafenib [366]. ENMD-1198 is a more recently 
developed 2ME2 analogue which has been selected as the most promising 2ME2 analogue 
in development [367]. ENMD-1198 was found to be well-tolerated in a phase I dose-
escalation study [368], whilst the tolerability and effectiveness of 2ME2 has been 
demonstrated in phase I and II studies [333]. 
Chemotin 
Chemotin is a naturally occurring fungal metabolite found to inhibit HIF by preventing 
transcriptional activity of the HIF C-TAD through the inhibition of HIF-p300 interactions [369]. 
This was shown to inhibit p300 binding to both HIF1 and HIF2, reducing both VEGF expression 
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and proliferation in colorectal carcinoma cell lines [370]. Whilst the high toxicity of chemotin 
precludes its clinical utility [333], similar natural compounds gliotoxin and chartocin have 
been shown to have antiproliferative effects in prostate cancer xenograft models, and appear 
to work through the downregulation of a number of HIF1 genes [371]. 
YC-1 and its analogues 
YC-1 also appears to be a promising compound for HIF targeted cancer therapy 
despite its mechanism of action being unclear. YC-1 is an activator of soluble guanylate 
cyclase, but has been shown to inhibit HIF activity via a mechanism independent of this 
action. The effects of YC-1 on HIF seem to be mediated at multiple levels as YC-1 is able to 
decrease EPO and VEGF through reduced levels of HIF1α protein and by reducing DNA 
binding [372], whilst also inhibiting HIF1 activity by preventing interactions with p300 [373]. 
Although these investigations have focussed on HIF1, the downregulation of EPO suggests 
that HIF2 may also be affected [374]. YC-1 has been shown to inhibit cell motility in preclinical 
models of various cancers [375] and has HIF1 inhibitory effects as well as anti-angiogenic and 
anti-tumour effects in xenograft models of liver, stomach, kidney, cervical and brain cancers 
[376]. YC-1 has not been tested in any clinical trials, but second generation analogues for the 
inhibition of HIF1 activity have been synthesised and are currently under preclinical 
evaluation [377].  
More specific inhibition of HIF1α 
Whilst the majority of the inhibitors discussed so far have indirect mechanisms, some 
attempts have been made to design HIF1-specific targeted therapies. A number of 
approaches have been taken to achieve this. Polyamides are small molecules which can be 
designed to bind pre-determined DNA sequences of up to 16 base pairs with high affinity. 
This allows polyamides to be targeted to specific transcription factor binding sites and to 
inhibit activity at that site [378].  Polyamides designed to target the HRE have been shown to 
be able to block VEGF expression in HeLa cells [379] as well as in prostate and glioma cell 
lines in a second study [380]. Issues have been raised concerning polyamide uptake in 
xenograft models [381], but if this can be overcome then these programmable molecules 
may represent an interesting novel approach to HIF targeted therapy. 
 Another approach to HIF1 specific inhibition is the use of synthetic antisense 
oligonucleotides (ASO), which can bind HIF1 mRNA leading to its degradation [382]. Two such 
59 
 
ASOs have proven effective in preclinical cancer models, RX-0047 and EZN-2968. RX-0047 has 
been shown to be cytotoxic in a number of cancer cell lines including breast cancer [383], 
and was able to inhibit tumour formation and metastasis in prostate and lung xenograft 
models respectively. EZN-2968 is a 16-mer nucleotide 100% complementary to the HIF1α 
coding sequence [333], which is able to inhibit HIF1α mRNA in a dose-dependent manner 
with much weaker effects on HIF2α [384]. EZN-2968 has been evaluated in multiple phase I 
clinical trials where it has been shown to reduce HIF1α mRNA and protein [385], and is also 
enrolled in a phase I trial as a proof-of-mechanism trial in hepatocellular carcinoma [386]. 
 A novel method of specific targeted therapies is the use of nanobodies; these provide 
a smaller alternative to monoclonal antibodies and have been shown to be highly robust in 
terms of stability and binding [382, 387]. Initial in vitro studies of a nanobody able to bind the 
ODD of HIF1α have shown it can prevent the activation of known HIF1 target genes [388], 
and more recently developed nanobody AHPC is able to recognise the HIF1α PAS-B domain 
and prevent dimerization, reducing tumour proliferation and metastasis in pancreatic cancer 
models [382]. However, nanobodies are still in their infancy and the transfection-mediated 
expression of nanobodies required for them to target intracellular proteins is currently a 
limiting factor in their clinical development [382].  
 
1.7.3 Specific inhibition of HIF2 
Specific HIF2 inhibition 
Whilst a large number of inhibitors are available to target HIF1α, and a number of 
these have demonstrated activity on HIF2α also, relatively little research has been done on 
the development of HIF2α specific inhibitors. However, recent work has led to several 
molecules with specific activity towards HIF2α, and whilst most research has been performed 
in the context of renal cell carcinoma (RCC), where VHL mutations often lead to an 
upregulation of HIF2α, these provide useful tools for the inhibition of specific HIFα proteins 
in other cancer types. 
HIF2α translation inhibitor (Compound 76, C76)  
In 2007 Sanchez et al. [280], having discovered an iron response element (IRE) in the 
5’ UTR of HIF2α mRNA, demonstrated that this element confers post-transcriptional 
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regulation of mRNA through a novel iron-dependent mechanism. This mechanism involves 
the binding of iron regulatory proteins IRP1 and IRP2 to the IRE in HIF2α mRNA when iron 
levels are low. This binding was shown to reduce translation of the mRNA and therefore 
reduce the accumulation of HIF2α independently of hypoxia. HIF1α mRNA lacks an IRE, and 
thus this is a HIF2α specific level of regulation probably linked to the role of HIF2α in 
erythropoiesis. By limiting HIF2α accumulation, the production of red blood cells in response 
to low oxygen is prevented when the iron required for this process is likely to be unavailable. 
In 2009 Zimmer et al. [283] performed a screen for compounds able to specifically inhibit 
HIF2α translation through modulation of IRP binding. They were able to identify a number of 
compounds which inhibited HIF2α translation in renal 786-O cells by promoting the binding 
of IRP1 to the IRE in the HIF2α 5’ UTR.  The lead compound from this study was compound 
76 (C76). Whilst C76 has not been involved in clinical studies for HIF2α inhibition in cancer, it 
offers a unique mechanism of specific HIF2α inhibition and as such will be one of the 
compounds investigated in this thesis. The structure of C76 is shown below.  
 
 
Inhibitors of HIF2α dimerization (Compound 2, PT2385 and PT2399) 
Most success to date with inhibitors of HIF2 activity have come from small molecules 
designed to bind a small cavity in the PAS-B domain of HIF2α. PAS domains are found in a 
large variety of proteins and often mediate protein-protein interactions which can be 
modulated by the binding of small molecule cofactors [389]. The PAS-B domain of HIF2α, 
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which facilitates heterodimerisation with HIFβ subunits, contains a binding cavity in the 
absence of any known cofactors. The design of small molecules to bind this cavity resulted in 
the development of a number of compounds which could inhibit the dimerization of HIF2 
through allosteric changes to the PAS-B domain [389, 390]. A study by Scheuermann et al. in 
2013 [391] was able to functionally characterise a number of these molecules and 
demonstrated that lead compound, compound 2 (C2), inhibited VEGF expression without 
changes to HIF2α mRNA or protein levels in 786-O cells, a cell line where HIF activity is fully 
attributable to HIF2 [392]. The specificity of C2 was confirmed in Hep3B cells where it was 
demonstrated that it can reduce the hypoxic upregulation of mRNA for the HIF2 target gene 
EPO with no discernible effect on HIF1 target gene PGK1, indicating the specific inhibition of 
HIF2 activity. Additionally chromatin immunoprecipitation experiments demonstrated that 
C2 prevented the hypoxia induced DNA binding of HIF2α, with no effect on HIF1α [391]. C2 
is one of the HIF2 inhibitors that will be used in this thesis, the structure of C2 is shown below.  
 
 
The modest cellular potency and poor physical properties of these inhibitors led to 
the design of second generation HIF2 dimerisation inhibitors [393]. PT2385 and PT2399 are 
novel HIF2 dimerisation inhibitors which function through selective binding to the HIF2α PAS-
B domain. These compounds have been developed by Peloton therapeutics mainly for 
research into HIF2 inhibition as a therapeutic strategy for RCC. PT2385 has been shown to 
reduce HIF2α-HIF1β binding at nanomolar concentrations in 786-O cells, and was able to 
reduce HIF2-driven expression of VEGFA, CCND1, PAI1 and GLUT1 genes with no effect on 
HIF1 target genes PGK1 and PDK1 in renal cell line models [393]. In addition P2385 treatment 
reduced the expression of HIF2 target genes in xenograft models, whilst also reducing tumour 
size, ki67 expression and circulating human VEGF levels, and increasing active caspase-3. 
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Interestingly, in xenograft models PT2385 was able to reduce HIF2α mRNA and protein, 
suggesting another level of HIF2α regulation which may occur as a result of its failure to bind 
HIF1β [393]. Preliminary results from a phase I dose escalation study for PT2385 
(NCT02293980) in patients with RCC found no dose limiting toxicities among forty-three 
patients. At the time when this data was presented they had shown one patient with 
complete response, three with a partial response and sixteen patients with stable disease 
[394]. PT2385 is currently part of a phase II trial to assess its effect on response and 
progression-free survival in VHL mutated RCC (NCT03108066) [395]. Whilst no data is 
available for the efficacy of PT2385 in other cancer types it is used in this thesis as a highly 
promising HIF2 specific inhibitor. The structure of PT2385 is shown below.  
 
PT2399 is a close analogue of PT2385 currently in preclinical development. Chen et 
al. 2016 [396] were able to demonstrate that PT2399 had high efficacy in patient-derived 
xenografts of VHL mutated RCC, suppressing tumorigenesis in 56% of cases. PT2399 was 
found to be more effective and better tolerated than the angiogenesis inhibitor sunitinib in 
these experiments. They also determined a HIF2-dependent gene signature which was 
altered in sensitive but not resistant tumours suggesting a requirement for changes to HIF2-
mediated gene transcription for drug efficacy [396].  
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These promising clinical and preclinical results for HIF2 dimerization inhibitors in RCC 
suggest that these are clinically viable compounds for treating HIF2-driven cancers. These 
compounds may provide a good starting point for the assessment of HIF2 inhibition as a 
therapeutic strategy in other cancer types such as breast cancer. 
 
1.7.4 Targeting HIFs through growth factor signalling 
Given that HIFα proteins have been shown to be regulated in normoxia by growth 
factor signalling, perturbations of growth factor signalling may also be used as an indirect 
method for targeting HIF-driven cancer pathogenesis. These effects are predominantly seen 
through inhibition of the PI3K/AKT/mTOR pathway [333]. Several studies have shown that 
inhibition of mTOR by rapamycin and its derivatives can inhibit HIF1α and HIF2α levels under 
both normoxia and hypoxia [397-401]. Furthermore, the inhibition of PI3K by well 
characterised inhibitors LY294002 and wortmannin, as well as by a novel class of HIF1 
targeting agents called glyceollins, have been shown to inhibit translation of HIF1α [402, 
403]. Resveratrol, a natural compound derived from grapes, has been shown to have 
anticancer activity in preclinical models of a number of cancer types including breast. 
Resveratrol has been shown to act through various mechanisms, including through PI3K 
inhibition, resulting in lowered HIF1α levels [404], and  it has been shown to reduce xenograft 
tumour growth and angiogenesis and VEGF expression in breast cancer cell line models [405], 
in line with a HIF-dependent mechanism. Studies such as these raise the possibility that 
targeting growth factor signalling pathways such as the PI3K pathway, perhaps in 
combination with HIF inhibitors may be a more effective way of reducing HIF-driven cancer 
progression.  
 
1.8 The HER family of growth factor receptors 
The HER receptor family (otherwise known as epidermal growth receptor 
(EGFR/ErbB) family) is a group of four transmembrane growth factor receptor tyrosine 
kinases which transduce signals from soluble growth factors outside the cell to downstream 
signalling pathways inside the cell. The four receptors EGFR (HER1/ErbB1), HER2 (ErbB2), 
HER3 (ErbB3), and HER4 (ErbB4) have similar structures all consisting of four extracellular 
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domains (I-IV) with two ligand binding domains (I and III) and two cysteine rich domains (II 
and IV) (of which domain II is important for receptor dimerization). These are connected by 
a single pass transmembrane region to the intracellular kinase domain and a C-terminal tail 
containing a number of phosphorylation sites [406-409]. Upon ligand binding to domains I 
and III conformational changes in domain III release its dimerization arm [408, 410-412]. This 
allows receptor monomers to form dimers with other HER receptor members, either as 
homodimers with equivalent members or as heterodimers with other members of the family 
[407]. HER receptor dimers then undergo conformational changes which allow the kinase 
domain to phosphorylate multiple tyrosine residues on the c-terminal tails of themselves 
(autophosphorylation) and their partnered receptor (transphosphorylation). Phosphorylated 
tyrosine residues then act as docking sites for a variety of intracellular proteins which recruit 
signalling molecules to the receptor. This initiates a signalling cascade, the nature of which 
depends on which tyrosine residues are activated on which receptors [406, 413, 414]. 
The HER receptors have a large number of growth factor ligands which are able to 
bind and initiate receptor signalling. Different HER ligands show preference for different HER 
receptors conferring specificity (Figure 1.7). EGFR has the largest number of known ligands 
(EGF, TGFα, ARG, BTC, HBEGF and ERG), whilst HER3 and HER4 generally show preference for 
the neuregulin family of ligands (NRG1, NRG2, NRG3 and NRG4) (an overview of ErbB 
receptor structures and ligands can be seen in Figure 1.7) [407, 414]. Interestingly, HER2 has 
no known binding ligands meaning activation of the HER2 receptor under normal 
physiological conditions requires the ligand activation of another family member and the 
formation of a heterodimeric receptor with HER2. In contrast, HER3 has an inactive kinase 
domain meaning in the presence of a HER3 ligand this receptor is also required to dimerise 
with other HER family members to initiate intracellular signalling. In this way the nature of 
signalling events downstream of HER signalling depends on the ligand, the dimeric receptor 
pair which form and the extent of specific tyrosine residue phosphorylation [415].  
The two predominant intracellular signalling pathways activated downstream of HER 
receptor signalling are the Raf/MEK/ERK and PI3K/Akt/mTOR pathways, and over activation 
of these pathways is a common occurrence in many forms of cancer (Figure 1.8). The 
Raf/MEK/ERK pathway is typically activated through the Grb2 adapter protein which binds 
to phosphorylated tyrosine residues on activate HER receptors and recruits the SOS guanine 
exchange factor. The recruitment of SOS to the cell membrane allows GDP-bound Ras to 
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exchange GDP for GTP, thereby returning to its active state. Ras in turn activates Raf-1, which 
is considered the first protein in the kinase cascade which leads to the activation of ERK1 and 
ERK2. Phosphorylated ERK1/2 is able to translocate to the nucleus and activate transcription 
factors such as Elk-1 and Ets-1 [416]. 
PI3K is a kinase consisting of two subunits the catalytic p110 subunit and the 
regulatory p85 subunit. PI3K signalling is initiated when p85 binds to phosphorylated tyrosine 
residues on activated HER receptors. This binding dissociates p85 from p110, allowing p110 
to catalyse the conversion of PIP2 to PIP3 at the plasma membrane. PIP3 binds Akt allowing 
its phosphorylation by phosphoinositide dependent kinase 1 and 2 (PDK1/PDK2). The 
phosphorylation of Akt leads to a number of downstream processes including the 
inactivation of proapoptotic factors Bad and procaspase-9 (promoting cell survival), the 
stimulation of cell growth and proliferation by inhibiting β-catenin antagonist GSK3, and the 
increase in protein synthesis through regulation of mTOR [417].  
In cancer cells, the stimulation of the PI3K/AKT or Raf/MEK/ERK pathways is a 
common contributor to cancer pathogenesis. This can occur through overexpression or 
activating mutations at the receptor level or at the level of intracellular signalling. In breast 
cancer perturbations of the PI3K pathway are most commonly caused by activating 
mutations in the PIK3CA gene (around 25%), but PIK3CA amplification, loss of PTEN function 
(an enzyme responsible for the reverse catalysis of PIP3 to PIP2), Akt1 mutations and HER2 
amplification all promote  oncogenic signalling through this pathway [418, 419]. Dysfunction 
of the Raf/MEK/ERK pathway is also seen in breast cancer, however Ras and Raf mutations 
are relatively rare (MAP3K1 mutations have been shown to exist in 14% and 5% of luminal A 
and luminal B breast cancers). Deregulation of gene expression associated with the 
Raf/MEK/ERK pathway is more common in triple-negative breast cancers, a subtype often 
characterised by high EGFR activity. Alteration of this pathway is able to promote cancer by 
allowing growth signal autonomy, insensitivity to antiproliferative signals, inhibiting 












Figure 1.7: HER receptor activation by HER ligands 
 
A schematic representation of HER ligand binding to HER family receptors. Known 
ligand-receptor interactions are shown by black arrows. Grey arrows represent 
interactions which induce only moderate signalling. EGFR has the largest number of 
known ligands, whilst ErbB2 has none. The neuregulins (NRG) show preference for ErbB3 
and ErbB4. Ligand binding (domains I and III) induces receptor dimerization leading to 
phosphorylation of receptor carboxy-terminal tails (C) via the intracellular kinase 
domain (K). HER3 lacks an active kinase domain and so relies on kinase activity from 
other receptors to initiate downstream signalling.  Epidermal growth factor (EGF), 
transforming growth factor-α (TGFα), amphiregulin (ARG), betacellulin (BTC), heparin-





Figure 1.8: PI3K/AKT and Raf/MEK/ERK pathways downstream of RTK signalling 
 
A schematic showing the predominant intracellular signalling pathways 
downstream of HER signalling. Ligand binding to HER receptors results in receptor 
dimerization (top). The resulting phosphorylation of c-terminal receptor tails leads 
to the docking of various proteins such as Shc and Grb2 which mediated the initiation 
of major cellular signalling pathways. The activation of PI3K/AKT and Raf/MEK/ERK 
pathways in this way lead to a number of cellular responses which contribute to 
cancer pathology (bottom). Figure adapted from Saxena and Dwivedi 2012 [503]. 
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1.9 HER-HIF interplay in breast cancer  
As discussed above, a number of studies have been conducted to assess the 
relationship between HIF1α expression and clinical features in breast cancer. Interestingly, a 
number of these studies were able to demonstrate an association between HIF1α and HER2. 
A study by Bos et al. in 2003 [285] involving 150 samples from node negative early stage 
breast cancer found that HIF1α expression was significantly associated with HER2 both in 
terms of protein expression measured by IHC and in terms of HER2 amplifications determined 
through FISH. These findings were supported by similar studies showing a significant 
association between these two factors by Kronblad et al. in 2006 [289] using a cohort of 337 
premenopausal stage II breast cancers and by Yamamoto et al. in 2008 in an assessment of 
171 invasive breast cancer samples. An association between HER2 and CAIX expression has 
also been demonstrated [420], suggesting that HER2 is associated with HIF activity. 
Furthermore, in an investigation into the association between HIF1α and HER2 expression 
and their connection to patient outcome, Giatromanolaki et al. (2004) [293] were able to 
demonstrate an interesting relationship; when divided into low and high expression groups 
for HER2 or HIF1 a cohort of 146 patients with infiltrating carcinoma of the breast (not 
otherwise specified) demonstrated significantly worse overall survival when either factor was 
highly expressed in relation to their low expressing counterparts. However, when patients 
were stratified by both factors, significantly worse overall survival was found for patients 
with high expression of both factors only. Patients with high expression of HER2 or HIF1α 
only were shown to have comparable overall survival to those with low expression of both 
factors. This suggests that HIF1α expression is required for the aggressive characteristic 
which lead to worse prognosis in HER2-positive breast cancers.  Together, these clinical 
studies demonstrate a clear, pathologically relevant association between HER2-positivity and 
the expression of HIF1α in breast cancer. Interestingly, similar associations between HER2 
and HIF2α [321] and between HIF1α and EGFR [285] have also been shown, suggesting an 
important relationship between growth factor receptors and HIF signalling pathway in this 
disease. 
 In 2001 a study by Laughner et al. [220] demonstrated that HER2 overexpression in 
mouse 3T3 cells was able to increase the level of HIF1α protein in normoxia leading to the 
increased expression of VEGF mRNA, and treatment of MCF7 breast cancer cells with the 
HER3 ligand neuregulin-1β (NRG-1β) was able to elicit a comparable effect. The upregulation 
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of HIF1α in this study was shown to require PI3K, Akt and mTOR signalling, and be a result of 
a growth factor driven increase in HIF1α translation. Further work by Li et al. in 2005 [421] 
supported this mechanism, and was able to demonstrate a HER2-driven increase in HRE 
transcription in 3T3 cells as well as MDA-MB-453, a breast cancer cell line naturally 
overexpressing the HER2 receptor. In MDA-MB-453 cells, normoxic HIF1α expression was 
reduced by the transfection of cells with a dominant-negative form of Akt, demonstrating 
that HIF1α levels were constitutively driven by Akt signalling, and could be inhibited [421].  
 Since these initial mechanistic studies describing the normoxic expression of HIF1α a 
handful of studies have investigated this relationship in preclinical models, providing 
evidence for the pathological role of HER-HIF interplay in breast cancer. In 2006, a study by 
Peng et al. [422] was able to demonstrate that the treatment of breast cancer cell lines with 
EGF, the natural ligand for EGFR, was able to increase HIF1α expression in normoxia, and that 
in this context HIF1α contributed to EGF-mediated resistance to docetaxel through the 
expression of the anti-apoptotic gene survivin (BIRC5). In 2013, Whelan et al. [423] 
demonstrated that knocking out HIF1α expression in HER2-overexpressing cell lines resulted 
in increased apoptosis in 3D culture models and that tumours grown in a HIF1 knock-out 
MMTV-Neu mice model had significantly reduced tumour volume, compared to HIF1α wild-
type mice. Finally, a study by Kazi et al. in 2014 [424] was able to demonstrate an increase in 
the normoxic expression of HIF1α associated with AI resistance in long-term letrozole treated 
(LTLT) breast cancer cells. This increase in HIF1α was shown to be driven by the increased 
expression and activity of the HER2 receptor and lead to an increase in the expression of 
multidrug resistance gene BCRP1. To further corroborate this role for HIF1α in AI resistance 
the authors were also able to demonstrate that the stabilisation of HIF1α using CoCl2 was 
able to increase the resistance of AI-sensitive cells to letrozole, and this effect was ablated 
by co-treatment with HIF1α siRNA. 
 Whilst little research has investigated whether the normoxic upregulation of HIF2α 
by growth factor signalling can occur in breast cancer, a number of studies have highlighted 
a role for hypoxia and HIF2α activity in promoting the expression and activity of growth factor 
receptors, predominantly EGFR. It has been shown in a number of cell lines, including MCF7 
and MDA-MB-231 breast cancer lines, that hypoxia can increase EGFR expression [425-427].  
This was shown by Franovic et al. in 2007 [425] to be a result of a HIF2α-driven increase in 
EGFR translation, and in a later study they were able to show that HIF2α drives EGFR and 
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IGFR expression and activity, and that transfection with a dominant-negative variant of HIF2α 
resulted in reduced growth in a diverse panel of cell lines [428]. Furthermore, an investigation 
into tamoxifen and fulvestrant resistance in ER-positive cell lines implicated a bidirectional 
relationship between HIF2α and EGFR. Alam et al. 2016 [426] demonstrated, using MCF7 and 
antioestrogen resistant MCF7 lines, that HIF2α (but not HIF1α) was increased in response to 
the antioestrogens tamoxifen and fulvestrant, and was constitutively higher in antioestrogen 
resistant cell lines. Inhibition of HIF2α was also able to restore sensitivity to tamoxifen and 
fulvestrant. Since EGFR activation is believed to contribute to antioestrogen resistance in 
breast cancer [429], the relationship of HIF2α and EGFR was investigated and expression in 
these cell lines was found to be interdependent. Knockdown of either factor with siRNA 
resulted in a reduction of the other in antioestrogen resistant cell lines [426].      
Together these studies have demonstrated important roles for HER-HIF interplay in 
breast cancer, suggesting that in the context of growth factor activation both HIF1α and 
HIF2α contribute to pathogenesis even in normoxia. The potential for HIF signalling to drive 
breast cancer progression in hypoxia has been well-documented (Section 1.6.6), but still little 
is known about how growth factor receptor expression may contribute to this role in hypoxia. 
Further work is required to understand the different roles of HIF1α and HIF2α under 
conditions of high growth factor signalling such as in HER2-positive breast cancers, how they 
alter cell behaviour in normoxia and hypoxia, and whether HIFs represent a targetable 
pathway in growth factor-driven tumours. 
 
1.10 Aims and objectives 
Given the negative consequences of hypoxia and HIF signalling shown to be 
associated with worse prognosis in cancer, the emerging differences between HIF1α and 
HIF2α signalling and regulation, and the novel understanding that HIF1α can be modulated 
in normoxia by growth factor signalling through HER family receptors, this thesis 
hypothesises that growth factor signalling will have important consequences for the 
normoxic regulation of HIF2α as well as HIF1α, that the overexpression of the HER2 receptor 
in HER2-positive breast cancer cells will affect HIF signalling as a result of this growth factor–
mediated regulation, and that modulation of HIFs through HER2 signalling will also alter the 
cellular response to hypoxia in terms of HIF upregulation and HIF-driven gene transcription. 
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This signalling relationship between HIFs and HER2 may have important consequences for 
breast cancer progression and aggressiveness in both normoxic and hypoxic tumour regions. 
The work presented in this thesis aims to further our understanding into the nature of HER-
HIF interactions in breast cancer and their role in HER2-positive breast cancer, with a 
particular focus on the less well understood HIF2α. This was achieved by means of the 
following objectives: 
 To investigate the effect of HER2 overexpression on the hypoxic regulation of HIF1α 
and HIF2α, and downstream targets in 2D and 3D breast cancer cell line models 
 To characterise the role of HER2 overexpression on the transcriptional response to 
hypoxia by assessing gene expression changes in acute and chronic hypoxia in low-
HER2 and HER2-overexpressing breast cancer cell lines 
 To further investigate the potential for growth factor signalling to drive the 
upregulation of HIF1α or HIF2α in breast cancer cell lines by monitoring HIF1α and 
HIF2α changes induced by ligand stimulation or HER2 overexpression and 
investigate the pathways involved 
 To evaluate the efficacy of HIF2 inhibition in low-HER2 and HER2-positive breast 
cancer cell lines through HIF2α knockdown and HIF2-specific molecular inhibitors. 
 To use publically available gene expression and clinical datasets to understand the 




Chapter 2: Materials and methods 
 
2.1 Materials 
(Materials were obtained from Sigma-Aldrich unless otherwise stated) 
2.1.1 Cell lines 
A number of human breast cancer cell lines were used in this study. A full list and 
description of cell lines can be seen in Table 2.1.  All cell lines were acquired from the ATCC 
(American Tissue Culture Collection) with the exception of MCF7-HER2/18 and MCF7-Neo, 
which are genetically modified lines derived from MCF7 in Kent Osborne’s laboratory [430]. 
Short Tandem Repeat (STR) profiling (performed by Public Health England Culture Collections 
Cell Line Authentication Service) was used to verify cell line identities at the start of the 
project.  
Table 2.1: Cell Lines  
Cell Line Origin Molecular Subtype Receptors 
BT474 Primary site of IDC Luminal ER+, PgR+, HER2+ 
HBL100 Derived from the 
milk of a healthy 
woman 
Basal B ER-, PgR-, HER2- 
(Triple Negative) 
MCF7 Pleural effusion of 
IDC 
Luminal ER+, PgR+, HER2- 
MCF7-HER2/18 Derived from 
MCF7 in the 
Osborne lab [430] 
Luminal ER+, PgR+, HER2+ 
MCF7-Neo Derived from 
MCF7 in the 
Osborne lab [430] 
Luminal ER+, PgR+, HER2- 
MDA-MB-231 Pleural effusion of 
AC 
Basal B ER-, PgR-, HER2- 
(Triple Negative) 
MDA-MB-361 Primary site of AC Luminal ER+, PgR-, HER2+ 
SKBR3 Pleural effusion of 
AC 
HER2+ ER-, PgR-, HER2+ 
T47D Pleural effusion of 
IDC 
Luminal ER+, PgR+, HER2- 
ZR751 Ascites fluid of 
IDC 




2.1.2 Genetically modified cell lines 
Two genetically modified cell lines were used in this study: MCF7-HER2 and MCF7-
Neo, both of which are derived from wild-type MCF7 cells by Benz et al. [430]. MCF7-HER2 
was genetically modified to overexpress the HER2 receptor by the stable transfection of a 
pRK5 expression plasmid containing full length HER2 cDNA under the control of the 
cytomegalovirus promoter/enhancer. This was co-transfected with a second pRK5 plasmid 
containing the selection gene neomycin phosphotransferase (neo) under the control of the 
SV40 promoter to allow selection with the antibiotic G418. The control cell line, MCF7-Neo, 
was created by transfection with the selection plasmid alone. Cell lines were selected with 
G418 treatment and assayed for HER2 overexpression. Subclones MCF7-HER2-18 and MCF7-
Neo-3 were identified by Benz et al. as successfully transfected cells and used for further 
study. These are the two cell lines that have been used for this study and are referred to in 
this report as MCF7-HER2 and MCF7-Neo for simplicity [430].   
Two processes were used to verify the characteristics of these cell lines: at the start 
of the project STR profiling (at ECACC) was used to confirm they were of MCF7 origin, and 
western blotting was used to assess the expression of important receptor proteins (including 
HER2). STR profiling demonstrated that MCF7-HER2 was, as expected, derived from MCF7 
cells. However MCF7-Neo did not match MCF7 lines, suggesting this cell line has been 
misidentified. This was further confirmed in the western blotting experiment, which 
demonstrated receptor expression inconsistent with MCF7. MCF7-Neo was therefore 
recognised as an unsuitable control for the MCF7-HER2 cell line in this study and instead 
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2.2 Methods 
2.2.1 Routine culture of adherent cell lines 
All cell lines were cultured in Dulbecco’s Modified Eagle Medium (DMEM) (Gibco) 
containing low glucose (1 g/L), sodium pyruvate (110 mg/L) and phenol red (15 mg/L). This 
was supplemented with 10% heat-inactivated foetal bovine serum (FBS) (Gibco), 100 U/ml 
penicillin and 100 µg/ml streptomycin (Gibco) (referred to as complete DMEM). Cell lines 
were grown in a humidified atmosphere maintained at 37 °C, 5% CO2 and atmospheric O2 
(approximately 20%). Genetically modified cell lines MCF7-HER2 and MCF7-Neo were 
cultured with the addition of 1 mg/ml G418 (Sigma) to select for cells expressing the 
neomycin phosphotransferase gene. 1 mg/ml G418 was used as this concentration was 
effective at preventing the proliferation of regular MCF7 cells in SRB assays, whilst permitting 
the growth of both genetically modified cell lines (Figure 2.2).  
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Upon reaching 70-90% confluence, cell lines were passaged into new flasks. To do 
this, old media was discarded and cells were washed in phosphate-buffered saline (PBS). Cells 
were detached from the surface of flasks by 5 min incubation at 37 °C with 5 ml 0.05% trypsin-
EDTA solution (Gibco). Trypsin activity was halted by the addition of 5-10 ml complete 
DMEM. Cell suspensions were then transferred to suitable tubes and centrifuged at 2,500 
rpm for 5 min in a Heraeus Labofuge 200. The supernatant was discarded whilst cell pellets 
were re-suspended in fresh DMEM and the desired proportion of cells seeded into new flasks.  
All FBS was heat-inactivated prior to use. This was warmed at 37 °C for 15 min then 
heated to 56 °C for 30 min. This was then aliquoted and stored at -20 °C for later use.  
Cryopreservation of cells in liquid nitrogen 
To prepare cells for long term storage in liquid nitrogen, cells were grown to 70-90% 
confluence, trypsinised as above and re-suspended in freeze mix (FBS containing 10% DMSO 
(Sigma Aldrich)). These were transferred as 1 ml aliquots into cryovials suitable for liquid 
nitrogen storage. These were then kept at -70 °C for at least 24 hrs before being placed into 
liquid nitrogen tanks. To resume culture after storage in liquid nitrogen, 1 ml cell aliquots 
were quickly thawed in warm complete DMEM and seeded into a new flask.  
 
Hypoxic cell culture 
To culture cells at reduced oxygen tensions, cells were transferred to a Whitley H35 
hypoxystation. The hypoxystation contains a humidified atmosphere at 37 °C, with CO2 
maintained at 5% and O2 held at 0.5% (balance with N2).  
Charcoal stripping of foetal bovine serum 
Charcoal-stripped serum was used for experiments requiring reduced basal levels of 
hormones, growth factors and cytokines found in unstripped FBS [431]. This was obtained 
pre-prepared (Sigma Aldrich), or prepared in house for comparison with unstripped FBS. 
Stripped serum was prepared in house as follows: 1 litre of FBS was incubated for 2 hrs at 37 
°C with 2000 units of type IV sulphatase (Sigma Aldrich) and the pH adjusted to 4.2. Charcoal 
(5g) and dextran T70 (25mg) (Sigma Aldrich) were mixed in 50 ml of distilled water at 4 °C. 
The charcoal mix was added to the heat-inactivated FBS and left overnight at 4 °C. This was 
centrifuged at 4500 rpm for 1 hr at 4 °C using a Rotina 420R centrifuge. The FBS supernatant 
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was decanted off and re-adjusted to a pH of 4.2. A second batch of activated charcoal was 
added overnight as before and centrifuged again to remove as much FBS from the charcoal 
pellet. Centrifugation was repeated one last time to remove residual charcoal, FBS was 
decanted and pH adjusted to 7.2. Charcoal stripped FBS was filter-sterilised by passing 
through a 0.45 µm PDVF membrane filter (Thermo Fisher). This was aliquoted and stored at 
-20 °C for later use. 
For experiments where low basal stimulation by endogenous factors was required, 
2.5% charcoal-stripped serum was added to phenol-red free DMEM. Phenol red is known to 
have low level oestrogenic activity [432, 433] and therefore its exclusion from media allows 
growth conditions with as little basal stimulation as possible.  
 
2.2.2 Multicellular spheroids 
To form multicellular spheroids, cells were grown in T175 flasks until 70-90% 
confluent. These were then trypsinised, centrifuged and re-suspended in complete DMEM 
(as above), before syringing at least 3 times through a 21 gauge needle to form a 
homogenous single cell suspension. Cell suspensions were put in spinner flasks which use 
magnetic rods to constantly stir the media (VWR). These flasks were placed on a Cellspin 
stirring plate (Integra Biosciences) to maintain a constant stirring speed of 30 rpm. Spinner 
flasks were kept in standard cell culture conditions (humidified atmosphere of 5% CO2 at 37 
°C) for 1-2 weeks, with fresh DMEM added every 3-5 days. Once spheroids had reached an 
approximate size of 1-2 mm in diameter they were decanted into petri dishes and processed 
as required. 
Hypoxyprobe labelling of spheroids 
To allow hypoxic areas of spheroids to be visualised by IHC, spheroids first had to be 
stained with Hypoxyprobe-1 (HP1). HP1 is a commercially available pimonidazole based 
probe for detecting cellular hypoxia. Pimonidazole is activated by reduction exclusively at low 
oxygen concentrations and covalently binds to thiol groups in cellular proteins [434, 435]. 
This protein adduct can then be detected using antibodies directed towards the 
pimonidazole probe. The reduction of HP1 which is required for protein binding is completely 
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inhibited at concentrations of oxygen ≥14 μM, and half maximal inhibition occurs at 4 μM 
oxygen [434]. 
Spheroids were washed with warm PBS and then incubated for 1 hr in DMEM 
containing 100 µM HP1. Spheroids were then transferred to a 1.5 ml Eppendorf tube and 
washed again with warm PBS. These were then fixed in 4% formaldehyde for at least 24 hrs 
ready for further processing. 
 
2.2.3 Sulforhodamine B proliferation assay 
Sulforhodamine B (SRB) assays were used to compare cellular proliferation by direct 
measurement of cellular protein-bound SRB dye over a designated time course. To do this, 
cells were first seeded at 500-4000 cells per well in a 96-well plate in 200 µl of complete 
DMEM. The cell seeding density was dependent on the cell line as well as the experimental 
design. Typically, cells were allowed to grow for 48 hrs before being treated with the desired 
compounds. This was done for an individual 96-well plate for each time point. If treatment 
in low serum or stripped serum media was required, cells were first seeded in full DMEM and 
allowed to settle for 48 hrs before being washed with PBS and the desired media added. 
These would be incubated for another 48 hrs before being treated. After treatment, plates 
were fixed at the indicated time points by the addition of 50 µl of 25% trichloroacetic acid 
directly to the media and left at 4 °C for 1 hr, before being washed 10 times with H2O and 
being dried in a 50°C oven. 50 µl of 0.4% SRB solution (made up in 1% acetic acid solution) 
was added to each well and plates left on a rocker for 30 min at room temperature. Excess 
SRB solution was tipped off and wells were washed 4 times in 1% acetic acid. Plates were 
allowed to dry in an oven at 50 °C. Bound SRB dye was solubilised by the addition of 150 µl 
10 mM Tris solution (pH 10.5) and left on a rocker at room temperature for 30 min. 
Absorbance was measured at 540 nm on a BP800 biohit plate reader giving OD values 






2.2.4 Whole cell lysate acquisition 
Whole cell lysates were acquired from adherent cell lines and were used to examine 
protein expression by western blotting. Cells were grown and treated according to the 
desired experimental comparison; an appropriate number of cells were seeded so that 
lysates could be collected at 70-90% confluence. Before lysate collection, whole cell lysis 
buffer was prepared as follows: 30 ml 500 mM Tris (pH7.5), 30 ml of 50 mM EGTA (pH 8.5) 
and 90 ml of 500 mM NaCl were combined and mixed with a further 150 ml of dH2O. This 
was separated into 10 ml aliquots and stored at -20 °C for future use. Preparation of lysis 
buffer was completed by the addition of detergent, protease and phosphatase inhibitors no 
more than half an hour before use. To a single 10 ml aliquot, 100 µl Triton X-100 (Sigma), 50 
µl of Aprotinin (Sigma), 100 µl of Phosphatase inhibitor cocktail 2 (Sigma), 100 µl of 
Phosphatase inhibitor cocktail 3 (Sigma) and one Complete mini protease inhibitor tablet 
(Roche) were added and mixed by vortexing until completely solubilised. To collect lysates, 
cells were washed with ice-cold PBS and all subsequent steps were completed on ice to 
minimize protein degradation. PBS was removed and 400 µl of the complete lysis buffer was 
added to 160 mm dishes; this was reduced to 200 µl and 100µl for 100 mm dishes or 6-well 
plates respectively. Cells were lysed on ice for 10 min before plates were scraped and lysates 
transferred to a 1.5 ml Eppendorf tube. Samples were centrifuged at 13,300 rpm at 4 °C for 
6 min in a Heraeus Fresco17 bench top centrifuge. Sample supernatants contain the cellular 
protein and were stored at -80 °C for future use. 
 
2.2.5 Nuclear and cytoplasmic cell lysate acquisition 
Lysates containing the nuclear or cytoplasmic fractions were collected for later use 
in western blot experiments. Solution A [10 mM HEPES pH 7.8, 10mM KCl, 2 mM MgCl2, 0.1 
mM EDTA], solution B [10% IGEPAL CA-630 (sigma) in dH2O] and solution C [50 mM HEPES 
pH 7.8, 2 M KCl, 3 M NaCl, 0.5 M EDTA, 10% Glycerol] were prepared in advance. Solutions A 
and C were stored at -20 °C whilst solution B was stored at 4 °C until needed. Solutions A and 
C were completed by the addition of 50 µl of Aprotinin (Sigma), 100 µl of Phosphatase 
inhibitor cocktail 2 (Sigma), 100 µl of Phosphatase inhibitor cocktail 3 (Sigma) and one 
Complete mini protease inhibitor tablet (Roche) to each; these were mixed by vortexing until 
solubilised. To collect lysates, cells were washed with ice-cold PBS before being scraped in 1 
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ml of ice-cold PBS and transferred to a 1.5 ml Eppendorf tube. Samples were centrifuged at 
13,300 rpm at 4 °C in a Heraeus Fresco17 bench top centrifuge for 1 min. Supernatant was 
discarded and cellular pellets were re-suspended in 400 µl, 200 µl or 100 µl of completed 
solution A for 160 mm, 100 mm or 6-well plates respectively. Samples were left on ice for 15 
min and 15 µl, 7.5 µl or 3.75 µl of solution B added. These were mixed by vortexing for 30 
secs before being centrifuged at 13,300 rpm at 4 °C for 1 min. The supernatant was removed 
and stored at -70 °C as the cytoplasmic fraction. To the pellet 50 µl (160 mm dishes) or 25 µl 
(100 mm or 6-well plates) of solution C was added. Samples were left on a rotating table at 
4 °C for 20 min. These were then centrifuged at 13,300 rpm at 4 °C for 5 min. Supernatant 
was removed and stored at -70 °C as the nuclear fraction.   
 
2.2.6 Bicinchoninic acid protein quantification assay 
The bicinchoninic acid (BCA) assay allows the quantification of protein in cellular 
lysates. 5 µl of each lysate was diluted 1:10 in dH2O and a standard curve of protein 
concentrations was created by the dilution of 1 mg/ml protein standard (Sigma) in dH2O. BCA 
reaction mix was created by 1:50 dilution of copper sulphate II solution (Sigma) in BCA 
solution (Sigma). 1 ml of reaction mix was added to each lysate and protein standard sample 
before being vortexed briefly and incubated at 60 °C for 15 min. After this incubation, 200 µl 
of each sample was pipetted in duplicate into a 96-well plate and the absorbance of samples 
at 540 nm was read using a Biohit BP800 plate reader. The comparison of the absorbance in 
protein lysates with protein standards of known concentration allowed the determination of 
lysate concentration.  
2.2.7 SDS polyacrylamide gel electrophoresis 
SDS polyacrylamide gel electrophoresis was used to separate denatured proteins 
within cellular lysates according to size, facilitating the downstream detection of proteins of 
interest. 
Quantified protein lysates were diluted to 40 µg of protein in 30 µl of lysis buffer 
(although for some experiments different amounts of protein were used). 10 µl of 4x loading 
buffer [32 mM Tris, 4% SDS, 20% β-mercaptoethanol, 0.016% bromophenol blue, and 40% 
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glycerol in distilled H2O] was added to each sample and these were denatured at 95 °C for 3 
min. Tubes were spun down in a bench-top microcentrifuge (Eppendorf minispin) and stored 
on ice until they were loaded onto gels for electrophoresis. 
Polyacrylamide gels were prepared immediately before running SDS-PAGE. 7.5% 
acrylamide resolving gel mix was made with 10 ml of 30% acrylamide solution, 15 ml of 1 M 
Tris (pH8.85), 400 µl of 10% SDS and 14.6 ml of dH2O. To initiate the setting of the gel mix, 
100 µl of TEMED (National Diagnostics) and 100 µl of 10% ammonium persulphate (Sigma) 
were added and the solution was immediately mixed and pipetted into the glass moulds. A 
layer of isopropanol was added to the top to avoid drying out of the gel, and this was left for 
20 min or until set. A 3.6% stacking gel solution was made with 3.6 ml of 30% acrylamide, 10 
ml of 0.375M Tris (pH 6.8) and 16 ml of dH2O. Isopropanol was removed and the resolving 
gel washed gently with dH2O. 100 µl of TEMED and ammonium persulphate were added to 
the stacking gel, which was immediately mixed and added to the top of the stacking gel. 10 
or 15-well combs were placed into the stacking gel and this was left for 20 min or until set. 
 Set gels were placed into the Bio Rad Mini Protean electrophoresis cell with 1 litre 
of running buffer (25 mM Tris, 192 mM glycine, 0.1% (w/v) SDS). 40 µl denatured protein 
samples were loaded into wells alongside 10 µl molecular weight ladder (prestained protein 
marker, broad range (11-190 KDa), Cell Signalling Technology) and gels were run at 80 V for 
15 min followed by 150 V for 45 min or until proteins were adequately resolved.   
 
2.2.8 Protein transfer to PVDF membrane and probing 
Resolved proteins were transferred onto methanol-activated Immobilon-P transfer 
PVDF membrane (Merck Millipore) by running at 100 V for 1.5 hrs at 4 °C using the Protean 
Transfer Cell equipment (Bio Rad) filled with 1 litre of transfer buffer (192 mM Glycine, 25 
mM Tris). Once transferred, the membranes were removed and blocked in suitable blocking 
buffer for 1 hr at room temperature. Membranes were probed with primary antibodies 
diluted in blocking buffer overnight at 4 °C. For a complete list of antibodies, including their 
dilutions and buffers used, please see Table 2.2 in section 2.1.3. Primary antibodies were 
discarded and membranes washed 3 times in PBS with the addition of 0.1% Tween20 (PBST) 
for 5 min on a rocker. Membranes were incubated with fluorescently-labelled secondary 
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antibodies (Li-Cor IRDye 800cw and IRDye 680LT) with separate wavelengths targeted against 
the species-specific domain of individual primary antibodies, thus allowing two primary 
antibodies from different species to be labelled and distinguished from one another. 
Secondary incubations were performed for 45 min on a rocker at room temperature, whilst 
protecting the blots from light to avoid loss of signal strength. Secondary antibody mixes 
were then removed and blots were washed 3 times in PBST on a rocker for 5 min, followed 
by 3 similar washes in PBS. Membranes were scanned using a Li-Cor Odyssey scanner, and 
the levels of proteins quantitatively compared using the Image Studio software suite (Li-Cor). 
Proteins of interest were routinely probed for alongside a loading control which could be 
used to normalise target expression across samples.  
2.2.9 Immunohistochemistry of paraffin embedded tissue 
Embedded tissues were sectioned and mounted onto glass slides. Tissue sections 
were de-waxed in xylene for 5 min (x2) and rehydrated in 100%, 100%, 80% and then 50% 
ethanol for 2 min each, before gently washed in running water. Antigen retrieval solution (82 
mM Sodium citrate, 18 mM Citric acid) was placed in a pressure cooker and pre-heated in a 
microwave on full power for 10 min. Rehydrated slides were then placed into the antigen 
retrieval solution and the pressure cooker placed in the microwave for 5 min. This was left to 
cool for 20 min and slides were then washed twice for 5 min in PBST on an orbital shaker. 
Endogenous peroxidase activity was blocked by a 10 min incubation with 3% H2O2 solution 
on an orbital shaker at room temperature before being washed for 5 min in PBST. Slides were 
removed from the PBST and tissue sections were blocked from non-specific protein binding 
by the addition of Total Protein Block (Dako); these were left at room temperature for 10 
min. Protein block was removed and primary antibodies diluted in Dako Antibody Diluent 
were added and left at room temperature for 1 hr (See Table 2.2 for a list of antibody 
dilutions used). Slides were washed twice for 5 min in PBST before the addition of Envision 
labelled polymer (Dako) directed towards either rabbit or mouse primary antibodies 
depending on the primary antibody used. Slides were incubated at room temperature for 30 
min before being washed twice more for 5 min with PBST. DAB chromophore was diluted 
1:50 in DAB substrate buffer (Dako) and 50 µl was added to tissue sections for 10 min to allow 
staining to develop. Counterstaining was performed by placing slides in haemotoxylin for 45 
secs, washing in running water for 30 secs, placing in Scott’s Tap Water Substitute (STWS) for 
30 secs and back into running water for 30 secs. Tissue sections were dehydrated by placing 
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slides in 50% then 80% ethanol for 30 secs each, followed by 100% ethanol twice for 2 min 
and xylene twice for 5 min. Slides were mounted with coverslips using DPX mountant.  
High resolution images were taken using the Hamamatsu Nanozoomer slide scanner.  
 
2.2.10 Wound healing assays 
Wound healing assays were performed using 35 mm µ-dishes with 2-well culture-
inserts (Ibidi). These allowed cells to be grown to confluence before the removal of an insert 
which leaves a defined 500 µm cell-free gap. This allows cell migration into the gap to be 
measured over a time course of 1-4 days. 
Briefly, 70 µl of a 7 x 105 cells per ml cell suspension was seeded into each well of the 
culture-insert dishes. Cells were seeded in complete 10% FBS DMEM, left for 24 hrs or until 
confluent, before the culture-insert was removed and cells were gently washed with PBS and 
changed into 0.2% FBS DMEM. Dishes were imaged at 0, 6, 24 hrs and every 24 hrs thereafter 
up to 96 hrs. Images were taken using brightfield microscopy on a Zeiss Axiovert S100 
inverted microscope with a 2.5x objective. For experiments with inhibitory compounds, these 
were added at the desired concentration at the time of media change.   
 
2.2.11 Collagen invasion assays 
3D multicellular spheroids were grown as described above (Section 2.2.2). Spheroids 
were transferred to a petri dish and individual spheroids taken up into a pipette tip. The 
spheroid was mixed in the pipette tip with 500 µl of collagen mix [25% type-I collagen, 3 
mg/ml (Alphalabs), 45% 1:1000 acetic acid, 10% FBS, 10% 0.22 M NaOH, 10% 10x DMEM]. 
This was gently pipetted into 24-well plates and allowed to set at 37 °C in a cell culture 
incubator for 1 hr. Once the collagen mix had set, a P200 tip was used to run around the edge 
of the well, thereby releasing the set collagen gel. 0.5 ml of complete DMEM was added to 
each well. Spheroids were imaged at 0 hrs and every 24 hrs thereafter, using brightfield 
microscopy on a Zeiss Axiovert S100 inverted microscope with a 2.5x objective. Scoring of 







2.2.12 siRNA knockdown experiments 
Transfection of cells with siRNA oligonucleotides was performed for the targeted 
knockdown of HIF2α expression. Oligonucleotides and transfection reagents were purchased 
from Dharmacon and used as per the manufacturer’s instructions. Knockdown was 
performed with four individual oligonucleotides targeted to HIF2α, as well as a pool of these 
four combined into a ‘SMART pool’ product. Details of siRNA oligonucleotides can be seen in 
Table 2.3. 
Cells were seeded at a density of 2.5x105 cells per well in 6-well plates (or 1000 cells 
per well in 96-well plates) in antibiotic-free medium. For 6-well plates the protocol was 
performed as follows: after 24 hrs, cells were 50-70% confluent and ready to be transfected.  
20 µM siRNA solutions were reconstituted in 1x siRNA buffer (Dharmacon), aliquoted and 
stored at -20°C ready for use. On the day of transfection, 20 μM siRNA solution was added to 
200 µl of antibiotic-free/serum-free DMEM, such that final concentration would equal 25 nM 
for single siRNAs and 5–100 nM for SMARTpool siRNA. In a separate tube, 4 µl of Dharmafect 
transfection reagent 1 was diluted in 196 µl of antibiotic-free/serum-free DMEM. These 
tubes were gently mixed and both left at room temperature for 5 min before being combined 
and mixed gently again. These transfection mixes were incubated at room temperature for 
20 min. The seeded cells were washed once in PBS before the addition of 1 ml antibiotic-free 
10% FBS DMEM. Transfection mixes were made up to 1 ml by the addition of 600 µl antibiotic-
free 10% FBS DMEM, mixed gently and added dropwise to the desired cells. Transfected cells 
were left for 24 hrs before being changed to antibiotic-containing media. Cells were then 
treated as desired before the collection of protein lysates for western blotting. Transfections 
were always performed alongside untreated, mock (transfected without siRNA) and non-
targeting (transfected with a non-specific siRNA oligomer) controls. For 96-well plates the 
protocol was performed in the same way using 0.14 μl of transfection reagent per well. All 
other reagents were scaled down to produce a final volume of 200 μl per well; details of 





2.2.13 Gene expression analysis 
The gene expression microarray experiment was performed in collaboration with 
Arran Turnbull, Carlos Martinez, James Meehan and Chrysi Xintaropoulou. 
Sample collection  
MCF7 and MCF7-HER2 cell lines were cultured in complete DMEM and seeded into 
T-175 flasks. Normoxic samples were grown to 80% confluence and trypsinised (described in 
Section 2.2.1). Cell suspensions were counted and centrifuged at 1,200 rpm in a Heraeus 
Fresco17 bench top centrifuge for 5 min to form pellets of at least 3x106 cells. Three biological 
replicates were collected for each cell line and stored at -70° C until ready for RNA extraction. 
Hypoxic and cobalt chloride (CoCl2) treated samples were collected in the same way after the 
appropriate treatment. Acute hypoxic samples were cultured at 0.5% O2 in a Whitley H35 
hypoxystation (as described in Section 2.2.1) for 24 hrs before collection. Chronic hypoxic 
samples were continually cultured at 0.5% O2 for 10 weeks before collection. This included 
Table 2.3 : List of siRNA oligonucleotides 
Name Target/Role Sequence Catalogue 
Number 
HIF2α #1 HIF2α GGCAGCACCUCACAUUUGA J-004814-06 
HIF2α #2 HIF2α GAGCGCAAAUGUACCCAAU J-004814-07 
HIF2α #3 HIF2α GACAAGGUCUGCAAAGGGU J-004814-08 
HIF2α #4 HIF2α GCAAAGACAUGUCCACAGA J-004814-09 
HIF2α SMARTpool A pool of 4 
individual siRNAs 
targeting HIF2α  





Set of 4 
oligonucleotides 
with no  target, 
used as a negative 
control in siRNA 
transfection 
experiments 
A pool of 4 non-targeting 
oligonucleotide sequences. 





weekly passaging of cells for which media and reagents were all acclimatised to hypoxia prior 
to use. CoCl2 samples were treated with 400 µM of CoCl2 for 24 hrs before collection.  
RNA extraction 
RNA extraction from cell pellets was performed using the miRNeasy Mini Kit (Qiagen) 
as per the manufacturer’s instructions. Pellets were mechanically homogenised in 1 ml of 
QIAzol lysis reagent using a Tissuelyser LT (Qiagen) at 50 Hz for 5 min. 240 µl of chloroform 
was added and samples were centrifuged at 13,000 rpm for 15 min at 4°C (Heraeus Fresco17 
benchtop centrifuge). The upper aqueous phase was removed and added to 750 µl of 
ethanol. Samples were added to the RNeasy Mini columns and centrifuged at 13,000 rpm for 
15 secs at room temperature. Flow-through was discarded and columns were washed with 
350 µl RWT buffer and centrifuged again for 15 secs, discarding the flow-through. Columns 
were incubated with 80 µl of DNase mix (Qiagen) for 15 min at room temperature. Columns 
were washed with 350 µl of RWT buffer and twice with 500 µl of RPE buffer with 
centrifugation and flow-through removal after each step. RNA was then eluted from the 
columns by the addition of 30ul RNase-free water. RNA concentration and quality was 
assessed using a Nanodrop 2000c spectrophotometer. RNA samples were stored at -70°C for 
later use.   
Reverse transcription and amplification of cRNA 
RNA was reverse transcribed, labelled and amplified using the Illumina TotalPrep 
RNA Amplification Kit as per the manufacturer’s instructions. RNA samples were diluted in 
11 µl of nuclease-free water to a total amount of 500 ng and incubated with 9 µl of Reverse 
Transcription Master Mix for 2 hrs at 42°C to form cDNA oligomers. This could then be 
incubated with 80 µl of Second Strand Master Mix at 16°C for 2 hrs, which allowed the 
formation of double-stranded complementary DNA, as well as the degradation of remaining 
RNA. 250 µl of cDNA Binding Buffer was then added to each sample and applied to a cDNA 
Filter Cartridge and centrifuged for 1 min at 13,300 rpm, discarding the flow-through. 500 µl 
of Wash Buffer was applied and the cartridges were centrifuged again at 13,300 rpm (flow-
through was once again discarded). cDNA was eluted with 20 µl of nuclease-free water (pre-
heated to 55°C), left for 2 min at room temperature before being centrifuged for 1 min at 
13,300 rpm and the eluate collected. The in vitro transcription of cDNA was used to create 
biotin-labelled cRNA. cDNA eluates were added to 7.5 µl of IVT Master Mix and mixed 
thoroughly by pipetting. Samples were incubated at 37°C for 14 hrs. The reaction was 
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stopped with the addition of 75 µl nuclease-free water. cRNA was then purified as follows: 
350 µl of cRNA binding buffer was added to each sample along with 250 µl of 100% ethanol 
and these were mixed by pipetting. Samples were transferred to cRNA filter cartridges and 
centrifuged at 13,300 rpm for 1 min (flow-through was discarded). Cartridges were washed 
with 650 µl Wash Buffer and centrifuged again, once again discarding the flow-through. 
Cartridges were then transferred to collection tubes, 200 µl of pre-heated (55°C) nuclease-
free water was added, and samples were incubated at 55°C for 10 min. Finally samples were 
centrifuged at 13,300 rpm for 1.5 min and the labelled cRNA was collected in the eluate. The 
concentration and quality of the cRNA was then assessed with a Nanodrop 2000c 
spectrophotometer.  
 
Hybridisation to HT-12 v4 beadchip array and data normalisation 
Biotin-labelled cRNA was sent to Hologic, a healthcare and diagnostics company in 
Manchester, who performed the hybridisation to the beadchip array and the scanning of the 
slides. Each chip held 12 samples, each sample being hybridised to an array of 47,000 probes 
derived from the National Centre of Biotechnology Information (NCBI) reference sequence 
(release 38, 2009). Samples were distributed over 4 chips, with the location of each sample 
chosen to reduce the bias of chip batch effects and processed using Illumina GenomeStudio 
to generate a raw dataset showing expression intensity of each probe. Undetected probes 
were excluded if they did not reach a minimum detection value in more than 3 samples. This 
detection value was defined by the Illumina probe detection P-value, with a P-value of 
greater than 0.05 being deemed as undetected. Probe expression was Log2 transformed and 
quantile-normalised using the Lumi Bioconductor package within R. Probes were mapped to 
Ensembl genes and annotated with Ensembl gene identifiers. Repeat samples were 
compared using multi-dimensional scaling (MDS) (Appendix 1.1) and assessed for consistency 
by hierarchical clustering (Appendix 1.2).   
2.2.14 Quantitative real-time PCR 
RNA was extracted from cellular pellets and quantified as described above. RT-PCR 
was performed using an applied Biosystems StepOnePlus Real-Time PCR System. Reverse 
transcription and amplification were performed in one step using the Taqman RNA-to-CT 1-
Step Kit and Taqman primers targeting genes of interest or ‘housekeeping’ genes. RNA was 
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quantified using a 5-point standard curve for each primer set. Comparison of gene expression 
between samples was done after normalisation of all values to the geometric mean of three 
‘housekeeping’ genes: PUM1, TBP and RPL37A. Details on individual gene assays for RT-PCR 
can be seen in Table 2.4 below.  
 
 
Table 2.4 : RT-PCR Taqman gene expression assay information 
Target Assay ID Context Sequence Amplicon 
length 
HIF1α Hs_00153153_m1 TACACACAGAAATGGCCTTGTGAAA 76 
HIF2α Hs_01026149_m1 TCACCAGAACTTGTGCACCAAGGGT 70 
PUM1 Hs_00472881_m1 TGGGGAACATCAGATCATTCAGTTT 77 
RPL37a Hs_01102345_m1 GTGCCTGGACGTACAATACCACTT 125 
TBP Hs_00427620_m1 GCAGCTGCAAAATATTGTATCCACA 91 
 
2.2.15 Survival analysis 
Survival analysis using the METABRIC dataset 
The METABRIC (Molecular Taxonomy of Breast Cancer International Consortium) breast 
cancer dataset was downloaded (cbioportal.org) and used for survival analysis performed in R. The 
METABRIC dataset consists of over 2,000 fresh-frozen breast cancer samples with gene expression and 
associated clinical data, providing a large dataset without the need for integrating multiple studies 
into a meta-analysis. Gene expression data for these samples was collected using an Illumina HT-12 
V3 array [437]. Patient treatments used in this study were relatively homogenous within clinically 
relevant subtypes; oestrogen receptor (ER)-positive and lymph node (LN)-negative samples generally 
did not receive chemotherapy, whilst ER-negative/LN-positive patients did and HER2-positive patients 
did not receive trastuzumab. This means that the effect of differential treatment types on gene 
expression is minimized, at least within these subgroups, allowing more simplistic interpretation of 
the data [437].   
Analysis using Kmplot 
Kmplot is an online tool for the rapid assessment of survival data in cancer. This tool 
includes a large dataset for breast cancer survival with gene expression and associated 
clinical outcome data for 5,143 breast cancer samples covering 22,277 genes [438-440]. 
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These samples were combined and normalised from a number of experiments using 
Affymetrix HG-U133A and HG-U133 Plus 2.0 arrays available at the online repository GEO, as 
well as gene expression datasets taken from the European genome-phenome archive (EGA) 
and The Cancer Genome Atlas (TCGA) [440]. This tool is able to produce Kaplan-Meier curves 
displaying log rank p-values and hazard ratio with a 95% confidence interval for cohorts 
stratified into high or low for single or multiple gene expression values, with clinical data 
available for overall survival (OS), recurrence-free survival (RFS) and distant metastasis-free 
survival (DMFS). Optimum cut-points for analysis are selected by computing each expression 
quartile between the upper and lower quartiles of gene expression and selecting the most 
significant [440]. The gene expression and clinical data used by Kmplot was compiled by 
combining analyses performed on two compatible Affymetrix platforms (HG-U133A and HG-
U133A Plus 2.0 arrays) available for download from GEO. Thirteen studies were selected 
which included at least 30 patients and provided raw expression data from these arrays as 
well as clinical survival information. Gene expression values were subjected to quality control 
and normalisation as described in Györrfy et al. 2009 [438].   
SurvivALL 
SurvivALL is a package for R (developed by Dominic Pierce, IGMM, University of 
Edinburgh) which allows the analysis of survival data using continuous data such as gene 
expression. A basic approach to survival analysis would typically select an appropriate cut-
point of gene expression data to compare survival in low vs high expressing samples, but this 
single cut-point approach does not give any indication of the robustness of any differences 
found (i.e. whether a significant difference is only seen when cohorts are defined in a very 
specific way). To improve on this approach, the SurvivALL package performs survival analysis 
on all possible cut-points, giving survival statistics including p-values and hazard ratios for 
each. This allows a greater understanding of survival differences as the position and number 
of significant cut-points is made clear. The SurvivALL package was therefore used alongside 
all survival analyses performed in R. This package was not used for Kmplot survival analysis, 





2.3 Characterisation of cell line models 
2.3.1 Confirmation of receptor expression by western blotting 
Breast cancers can be broadly categorised by their expression of several key nuclear 
receptors (ER and PgR) and cell surface receptors (HER2 and EGFR); the relative expression 
of ERα, PgR and HER2 is used to define tumours as Luminal (A or B), HER2+ or Triple Negative. 
These subtypes exhibit different characteristics in terms of tumour aggressiveness and 
prognosis; cell biology, including differences in cell signalling pathway activation and gene 
expression; as well as differing sensitivities to targeted therapies. In order to understand the 
implications of HIF signalling in breast cancer it is important to recognise these differences, 
and as such I intend to use a panel of cell lines which represent these subtypes through a 
broad range of receptor expression patterns. Initial characterisation of this panel involved 
the comparison of cell surface and nuclear receptor protein expression through western 
blotting (Figure 2.1). The expression of EGFR, HER2, HER3, ERα and PgR was compared in 
untreated whole cell lysates. With the exception of MCF7-Neo (discussed in Section 3.2.2) all 
cell lines showed expression patterns consistent with their subtype and the literature. EGFR 
was highly expressed in the triple negative cell lines MDA-MB-231 and HBL100, which both 
showed low expression of all other receptors. HER2-positive cell lines BT474, MDA-MB-361 
and SKBR3 all have moderate to high expression of HER2, but have differing expression of 
the other receptors; BT474 has relatively high ERα and PgR, SKBR3 shows moderate EGFR 
expression and MDA-MB-361 has high HER3. Whilst considered an ER-positive cell lines, ER 
was not detectable in MDA-MB-361, this may be due to an intermediate level of expression 
in this cell line [441] not detectable with the antibody used. Other ER-driven cell lines MCF7, 
T47D and ZR751 show predominantly high ERα expression as well as low EGFR and HER2. As 
expected MCF7-HER2 shows a similar expression profile to MCF7, with the exception of 
increased HER2 expression. This characterisation demonstrates two important points about 
this cell line panel. First of all, these cell lines represent the range of receptor expression 
profiles expected of the different molecular subtypes seen in breast cancer. Secondly, the 
categorisation of these cell lines by subtype alone is not sufficient in describing their receptor 
profiles and by extension their biology. This point is best demonstrated by the HER2-positive 
cell lines. These cell lines show a diversity of receptor levels alongside their high HER2 
expression. This is an important consideration when comparing cell lines broadly by subtype, 
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but the inclusion of such cell lines in this panel means that comparisons within the HER2-
positive group may be just as interesting as a broader comparison of subtypes. 
2.3.2 Confirmation of the effects of selection antibiotic G418 on wild-
type and genetically modified MCF7 cells 
Preliminary SRB assays were performed to determine optimum concentration of 
G418 to be used in cell culture for the growth of genetically modified MCF7-HER2 and MCF7-
NEO cell lines (Figure 2.2). Cells were seeded and grown in complete DMEM containing 0–5 
mg/ml G418 for 10 days. It was expected that wild-type MCF7 cells lacking any form of 
resistance cassette would be sensitive to G418 treatment, whilst genetically modified MCF7-
HER2 and MCF7-Neo cell lines should show high resistance conferred by the expression of 
the Neomycin resistance gene. MCF7 cells showed reduced growth rate at concentrations as 
low as 0.5 mg/ml, and cell growth was completely ablated by 5 days at concentrations of 1 
mg/ml and above. In contrast, MCF7-HER2 and MCF7-Neo showed the expected resilience 
against G418, showing no reduction in growth rate at concentrations of up to 2 mg/ml. These 
cells were still able to grow at 5 mg/ml, the highest concentration tested, but the growth rate 
was marginally reduced. Therefore, a concentration of 1 mg/ml was selected as this was able 

















Figure 2.1: Characterisation of cell line receptor expression 
Whole cell lysates from a panel of cell lines were run on a 7.5% bis-acrylamide gel. 
After membrane transfer, blots were probed for various cell surface receptors as 
















Figure 2.2: G418 sensitivity in MCF7 and genetically modified MCF7 derivative lines 
Sulforhodamine B assays were used to compare cell growth in MCF7, MCF7-HER2 and MCF7-
Neo cell lines treated with G418. The top 3 panels show how cell proliferation is affected by 
a range of G418 concentrations in individual cell lines over a 10 day period. The bottom panel 
shows a comparison of how the 3 cell lines respond to 1 mg/ml, the concentration used for 
routine cell culture.   
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Chapter 3: HER2 overexpression in MCF7 cells 
drives an increased response to hypoxia 
 
3.1 Introduction 
 The ability of growth factor signalling to modulate hypoxia-inducible factor α-subunit 
levels in normoxia has demonstrated that the control of HIFα upregulation and HIF 
transcriptional activity is more complex than the canonical oxygen-dependent mechanism 
originally proposed. Growth factor stimulation by neuregulin-1β treatment, or activation of 
the HER2 receptor signalling pathway has been shown to increase HIF1α levels in breast 
cancer cell lines [220, 421, 424], and the ability of HER2 and EGFR receptor signalling to act 
through HIF1α or HIF2α has been demonstrated in the context of aromatase inhibitor or anti-
oestrogen resistance [424, 426]. In patient tumour samples, HIF1α expression has been 
shown to correlate with HER2 expression [285, 289, 442] and also poor clinical outcome [284, 
286, 287, 443] in a number of studies [444]. The role of HIF2α has been less extensively 
studied, however its correlation with HER2 expression [321] as well as poor outcome and 
distant metastasis [261] in breast cancer has also been demonstrated. In addition to an 
established role in survival and outcome, these studies suggest that both HIF1α and HIF2α 
may have a relationship with HER2 signalling in breast cancer.  
 Despite recognition of growth factor-HIF interplay in breast cancer, this has been 
largely treated as a separate mechanism to the hypoxic regulation of HIFs, with little research 
into how growth factor signalling modifies the cellular response to hypoxia. In this chapter I 
aim to determine whether the expression of the HER2 growth factor receptor affects the 
upregulation of HIFα subunits in response to hypoxia by assessing the extent of HIF1α and 
HIF2α in a panel of cell lines as well as in an isogenic cell line model of HER2 overexpression. 
Beyond this, I will use this isogenic cell line model to investigate the effect of HER2 on the 
expression of important hypoxic response genes in 2D and 3D culture models. Using this 
approach I am able to provide initial evidence of the importance of HER2 receptor expression 
in driving an enhanced cellular response to hypoxia. This includes the increased hypoxic 
activation of genes known to drive aggressiveness and invasion characteristics and reduced 
survival in breast cancer. Previous research (discussed in chapter 1) has shown that breast 
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cancer cell lines, including MCF7, upregulate HIF1α and drive hypoxic response genes both 
canonically in response to hypoxia, and in response to NRG1β in normoxia [220, 421]. HER2 
overexpression in mouse 3T3 cells has also been shown to increase HIF1α levels in normoxia 
[220, 421]. With this in mind, it is suspected that HER2 may modify the hypoxic response 
through HIF1α, and we anticipate that breast cancer cell lines may demonstrate an increased 
level of HIF signalling in response to hypoxia when HER2 is highly expressed. Additionally, 
there is some evidence for a bidirectional relationship between HIF2α and growth factor 
signalling (through EGFR) in breast cancer cell lines [425], it is therefore also anticipated that 
the hypoxic induction of HIF2α may be dependent on the levels of growth factor receptors in 
these cell lines.     
3.2 HIF induction by hypoxia is highly variable and cell line-
dependent 
 Initially, the hypoxic upregulation of HIF1α and HIF2α was assessed across a panel of 
breast cancer cell lines. This panel was selected to represent the three main subtypes of 
breast cancer as well as an array of different growth factor receptor profiles. The hypoxic 
stabilisation of the oxygen-labile HIF alpha subunits (HIF1α and HIF2α) was compared by 
western blotting of nuclear lysates collected in normoxia or after 24, 48 or 72 hours at 0.5% 
O2. Western blotting and densitometric quantification can be seen in Figure 3.1. This 
demonstrates the variability of the hypoxic regulation of HIFα subunits across cell lines. As 
expected, all cell lines showed increased levels of nuclear HIF1α and HIF2α in response to 
hypoxia, however the extent to which HIFα subunits were increased in response to hypoxia 
is clearly highly dependent on cellular context. Induction of HIF- subunits did not obviously 
correlate with receptor subtypes (defined by the expression of ER, PR and HER2), as a large 
amount of variation between cell lines was seen both within and between subtype 
categories. This included no clear difference between cell lines with high HER2 expression 
versus those with low HER2. 
In general, HIF1α appears less variable than HIF2α, with the exceptions of the HER2-
positive cell line SKBR3, which showed low HIF1α induction, and the triple-negative cell line 
HBL100, which showed high HIF1α induction. However, a marked variability between cell 
lines was observed in the longevity of induced HIF1α in hypoxia. MCF7, MCF7-HER2 and 
HBL100 all showed high levels of HIF1α protein after 48 hrs and in the cases of MCF7-HER2 
and HBL100 relatively low reductions even by 72 hrs. In contrast, ZR751, T47D, BT474, SKBR3 
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and MDAMB231 all showed a relatively rapid decrease in HIF1α protein levels. This variability 
did not appear to correlate with molecular subtype, nor did HIF1α longevity correlate with 
the magnitude of initial induction in hypoxia. HIF2α was commonly induced by 24 hrs and 
remained at high levels throughout the 72 hr time course. Across cell lines the magnitude of 
HIF2α induction was highly variable, however the magnitude once again did not correlate 
with molecular subtypes or the expression of HER2 in this panel. MCF7 and BT474 showed 
the lowest induction of HIF2α, whilst ZR751, SKBR3 and HBL100 showed the highest (with 
T47D, MCF7-HER2 and MDA-MB-231 showing moderate induction), although differences in 
the levels of the TBP control between cell lines means that caution should be taken when 
directly comparing normalised results. This comparison of cell lines showed no obvious 
relationship between HIF1α and HIF2α levels in hypoxia, and no definite indication that levels 
of hypoxic induction are determined by HER2 expression.  
 In this experiment the high variability of HIFα induction between cell lines meant that 
no obvious relationship was seen between HER2 expression and HIFα levels across cell lines. 
Despite this, the inclusion of MCF7 and its HER2-overexpressing isogenic counterpart MCF7-
HER2 suggests that HER2 overexpression in this context may alter the upregulation of HIFα 
subunits, especially HIF2α in response to hypoxia. This two cell line model is used in the 











Figure 3.1: Hypoxic upregulation of HIF1α and HIF2α in nuclear fractions across breast cancer cell lines  
A panel of breast cancer cell lines representing different molecular subtypes were cultured either in normal 
culture conditions (20% oxygen) or under hypoxia (0.5% oxygen) for up to 72 hours. Lysates of the nuclear 
fraction were collected at 24, 48 and 72 hours and after protein quantification, 20 µg of these lysates was 
loaded and run by gel electrophoresis. Western blotting was performed to detect the expression of HIF1α, 
HIF2α and Tata-binding protein (TBP). TBP was used as a loading control to which HIF1α and HIF2α 
densitometry quantification was normalised (n=1).  
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3.3 The effect of HER2 overexpression on the cellular 
response to hypoxia in MCF7 and MCF7-HER2 
The MCF7 and MCF7-HER2 isogenic cell lines provide a more direct system for 
studying the effects of HER2 signalling on HIF regulation in breast cancer, as any deviations 
in cell behaviour can be more directly attributable to the overexpression of the HER2 
receptor. As such, differences seen in HIF-upregulation between these two cell lines in Figure 
3.1 suggest a role for HER2 in the response to hypoxia. To understand how HER2 
overexpression can modify the cell’s behaviour in hypoxia, proliferation and motility of these 
cell lines were compared under normal and hypoxic oxygen concentrations. The hypoxic 
upregulation of HIF1α and HIF2α was compared between the two cell lines and the 
upregulation of known hypoxia response genes CAIX and LDHA examined. Furthermore, the 
upregulation of these factors in the presence of the EGFR/HER2 inhibitor lapatinib was 
assessed to determine whether cell line differences could be reversed by the inhibition of 
growth factor signalling.     
 
3.3.1 Overexpression of the HER2 receptor in MCF7 does not increase 
cellular growth in response to hypoxia, but increases hypoxic cellular 
motility 
Sulforhodamine B (SRB) assays were used to compare normoxic and hypoxic 
proliferation between MCF7 and MCF7-HER2 cell lines. These were used to determine the 
effect of acute and chronic hypoxia on the growth rate of these cell lines. Cells were seeded 
onto 96-well plates and grown under either normal culture conditions or in 0.5% oxygen for 
up to 7 days. For chronic hypoxia, cells were continuously passaged in 0.5% oxygen conditions 
for 10 weeks before being seeded into 96-well plates in hypoxia; 3, 5, or 7 days after seeding, 
cells were fixed and SRB assay used to determine relative cell densities. No differences 
between the cell lines under normoxia, acute or chronic hypoxia were observed (Figure 3.2A). 
Cell number under both hypoxic conditions in both cell lines was reduced relative to 
normoxia and this was apparent at each time point. This suggests a deleterious effect of 
hypoxia on cell population growth with no significant differences seen when the HER2 
receptor was overexpressed. This is the case when cells are initially exposed to hypoxia, and 
also after long-term acclimatisation to low oxygen conditions (chronic hypoxia). This 
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experiment shows that in this model increased HER2 expression does not drive significantly 
increased proliferation in normoxia or protect against the reduction in proliferative rate seen 
in hypoxia.  
 Next, wound healing assays were used to assess the role of HER2 overexpression on 
cell motility in normoxia and hypoxia. Hypoxia is considered a driver of cellular motility in the 
tumour microenvironment [315, 445], with the presence of hypoxic regions correlating with 
increased aggressiveness of the tumour in terms of invasion and metastasis [446]. For this 
reason, increased cell motility could be considered a more probable phenotypic outcome of 
an altered response to hypoxia in the presence of HER2 overexpression. To assess this, cells 
were seeded at confluent levels into plates containing removable inserts. Once the cells had 
attached, these inserts were removed to create a wound of fixed size (500 μm). The plates 
were cultured in either normoxia or 0.5% oxygen and the size of the wound at various points 
along its length was measured daily for 4 days. In normoxia, wound healing in terms of area 
covered was equivalent between the cell lines, with no significant difference found between 
them, even though the mean wound coverage was greater in MCF7-HER2 at each time point. 
Despite this, there were clear phenotypic differences between the cell lines in terms of how 
they covered the wound; whilst MCF7 remained as an epithelial sheet with strong cell-cell 
adhesion, MCF7-HER2 invaded as individual cells, with weaker cell-cell adhesion and more 
obvious lamellapodia (Figure 3.3). This is indicative of an epithelial-to-mesenchymal 
transition (EMT) phenotype (the role of EMT will be discussed in more detail in Chapter 4). 
Wound healing in hypoxia demonstrated differences between the two cell lines. In MCF7 
cells, wound healing in hypoxia was significantly reduced when compared to normoxia (p = 
0.0013, two-way ANOVA with Sidak’s multiple comparison test), equating to an average of 
12% coverage by 96 hrs compared to 46% in normoxia. In MCF7-HER2 wound healing was 
increased in hypoxia, covering on average 89% of the wound compared to 68% in normoxia. 
Whilst the differences between normoxia and hypoxia for MCF7-HER2 were not found to be 
statistically significant, the differences between hypoxic wound healing between cell lines 
was significant, being higher in MCF7-HER2 (p<0.0001, two-way ANOVA with Sidak’s multiple 
comparison test) at 48, 72 and 96 hrs. This demonstrates that motility in hypoxia is higher in 






Figure 3.2: The effect of hypoxia on proliferation and wound healing in MCF7 cell lines 
A) MCF7 and MCF7-HER2 growth was assessed over 7 days by Sulforhodamine B assay of MCF7 and 
MCF7-HER2 grown in normoxia (20% oxygen) or hypoxia (0.5% oxygen), chronic hypoxic cells were 
continually passaged under hypoxia for >10 weeks before the start of the experiment. Both un-normalised 
OD values over 7 days (top) and growth relative to normoxia (bottom) are shown. Error bars represent 
the standard deviation (n=6) B) Relative wound area measurements for wound healing assays using MCF7 
and MCF7-HER2 under normoxic or hypoxic conditions in 0.2% FBS DMEM. This is a representative 
example of n=3 biological repeats. Two-way ANOVA was used to determine significance both between 
cell lines and oxygen conditions. P-values for individual comparisons are displayed for each graph (Two-










Figure 3.3: Representative images of MCF7 and MCF7-HER2 wound healing assays 
Representative images from wound healing assays showing differences between MCF7 and MCF7-HER2 
in normoxia and hypoxia. Cells were seeded in complete 10% FBS DMEM until confluent. Media was 
changed to 0.2% FBS and grown in normoxia or hypoxia after the removal of an insert which obstructs 
cellular growth over a 500 μM region. Cell movement into this region was assessed over 4 days (Figure 
3.2). Images shown are from 0 hrs (top) and 48 hrs (bottom) after the removal of the insert.  
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3.3.2 HER2 overexpression modifies the hypoxia-mediated stabilisation 
of HIF proteins in MCF7-HER2 cells 
The hypoxic regulation of HIFα subunits was next assessed in the isogenic MCF7 and 
MCF7-HER2 cell line models to determine whether growth factor signalling could modulate 
HIF levels under hypoxic conditions. The levels of HIF1α and HIF2α protein were assessed by 
western blotting of MCF7 and MCF7-HER2 whole cell, nuclear and cytoplasmic lysates grown 
in normoxia (20% oxygen) or hypoxia (0.5% oxygen). By using both whole cell lysates and 
lysates enriched for either the nuclear or cytoplasmic cellular fraction the localisation of HIFα 
protein in normoxia or hypoxia in these cell lines can be assessed. Canonically HIFα protein 
is understood to translocate to the nucleus when in abundance, and this translocation is 
required for HIFα to form active transcription factors. Therefore the level of nuclear HIFα is 
indicative of transcriptionally active protein. Conversely, by looking at the levels of whole cell 
and cytoplasmic HIFα, we do not overlook the possibility that non-canonical regulation by 
growth factor signalling might also alter the typical localisation of the protein.  
In whole cell lysates, HIF1α levels were comparable between the two cell lines 
(Figure 3.4). The protein was shown to be below detectable levels in normoxia but increased 
after 24 hrs in hypoxia. Levels were seen to increase further at 48 hrs before declining 
partially at 72 hrs. This pattern of stabilisation at early hypoxic time points followed by a 
decline at later time points has been described in neuroblastoma cell lines [447], and the HIF-
associated factor (HAF), which is thought to mediate this effect, has been shown to degrade 
HIF1α in hypoxia in pancreatic, glioblastoma and RCC cell lines [264]. It was therefore not 
surprising to see a similar pattern of hypoxic regulation in breast cancer cell lines. No 
difference in HIF1α induction was seen when HER2 was overexpressed.  HIF2α upregulation 
in MCF7 remained relatively low (close to the detection limit with this antibody) but was seen 
to increase steadily in response to hypoxia, with the highest levels seen at 72 hrs. While this 
agreed with the HIF1α and HIF2α dynamics as described in the literature [265], HIF2α 
expression in the MCF7-HER2 cell line was markedly increased. This included higher levels in 
normoxia and higher levels in response to hypoxia when compared to wild-type MCF7. Whilst 
no significant differences were detected between cell lines for HIF1α upregulation, cell line-
dependent differences in HIF2α upregulation were shown to be statistically significant 
(p=0.0280, two-way ANOVA), with multiple comparisons showing significant differences 
between HIF2α levels between the two cell lines after 48 hrs in hypoxia (p=0.0138).  
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As transcription factors, the cellular location of HIF1α and HIF2α is integral to their 
function. Canonically, HIFα subunits increase in the cytoplasm when oxygen is limiting for the 
activity of PHD hydroxylases, and dimerise with HIFβ to form active transcriptional units in 
the nucleus [192, 195, 448]. Thus, in hypoxia the level of HIFs in the nuclear compartment 
are representative of the active transcription factor. To assess whether increases in HIF2α 
upregulation in hypoxia coincided with increased nuclear levels of the protein, and to 
otherwise consider the effect of HER2 expression on the shuttling and cellular location of 
HIF1α and HIF2α, protein levels over a 72 hr hypoxic time course were assessed in nuclear 
and cytoplasmic cell lysates of MCF7 and MCF7-HER2 cells (Figure 3.4 C/D).  
The expression of HIF1α was strongly upregulated in the nuclear compartment from 
24 hrs but remained below detectable levels in the cytoplasmic compartment. Temporally, 
the pattern of nuclear HIF1α upregulation in response to hypoxia matched that seen in whole 
cell lysates and is consistent with the pattern described in the literature [265]. Whilst HIF1α 
levels were comparable between the two cell lines, the decrease in protein seen at 72 hrs 
appeared reduced in the context of HER2 overexpression. Unfortunately, this could not be 
confirmed statistically but the potential mechanisms and consequences of this effect will be 
discussed at the end of this chapter (Section 3.5).  
HIF2α expression was detectable in the nuclear and cytoplasmic fractions of both cell 
lines and upregulated in all cases in response to hypoxia. Upregulation was seen at 24 hrs 
under hypoxic conditions and remained increased for the 72 hr time course. In agreement 
with whole cell lysates, HIF2α levels were induced to a greater extent in the MCF7-HER2 cell 
line when compared to wild-type MCF7. This was the case in both nuclear and cytoplasmic 
fractions, suggesting an upregulation of the protein in its active nuclear transcription factor 





Figure 3.4: The upregulation of HIF1α and HIF2a by hypoxia in MCF7 and MCF7-HER2 cell lines 
Western blot analysis of MCF7 and MCF7-HER2 whole cell lysates collected in normoxia (20% oxygen) or 
hypoxia (0.5% oxygen). Whole cell, nuclear or cytoplasmic lysates were collected at 24, 48 and 72 hours 
hypoxia; 40 µg of lysates were used for gel electrophoresis. Western blotting for HIF1α, HIF2α, TATA-binding 
protein (nuclear loading control) and α-Tubulin (whole cell/cytoplasmic loading control) was performed. A) 
Western images show a representative example of HIF1α and HIF2α hypoxic upregulation in whole cell lysates 
of MCF7 and MCF7-HER2. B) Graphs display the average densitometry expression values relative to loading 
control with standard error of the mean (SEM) represented as error bars. The level of HIF2α was found to be 
significantly different between the two cell lines (two-way ANOVA p=0.0280) with Sidak’s multiple 
comparison showing significantly higher levels in MCF7-HER2 at 48 hrs when compared to MCF7 (p=0.0138); 
no significant differences were found between cell lines for HIF1α. (n= 5 experiments for HIF1α and n=4 for 
HIF2α).C) Representative examples of HIF1α and HIF2α in nuclear and cytoplasmic lysates of MCF7 and MCF7-
HER2 cell lines. D) Expression of HIF1α in nuclear fractions (n=1), and HIF2α in nuclear (n=2) and cytoplasmic 





3.3.3 Increased hypoxic upregulation of CAIX and LDHA in MCF7-HER2 
cells 
 In addition to HIFα subunit regulation, the hypoxic upregulation of two known HIF 
target genes, carbonic anhydrase IX (CAIX) and lactate dehydrogenase A (LDHA), was 
assessed in whole cell lysates by western blotting. Once again, samples were either normoxic 
(approximately 20% oxygen) or grown in hypoxia (0.5% oxygen) for 24, 48 or 72 hrs. CAIX is 
a membrane bound version of the enzyme responsible for the conversion of H2O and CO2 to 
HCO3- and H+ ions [449-451]. CAIX is generally associated with hypoxic regions in tumours and 
considered to be predominantly HIF1 driven. It has been associated with metastasis and poor 
prognosis in breast cancer [290, 452-454], and its potential as a therapeutic target is the 
subject of ongoing research [455, 456]. LDH is a glycolytic enzyme responsible for the 
conversion of pyruvate to lactate. As with numerous glycolytic enzymes LDHA has been 
shown to be a HIF1 target gene, and thus driven by hypoxia. Overexpression is common in 
breast cancer, and is associated with poor clinical outcome and resistance to therapy [457-
460].  
In these experiments CAIX protein levels were shown to be upregulated in hypoxia 
in both cell lines, with a steady increase seen up to 72 hrs (Figure 3.5). Whilst CAIX was not 
seen in normoxia in either cell line, the absolute levels at all hypoxic time points were 
considerably (approximately 4x) higher in the MCF7-HER2 cell line. This suggests that the 
hypoxic upregulation of the protein is stronger in the context of HER2 overexpression. CAIX 
upregulation was shown to be significantly different between cell lines (p=0.0332 two-way 
ANOVA), whilst multiple comparisons demonstrated significantly higher CAIX in the MCF7-
HER2 cell line at 48 and 72 hrs when compared to MCF7 (p=0.0204 and p=0.0150 
respectively, Sidak’s multiple comparisons). LDHA upregulation was seen in response to 
hypoxia in both cell lines. Protein levels were low in normoxia but induced at 24 hrs, with 
increasing levels up to 72 hrs. However, no significant difference is seen between MCF7 and 

















Figure 3.5: Increased upregulation of HIF target genes CAIX and LDHA in hypoxic MCF7-HER2 
Western blotting analysis of MCF7-HER2 whole cell lysates collected in normoxia (20% oxygen) or hypoxia 
(0.5% oxygen). Whole cell lysates were collected at 24, 48 and 72 hours hypoxia. 40 µg of lysates were used 
for gel electrophoresis. Western blotting for CAIX, LDHA and α-Tubulin (loading control) was performed. A) 
Representative example of western blotting results. B) Graphs display the average densitometry expression 
values relative to tubulin, with standard error of the mean (SEM) represented as error bars from n= 5 
experiments (HIF2α n=4). Two-way ANOVA with Sidak’s multiple comparison test was used to compare 
expression between cell lines. CAIX expression was significantly higher in MCF7-HER2 (p=0.0332) with 
































3.3.4 HER2-mediated CAIX and LDHA upregulation in hypoxia can be 
reduced by HER2 inhibition with lapatinib 
  To assess the relationship between HER2 overexpression and increased 
upregulation of HIF targets in hypoxia, the inhibition of growth factor signalling by lapatinib 
was investigated. Lapatinib is a small molecular tyrosine kinase inhibitor which blocks the 
kinase activity of HER1 (EGFR) and HER2 by occupying the ATP-binding pockets of these 
receptors. This prevents receptor transphosphorylation and thereby inhibits the initiation of 
the downstream signalling cascade [122]. MCF7-HER2 cells were treated with 1 µM lapatinib 
or DMSO vehicle only, 30 minutes prior to hypoxia treatment. Whole cell lysates were 
collected at 24 hr time points and probed for HIF1α, HIF2α, CAIX and LDHA. Whilst western 
blotting with an antibody specific for phosphorylated tyrosine residues 1221 and 1222 on the 
HER2 receptor demonstrated successful inhibition of HER2 receptor activation at all time-
points (Figure 3.6), effects on the upregulation of HIFα subunits and HIF target proteins were 
minimal, and no statistically significant effects in this set of experiments were shown. Hypoxic 
increases in HIF1α and HIF2α appeared mainly unperturbed, however results suggest that 
any effect from lapatinib on HIF1α may actually increase its upregulation rather than inhibit 
it. Lapatinib inhibited the upregulation of LDHA, with reduced levels at 48 and 72 hrs hypoxia 
(Figure 3.6), CAIX levels were also reduced to a small degree after treatment with lapatinib 
at 24, 48 and 72 hrs, however this effect was not statistically significant.  
 Multicellular spheroids for both MCF7 and MCF7-HER2 cell lines were grown for 1-2 
weeks and fixed in formalin, before being paraffin embedded, sectioned and stained for 
various targets through immunohistochemistry. The expression of HIF1α and HIF2α, as well 
as HIF targets were assessed and compared between cell lines (Figure 3.8A-C). This was done 
alongside staining with hypoxyprobe-1 (Pimonidazole HCl) [461] (see materials and 
methods), which was able to show the areas of the spheroids that had been exposed to low 




Figure 3.6:  The effect of HER2 inhibition with lapatinib on the hypoxic upregulation of HIFα and HIF 
target genes 
A) Representative examples of western blots from the graphs shown above. C) Western blots of HER2 
and phospho-HER2 (Tyr1221/1222) were performed to demonstrate the effective inhibition of HER2 
phosphorylation by lapatinib. B) Protein expression values relative to loading control (α-tubulin) from 
western blotting of whole cell collected in normoxia or after, 24, 48 or 72 hrs in hypoxia (0.5% oxygen). 
Cells were pre-treated with 1 μM of lapatinib or equivalent vehicle (0.01% DMSO) 30 minutes prior to 
the start of hypoxic treatment. Normoxic samples were treated with lapatinib or DMSO for 72 hrs prior 





   
Scoring of spheroid staining was done in two different ways; for nuclear staining the 
percentage of nuclei positively stained in each spheroid was calculated, and for cytoplasmic, 
membranous or mixed staining patterns, scores between 0 and 6 were assigned based on 
the area and intensity of the stain. The scoring system first assigned a score of 0-6 for the 
area of staining coverage (0 = 0-10% staining, 1= 10-25%, 2 = 25-40%, 3 = 40-55%, 4= 55-70%, 
5= 70-85% and 6 = 85-100%) and a score of 0-3 for staining intensity, with 0 representing no 
visible staining, 1 being faint staining and 3 being intense staining (this was scored 
independently of the area covered). A final score was established by dividing the area score 
by 2 and adding it to the intensity score. Scoring was performed using only the viable regions 
of the spheroids and excluding necrotic central areas which were clearly distinguished by a 
loss of cellularity. The results of this scoring procedure for each target assessed can be seen 
in Table 3.1.   
Staining for HIF1α was seen as nuclear staining in occasional cells, with surprisingly 
few stained nuclei in either cell line (<10% in all cases) (Figure 3.8A). Staining was not 
particularly consistent with hypoxyprobe-1 staining, generally occurring most frequently in 
the central viable region of spheroids rather than directly adjacent to necrotic regions. No 
discernible differences between cell lines were noted. HIF2α also showed no concordance 
with hypoxyprobe-1 or any tendency towards staining more centrally within spheroids, 
where oxygen concentrations would be expected to be lower. Instead, HIF2α staining was 
largely ubiquitous in terms of cytoplasmic staining, with randomly distributed positively 
stained nuclei. Staining of HIF2α was more intense in MCF7-HER2 spheroids when compared 
to wild-type MCF7 spheroids, with a median score of 6 for MCF7-HER2 compared to 2 for 
MCF7. This difference was most obvious in the cytoplasmic compartment but also included 
more frequently stained nuclei in the MCF7-HER2 spheroids. In general, HIFα staining 
patterns seen in these two cell lines in 3D are in agreement with western blotting results. 
HER2-driven differences are seen in HIF2α but not HIF1α. HIF1α is seen as solely nuclear 
staining, whereas HIF2α is visibly upregulated in both nuclear and cytoplasmic compartments 
(Figure 3.8A). 
Known HIF targets CAIX, LDHA, VEGF [462] and CD44 [463, 464] were also stained in 
MCF7 and MCF7-HER2 spheroids (Figure 8 B/C). All four of these proteins were more strongly 
stained in MCF7-HER2 spheroids when compared to MCF7. CAIX expression was very low in 
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MCF7 spheroids with essentially no staining being visible. This was expected as MCF7 cells 
have previously been shown to be low level expressers of CAIX even under hypoxia [456]. On 
the other hand, MCF7-HER2 showed an increased expression of CAIX with clear membranous 
staining and a median score of 3 (Figure 3.8B). Areas of staining seemed to develop 
preferentially on the outside edge of the spheroid as opposed to the hypoxic core and did 
not appear to correlate to hypoxyprobe-1 staining. LDHA expression was seen fairly 
ubiquitously in MCF7 cells but was only faintly expressed. In MCF7-HER2, LDHA expression 
was more highly expressed with higher intensity and more nuclear staining. LDHA was scored 
with a median value of 4.5 for MCF7 and 6 for MCF7-HER2 (Figure 3.8B). VEGF showed light 
to moderate cytoplasmic staining apparent across the entire spheroid with the exception of 
the peri-necrotic region where staining was absent, scoring 3.5 as a median value. MCF7-
HER2 showed more intense VEGF staining across the entire spheroid including the peri-
necrotic region with a median score of 5.75 (Figure 3.8C). CD44 was the only target tested 
that appeared to correlate with the hypoxic and peri-necrotic regions of the spheroids, 
although this was only seen in MCF7-HER2. Expression of CD44 in MCF7 was low, in some 
cases undetectable, and when present, of low intensity and including small areas of just a 
few cells (scoring 1.5 as a median score). MCF7-HER2 however showed intense staining, 
which was not ubiquitous but found primarily in peri-necrotic regions, with less staining 
observed on the outside of the spheroid (median score of 4.5) (Figure 3.8C). This correlated 
well with hypoxyprobe-1 expression in these spheroids.  
 Together IHC in 3D multicellular spheroids demonstrated that the overexpression of 
HER2 in MCF7-HER2 cells causes the increased expression of HIF targets. This overexpression 
was not limited to the peri-necrotic regions of the spheroids and most often showed no 






Figure 3.7: Multicellular spheroid structure and hypoxic regions 
 
A) Diagrammatic representation of the structure of multicellular spheroids. Reduced perfusion 
within the tightly packed spheroid drives the formation of gradients in oxygen, pH and metabolites, 
resulting in a hypoxic/acidic microenvironment within the spheroid mass. This leads to the 
formation of a necrotic core (red) and less well oxygenated regions surrounding the necrotic core 
(the peri-necrotic region(light blue)), with cells on the outside of the spheroid having unimpeded 
perfusion by the surrounding media (dark blue). B) Multicellular spheroids for MCF7 and MCF7-
HER2 cell lines were stained for hypoxyprobe-1. Hypoxyprobe-1 stains any cells which have been 







Figure 3.8a: HIF and HIF target gene expression in MCF7 and MCF7-HER2 3D multicellular spheroids 
Multicellular spheroids were grown for 1-2 weeks before being formalin fixed and paraffin embedded. Fixed 
tissue sections were stained by immunohistochemistry with antibodies towards: HIF1α and HIF2α. LHS: The 
staining pattern of representative spheroids is shown for each antibody in each cell line, with magnified version 
inset. RHS: Quantification of IHC scoring is shown for each protein. Bars represent mean scores, with error bars 
representing the SEM. Scores were compared between the two cell lines using a T-test with significance shown 




Figure 3.8b: HIF and HIF target gene expression in MCF7 and MCF7-HER2 3D multicellular spheroids 
Similar analysis to Figure 3.8a with three additional target proteins: CAIX and LDHA. LHS: the staining pattern of 
representative spheroids is shown for each antibody in each cell line, with magnified version inset. RHS: 
quantification of IHC scoring is shown for each protein. Bars represent mean scores, with error bars representing 
the SEM. Scores were compared between the two cell lines using a T-test with significance shown for each 



























Figure 3.8c: HIF and HIF target gene expression in MCF7 and MCF7-HER2 3D multicellular spheroids 
Similar analysis to Figure 3.8a/b with three additional target proteins: VEGF and CD44. LHS: the staining pattern 
of representative spheroids is shown for each antibody in each cell line, with magnified version inset. RHS: 
quantification of IHC scoring is shown for each protein. Bars represent mean scores, with error bars representing 
the SEM. Scores were compared between the two cell lines using a T-test with significance shown for each 









Table 3.1: Spheroid IHC Scoring  
HIF1α  
Percentage of stained nuclei MCF7 MCF7-HER2 P-value (T-test) 
Mean % 1.8 3.2 
P=0.2701 Range of % 0-8.7% 1.6-6.9% 
Number of Spheroids 10 7 
Combined Area/Intensity Scores 
(out of 6) 
MCF7 MCF7-HER2  
HIF2α  
Mean Score 3 5.4 
P=0.0002 
Median Score 2 6 
Range 1.5-5.5 3.5-6 
Number of Spheroids 17 9 
LDHA  
Mean Score 4.4 5.9 
P<0.0001 
Median Score 4.5 6 
Range 3.5-5 5.5-6 
Number of Spheroids 17 9 
CAIX  
Mean Score 0 3.1 
P<0.0001 
Median Score 0 3 
Range 0 1.5-4.5 
Number of Spheroids 11 7 
CD44  
Mean Score 1.1 4.4 
P<0.0001 
Median Score 1.5 4.5 
Range 0-1.5 4-4.5 
Number of Spheroids 17 10 
VEGF  
Mean Score 3.6 5.5 
P<0.0001 
Median Score 3.5 5.75 
Range 1.5-5 4-6 
Number of Spheroids 17 10 
Table 3.1: The results of scoring IHC in multicellular spheroids 
Scoring of 3D spheroids for each target and each cell line is shown. Scoring for HIF1α was given as 
a percentage of stained nuclei from a representative experiment. Other targets were scored out of 
6 based on area of staining and intensity. Mean, median and range of scores are shown from one 





 Previous research has shown a relationship between growth factor receptor 
signalling and HIF1α expression in normoxia. HER2 overexpression has been demonstrated 
to be sufficient for the upregulation of HIF1α in normoxia in mouse 3T3 cells [220], and this 
has been shown to increase the normoxic expression of the hypoxia response gene VEGF 
[421]. In breast cancer cell lines, treatment with the HER3 ligand neuregulin-1β increased 
normoxic HIF1α expression in MCF7 cells, and an increase in HER2 expression, caused by 
either long-term letrozole resistance or transfection of HER2 into MCF7 cells, has also been 
shown capable of increasing HIF1α levels [424]. In this way HER signalling can increase the 
levels and activity of HIF1α despite its canonical regulatory mechanisms being dependent on 
low-oxygen conditions. This novel mechanism demonstrates an important interplay between 
growth factor signalling and HIF activation, which is known to be a transcription factor for 
numerous genes involved in breast cancer progression. Despite this, it is unknown how 
growth factor signalling modifies HIF regulation in hypoxic conditions. The aim of this chapter 
was to assess how growth factor receptor expression affects HIFα upregulation in response 
to hypoxia and if changes were evident, to ask whether the upregulation of HIF target genes 
was also affected. 
An initial assessment of hypoxic HIFα protein upregulation across a small panel of 
breast cancer cell lines demonstrated a high level of variability. The panel showed little or no 
concurrence between HER receptor expression profiles and the hypoxic induction of HIF1α 
or HIF2α. This result demonstrated that a comparison of HIFα regulation in the presence or 
absence of growth factor receptors would not be feasible through the use of a varied cell 
panel because the numerous differences in the biology of these cells preclude a simple 
comparison of the hypoxic stabilisation of HIFα subunits. To address the question more 
directly, the MCF7 and MCF7-HER2 isogenic cell lines were used as a model for HER2 
overexpression. With this cell line model we were able to demonstrate that HER2 
overexpression can drive an increase in the hypoxic upregulation of HIF2α but not HIF1α and 
drive the expression of known HIF targets in 2D and 3D models.    
 Firstly, MCF7 and MCF7-HER2 were compared by SRB and wound healing assays 
under normoxic and hypoxic conditions to determine whether the overexpression of HER2 
provided an advantage in terms of growth rate or cell motility in hypoxia. In SRB assays, MCF7 
and MCF7-HER2 growth over 7 days was comparable. Growth rates were similar in normoxia 
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and were reduced to a similar extent in hypoxia. This included chronically hypoxic cells, which 
had been adapted to hypoxic growth for 10 weeks prior to the experiment. This work was 
unable to demonstrate a growth advantage of HER2 overexpression at this oxygen 
concentration (0.5%) and suggests that HER2 offers no protection from the deleterious 
effects of hypoxia on proliferation. With this in mind it was decided that investigation of cell 
motility might be a better way of phenotypically assessing cellular adaptation to hypoxia in 
the context of HER2 overexpression.  
 Increased cell motility is considered an accepted outcome of hypoxia in breast 
cancer. This has been demonstrated through the correlation of tumour hypoxia with 
increased invasion and metastasis of breast cancers [315, 445, 446] and investigated in terms 
of HIF1 signalling and the roles of known HIF1 targets [295, 455, 465]. We used our MCF7 
isogenic cell line model to investigate whether the overexpression of HER2 affected cellular 
motility in hypoxia using wound healing assays. Previous research has demonstrated an 
increased wound healing capacity in MCF7 cells overexpressing the HER2 receptor when 
compared to wild-type MCF7 cells in normoxia [466], but the effect of HER2 expression on 
hypoxic cell behaviour is unknown. This reported effect was obtained under different growth 
conditions, and whilst no significant difference between normoxic MCF7 and MCF7-HER2 
cells was seen in the experiments conducted in our lab, average wound healing in MCF7-
HER2 was consistently faster than MCF7. It is clear that the capacity of these cell lines for 
wound healing differs significantly in hypoxia (0.5% O2). Wound healing was significantly 
reduced in hypoxia compared to normoxia in the MCF7 cell line only, and was significantly 
greater in MCF7-HER2 than in MCF7 in hypoxia. This suggests that HER2 overexpression can 
drive increased motility in response to hypoxia, an effect that could play a significant role in 
the increased aggressiveness and invasion seen in HER2-positive solid tumours, where 
tumour hypoxia is often a factor. These wound healing assays were performed in low serum 
conditions to minimise the contribution of cellular proliferation to wound closure. However, 
the time required to see wound closure in MCF7 and MCF7-HER2 meant that meaningful 
comparisons could only be made 48 hrs after the removal of the wound insert, at which point 
cells are given ample time to divide, therefore cellular proliferation and motility are difficult 
to distinguish. Despite this, the earlier finding that these cell lines exhibit little difference in 
cell growth in response to hypoxia suggests that the difference shown in wound healing 
assays are due to increased motility not proliferation. An additional observation in these 
wound healing assays was the phenotypic differences in cellular motility between these two 
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cell lines. Whilst MCF7 covered the wound predominantly as invasive sheets, MCF7-HER2 
showed more single cell invasion and cellular characteristics which matched an EMT 
phenotype. This was seen in normoxia and hypoxia, so is not a direct result of hypoxia, but 
represents a HER2-driven change which may have consequences for the molecular response 
to hypoxia, discussed in Chapter 4.  The result of these wound healing assays provides initial 
evidence suggesting that HER2 overexpression in this model may have interesting effects on 
the cellular response to hypoxia and supports the more detailed investigation into the 
molecular mechanisms and consequences of HER2-driven hypoxia signalling. 
 Subsequent experiments on whole cell, nuclear and cytoplasmic cellular lysates 
collected from MCF7 and MCF7-HER2 were conducted to assess HIF1α and HIF2α 
upregulation by hypoxia in the context of HER2 overexpression. A comparison of these cell 
lines showed that HER2 expression had no discernible effect on hypoxic upregulation of 
HIF1α, however the differences in HIF2α were clear. HIF2α was induced to significantly higher 
levels in MCF7-HER2 when compared to MCF7, and higher hypoxic levels were also seen in 
nuclear and cytoplasmic fractionated lysates when compared to MCF7 cells. In whole cell 
lysates HIF2α levels also appeared to be higher in normoxia in the MCF7-HER2 cell line than 
in wild-type MCF7. Whilst this level was low compared to hypoxic upregulation of the protein, 
it poses the question of whether a larger pool of normoxic HIF2α contributes to the increased 
hypoxic upregulation. This question, as well as the mechanisms behind increased normoxic 
HIF2α will be investigated and discussed in Chapter 5. In terms of hypoxic upregulation, these 
data demonstrate that HER2 overexpression is able to enhance the cellular upregulation of 
HIFs in response to hypoxia, and suggests HIF2α is the major HIF affected. These findings are 
novel in two respects; firstly, it shows that HER2 overexpression is able to upregulate the 
normoxic expression of HIF2α in breast cancer, and secondly that in this context the hypoxic 
upregulation of HIF2α is increased. Whilst previous work has demonstrated an interplay 
between HER2/HER3 signalling and HIF1α regulation in normoxia, the effects of HER2 on 
HIF2α were not investigated in these studies and so remain unknown in breast cancer. A 
relationship between HIF2α levels and EGFR activity in both normoxia and hypoxia has 
previously been demonstrated in the context of tamoxifen and fulvestrant resistant MCF7 
cell lines [426], this supports the notion that growth factor signalling has a meaningful impact 
on not just HIF1α but also HIF2α levels in breast cancer cell lines. However, the novel finding 
that this can also occur in the context of HER2 overexpression suggests that the ability of HER 
family receptors to drive HIF2α may be robust and important in the context of HER2-positive 
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breast cancers. As described in Figure 3.1, cellular context is extremely important in 
discerning the relative upregulation of HIF1α and HIF2α in response to hypoxia. Thus, the 
relative contribution of HIF1α and HIF2α to growth factor-modulated hypoxic responses in 
breast cancer is also likely to be highly dependent on intrinsic cellular factors. The use of this 
MCF7 model of HER2 overexpression demonstrates the concept that HIFα regulation by 
hypoxia is prone to alteration by growth factor signalling, providing clear evidence for a role 
of HER2 signalling outside of the normoxic regulation of HIFs. In addition, this work provides 
evidence that in the context of a commonly used model of luminal breast cancer (MCF7), 
HIF2α may be a contributory factor to this effect, suggesting that the long accepted 
differences between HIF1α and HIF2α are relevant in the context of growth factor-hypoxia 
interplay and that further investigation into the role of HIF2α as a driver for the hypoxic 
response in breast cancer is warranted, especially in the context of HER2-positive breast 
cancer. 
Whilst whole cell levels of HIF1α appeared unaffected by HER2 overexpression in 
these experiments, subtle changes were seen in nuclear lysates.  Specifically, nuclear HIF1α 
levels were higher in MCF7-HER2 when compared to wild-type MCF7 at 72 hrs only. This 
increase suggests that whilst the nuclear upregulation of HIF1α in these cell lines was 
comparable, the downregulation of HIF1α after 48 hrs is inhibited. As this was seen in the 
nuclear compartment only, one possibility is that the binding of HIF1α with specific nuclear 
cofactors may be increasing its longevity, and potentially its activity, in the nucleus. 
Considering the extent of cofactors involved in HIF transcriptional activity and the specificity 
of cofactors for different HIF proteins [181, 467, 468], this raises the question of whether 
HER2 overexpression might modulate HIF1 levels and transcriptional activity in the nucleus 
by altering the expression of relevant cofactors. Considering the non-redundancy of HIF1 and 
HIF2, and the increasingly recognised role of HIF2α in cancer pathogenesis, this provides an 
example of how growth factor receptor expression may modulate both HIF1α and HIF2α 
levels, but in different ways.  
 The downstream consequences of increased HIF upregulation and hypoxic response 
were next assessed in terms of HIF target genes LDHA and CAIX. These are both considered 
HIF1-specific target genes [469, 470] and were selected because they are well-researched 
and considered important drivers of pathology in breast and other cancers [454, 458, 459]. 
As such, it was considered important to investigate whether HER2 modulation of hypoxic 
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response had an effect on such canonical hypoxia response genes. The investigation of a 
more varied set of HIF1 and HIF2 target genes to assess the relative contribution of both to 
HER2-driven hypoxic response has also been carried out as part of this research and is 
described in Chapter 4. The purpose of this set of experiments was to demonstrate in a more 
general sense the role of HER2 in modifying hypoxic gene expression. CAIX was chosen as a 
canonical hypoxia response gene, which has been shown to be inducible by hypoxia in a 
number of breast cancer cell lines. CAIX has been described previously as a driver of tumour 
aggressiveness and metastasis and has been shown to be a potential therapeutic target in 
breast cancer [455]. In addition, the expression of CAIX in response to hypoxia has been 
shown to be relatively low in MCF7 cells compared to other breast cancer cell lines, providing 
a model where increased induction may be more readily detectable [456]. LDHA is another 
canonical hypoxia response gene with important roles in tumorigenesis, being commonly 
upregulated in breast malignancies and associated with poor clinical outcome [459]. These 
data demonstrated no change in the normoxic levels of either of these proteins; however a 
significant increase in hypoxic CAIX upregulation in the HER2 overexpressing cell line was 
detected.  These experiments were able to show the increased expression of known hypoxia 
response genes in the context of HER2-overexpression. Once again this forms part of the 
novel finding that HER2 expression exerts important effects on the cellular response to 
hypoxia, not just increased HIF signalling in normoxia. An important unanswered question is 
whether the effects of HER2 expression on HIFα regulation directly drives the altered 
expression of these HIF target genes or whether there are other mechanisms involved. HER2-
mediated changes in HIFα were largely limited to HIF2α, whilst HIF1α changes were not seen 
before the 72 hrs. With the increased upregulation of CAIX present at all time points tested 
from 24 hrs onwards, this suggests that either increases in HIF2α are responsible for the 
increased expression of the gene, or that HIF1 transcriptional activity is increased by the 
presence of HER2 in the absence of any visible increase in HIF1α level; for example this may 
occur as a result of increased or altered HIF1 cofactor expression in the context of HER2 
overexpression leading to increased transcriptional activity. This offers a plausible 
mechanism by which the increased CAIX and increased nuclear stability of HIF1α in the 
context of HER2 overexpression may be explained. Despite the literature supporting CAIX as 
a HIF1 specific gene [470], a role for HIF2α in driving CAIX in MCF7-HER2 cannot be ruled out. 
HIF1 and HIF2 transcription factors are highly homologous and have both been shown to bind 
the same HRE consensus sequence, with a large overlap in target genes [239]. Therefore, 
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alongside the demonstration that HIF2α upregulation in hypoxia is increased by HER2 
overexpression in MCF7, it is feasible that increased HIF2 abundance may result in more 
promiscuous activity and target gene selection. With this in mind it should be acknowledged 
that research into HIF1 versus HIF2 target specificity in breast cancer has largely been 
conducted in ER+, HER2- breast cancer models such as MCF7 [239, 240, 243]. With no work 
having been done to discern how target gene selection may vary in the context of HER2 
overexpression, the assignment of HIF target genes as HIF1 or HIF2–specific in the literature 
may not stringently apply. Naturally, further work is required to determine whether the 
overexpression of such genes can be driven by HIF2 or whether this is caused by a HER2-
mediated increase in HIF1 transcriptional activity.  
 The dual tyrosine kinase inhibitor lapatinib was used to assess the role of growth 
factor signalling in driving the hypoxic response in terms of HIF1α, HIF2α, CAIX and LDHA 
protein levels. The preliminary data work suggests that LDHA and CAIX upregulation may be 
inhibited (at least partially) by lapatinib. In order to achieve better inhibitory effects in these 
experiments, longer term inhibition of HER2 may be required. Whilst 1 μM lapatinib was 
shown to reduce p-HER2 (tyr1221/1222) for the duration of the experiment, the inhibition of 
p-HER2 just 30 minutes prior to hypoxic exposure might not be sufficient time for 
transcriptional or secondary effects of HER2 inhibition to occur. It would be interesting to 
assess whether longer term treatment with lapatinib is able to reduce CAIX and LDHA 
upregulation to a greater extent, and also assess whether the hypoxic upregulation of HIF2α 
could be reversed given time for transcriptional effects to come in to play. Further work 
considering the relationship between HIF2α and HER2 expression is conducted in chapters 5 
and 7, providing more evidence supporting the role of HER2 overexpression in the hypoxic 
effects demonstrated in this chapter.  
 The majority of work conducted in this chapter was performed in cell lines cultured 
in 2D. Two-dimensional cell culture is a useful model in the investigation of cell behaviour 
and cell signalling as the format is highly amenable to experimental manipulation and 
imaging. The limitation of 2D culture is that it does not accurately represent the behaviour 
of cancer cells in the tumour microenvironment. 3D multicellular spheroids provide a cell line 
model which better represents the cellular environment of solid tumours. These spheroids 
are formed from tightly packed cells, more closely resembling the high level of cell-cell 
adhesion seen in healthy and cancerous tissue. This close adhesion leads to limited diffusion 
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of important nutrients and gases, resulting in a necrotic region surrounded by a hypoxic 
region and increasing oxygen concentration in moving outwards from the necrotic core. This 
diffusion limitation also leads to additional gradients of carbon dioxide and metabolites, as 
well as reduced pH in the poorly perfused inner regions. In this way 3D multicellular spheroids 
provide a model for the poor perfusion and oxygen gradient seen in solid tumours with the 
benefit of additional microenvironmental stresses, thereby providing a more realistic model 
of solid tumours. The work in this chapter aimed to use these models to confirm differences 
in HIFα and HIF target gene expression seen in our isogenic cell line model of HER2 
overexpression. This has been used to confirm the increased expression of HIF2α and HIF 
targets, whilst providing spatial expression patterns, allowing a comparison of expression 
levels over hypoxic and normoxic spheroid regions, which can be displayed through staining 
with hypoxyprobe-1.  
 The IHC analysis of MCF7 and MCF7-HER2 spheroids supported the findings from 
western blotting of 2D lysates. HIF2α (but not HIF1α) was more highly expressed in MCF7-
HER2 when compared to wild-type MCF7, and the expression of CAIX and LDHA was also 
increased in the HER2-positive cell line. In addition, the assessment of two additional targets, 
VEGF and CD44, provided additional evidence that the hypoxic response is enhanced by 
MCF7-HER2. VEGF is a canonical hypoxia response gene which plays an important role in 
driving angiogenesis and has been shown to be preferentially activated by HIF2α over HIF1α 
[178, 259, 471-473]. CD44 is a breast cancer surface antigen associated with stem cell 
characteristics and upregulated by hypoxia. HIF2α is recognised as an upregulator of genes 
which drive stem cell characteristics [464, 471, 474], and thus the expression of CD44 is an 
interesting target in the context of increased HIF2α upregulation. The upregulation of CD44 
by hypoxia has been previously described [475, 476], as has the fact that it can be directly 
driven by HIF1α in triple-negative breast cancer [476]. It has also been demonstrated that 
the intracellular domain of CD44 can increase stability and activity of HIF2α in glioma cells 
[475]. Additionally, if CD44 expression is increased in the context of high HER2, this provides 
a potential mechanism by which HIF2α expression may be increased in HER2 overexpressing 
breast cancer cells. In this study the expression of both VEGF and CD44 was considerably 
higher in the MCF7-HER2 cell line, implicating HER2-HIF interplay as a mechanism for the 
upregulation of these genes. Surprisingly, the majority of these HIF target genes showed little 
concordance with hypoxyprobe-1 expression. This may be due to a disparity between the 
level of hypoxia required for hypoxyprobe-1 to form its detectable substrate and the level 
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required for the upregulation of hypoxia-inducible gene transcription. In the context of the 
multicellular spheroid, tight packing of cells with a large amount of cell-cell adhesion might 
limit oxygen perfusion enough to permit the expression of HIF-driven genes even when close 
to the extremities of the spheroid. Alternatively, HER2 may promote the expression of these 
genes even in normoxia in the context of tightly packed multicellular spheroids. Either way, 
the higher expression of such genes in HER2-overexpressing cells in this 3D model 
demonstrate that HER2-driven increases in hypoxic protein expression can still occur in a 
more structurally accurate representation of the tumour microenvironment. 
 In overview this chapter has approached the question of whether growth factor 
receptor expression is able to modulate the cellular response to hypoxic conditions in terms 
of HIFα upregulation and HIF target expression.  A HER2-mediated increase in HIF2α and HIF 
targets CAIX and LDHA was demonstrated, and the increased expression of HIF target genes 
was shown in a 3D spheroid model system. This provides evidence that HER2 may act through 
direct effects on HIF2α in breast cancer and may be responsible for a generalised increase in 
hypoxic response in terms of HIF target gene expression. As mentioned, the closer 
investigation of the consequences for HER2 overexpression for the cellular response to 
hypoxia will be investigated in Chapter 4, whilst the mechanisms underlying the increased 
expression of HIF2α will be further investigated in Chapter 5.  
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Chapter 4: HER2 overexpression in MCF7 cells 




The MCF7 and MCF7-HER2 cell lines provide a useful comparative tool for 
investigating the effect of HER2 overexpression on the hypoxic response. This model was 
next used to investigate the effect of HER2 signalling on the transcriptional response to 
hypoxia using microarray analysis. Global gene expression was assessed in these two cell lines 
in normoxia, acute hypoxia and chronic hypoxia, and microarray analysis was performed 
using the Illumina HT12v4 beadchip array. This chip includes over 47,000 probes which 
provide genome-wide coverage of transcript expression. Using this technology, a detailed 
analysis was performed to assess how gene transcription is regulated in response to hypoxia 
and how this response varies in the context of HER2 overexpression. Investigating the global 
transcriptional response allows important pathways to be identified in terms of their 
transcript levels in normoxia and hypoxia in both cell lines. The genes and pathways involved 
in the HER2-driven hypoxic response were investigated in terms of both a generalised 
response, as well as a response of HIF1 and HIF2 target genes, to understand how these 
factors play a role in the exacerbated response to hypoxia. 
 
4.2 A comparison of hypoxia metagenes in MCF7 and MF7-
HER2 cells 
Hypoxia is a well-established indicator of poor prognosis in a number of solid tumour 
types [477]. As such, past research has sought to better identify where tumour hypoxia may 
be present so that more accurate prognoses may be made [478, 479]. One such method has 
been the development of hypoxia metagenes: a set of genes whose combined expression 
profile can be used to indicate when hypoxia-driven gene expression changes have occurred.  
In this section I used three published hypoxia metagenes [480-482] to assess the relative 
expression of hypoxia response in MCF7 and MCF7-HER2. To do this, RNA was extracted from 
MCF7 and MCF7-HER2 cells grown under normoxic conditions (20% O2), after 24 hr in hypoxia 
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(0.5% O2), or after 10 weeks continual growth in hypoxia. Samples were collected in triplicate 
and hybridized to the Illumina beadchip array to provide global gene expression data for each 
condition (full method can be found in Section 2.2.13), this data could then be used to 
compare the expression of hypoxic gene signatures. All three metagenes had been designed 
to assess hypoxic gene expression changes, but each had been determined through different 
methods. Therefore, the combined analysis of each of these metagenes in our microarray 
data provides a more robust assessment of hypoxic response in MCF7 and MCF7-HER2, so 
that the role of HER2 in this response can be broadly established. 
The three metagenes used in this analysis have all been previously described [480, 
481, 483]. These include a 99 gene signature created by Winter et al. (2007)[481], of which 
94 genes were available in our microarray dataset, a 51 gene signature from Buffa et al. 
(2010)[480] of which 50 genes are available in our dataset, and a complete 15 gene signature 
from Toustrup et al. (2011)[482, 483]. A full list of genes can be found in Appendix 1.1. Other 
hypoxic gene expression signatures are available ([484-487]), but these three were selected 
as they represent a varied set, with little overlap in the genes contained within them (Figure 
4.1). Additionally, due to the varied approaches taken in their design, each provided its own 
benefits for this analysis. The Winter et al. [481] metagene was selected as it has been 
demonstrated as a prognostic indicator in breast cancer and contains a relatively large 
number of genes which cluster with well-known hypoxic response genes. The metagene from 
Buffa et al. [480] was designed to be broadly applicable to multiple cancer types and so was 
chosen here for its robustness. It was developed in silico through co-expression networks of 
hypoxia-regulated genes in a combined analysis of 8 datasets, including 5 from breast cancer 
patients. The signature from Toustrup et al. [483] is a small (15 gene) signature; these genes 
were determined to be the optimum set able to differentiate tumours based on the oxygen 
level read by an electrode. The inclusion of this signature is important as it was verified by 
oxygen readings as opposed to the expression with expected hypoxia-response genes, which 
can be highly varied and context dependent. Additionally, the Toustrup signature considers 
the issue that a number of hypoxia response genes are also pH-dependent in their 
expression. By starting with predetermined hypoxia-responsive but pH-independent genes, 
their signature is potentially able to detect hypoxia more specifically. Whilst the Toustrup 
signature provides a highly specific hypoxia detecting gene set, the Winter and Buffa sets are 




Gene expression data from normoxic, acute hypoxic (24 hr) and chronic hypoxic (>10 
week) MCF7 and MCF7-HER2 cells from our HT12v4 beadchip array was used to compare the 
upregulation of hypoxia metagenes in response to hypoxia. Log2 expression values for 
hypoxic metagenes were mean centred and subject to hierarchical clustering by Pearson 
correlation. This was performed individually for the three metagenes. This demonstrated an 
increased hypoxic response in MCF7-HER2 when compared to wild-type MCF7 cells in both 
acute and chronic hypoxia (Figure 4.1). Clusters could be broadly placed into three 
categories, and these are colour-coded in Figure 4.1 (Genes in each cluster are indicated in 
Appendix 2.1). Red clusters represent genes which are increased in hypoxia in both cell lines. 
These clusters were present in all three metagenes, making up the entirety of the 15-gene 
signature. Importantly, red clusters in each gene set showed a greater change in expression 
in response to hypoxia in MCF7-HER2 when compared to wild-type MCF7, despite these cell 
lines having comparable levels in normoxia. Blue clusters were present in the two larger 
metagenes, though these represented a smaller number of genes than the red cluster in each 
set. Blue clustered genes were generally downregulated by hypoxia in MCF7, but 
interestingly were expressed at constitutively low levels in MCF7-HER2. Finally, an additional 
cluster (labelled in green) was seen in the largest dataset (Winter et al.). Expression of these 
genes did not change markedly in response to hypoxia in these samples but were 
constitutively more highly expressed in MCF7-HER2.  
A statistical comparison of gene expression within the red clusters was carried out 
for each metagene. A one-way ANOVA was used to compare the mean gene expression 
values of each treatment category. This was able to confirm a stronger upregulation of these 
gene clusters in MCF7-HER2 when compared to wild-type MCF7. A significant upregulation 
of genes in both acute and chronic hypoxia was seen for both MCF7 (acute: p<0.0172, 
chronic: p<0.007) and MCF7-HER2 (acute: p<0.0008, chronic: p<0.0008) cell lines in all three 
metagenes. However, whilst no significant differences were seen between normoxic MCF7 
and normoxic MCF7-HER2 gene expression, gene expression in hypoxia was significantly 
higher in the HER2 overexpressing cell line when compared to hypoxic MCF7 cells. This was 
seen in acute hypoxia for all three metagenes (Winter: p=0.0241, Buffa: p= 0.0027, Toustrup: 
p=0.004), and in the Buffa (p=0.0266) and Toustrup (p=0.0032) metagenes under chronic 
hypoxia. The online bioinformatics tool DAVID [488] was used to analyse these red clusters 
and the enrichment of gene ontology terms relating to biological processes was assessed. 




Figure 4.1: Gene expression analysis of three hypoxia metagenes to determine hypoxic response 
(Top Left) Venn diagram showing the overlap of genes between these three metagenes and the proportion of said 
genes in each group. (Main) Hierarchical cluster analysis of mean-centred log2 expression values of three 
metagenes in MCF7 and MCF7-HER2 cell lines treated in normoxia (20% O2), acute hypoxia (0.5% O2 for 24 hours), 
and chronic hypoxia (0.5% O2 for 10 weeks). The notable gene clusters are colour-coded on the right hand side. 
Green represent clusters constitutively higher in MCF7-HER2, red clusters are generally induced by hypoxia more 
strongly in MCF7-HER2 and blue clusters are downregulated by hypoxia and constitutively lower in MCF7-HER2. 







Winter et al. Buffa et al. 
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this showed a significant increase (p<0.001) in a number of GO terms pertaining to hypoxic 
response and glycolysis in all three metagenes, with glycolytic processes and glucose 
metabolism highly represented in the red clusters of the Buffa and Winter metagenes. Genes 
in these clusters include a large proportion of known glycolysis genes (ALDOA, PDK1, PFKFB3, 
PFKP, ENO1, PGK1, GPI, HK2 and PGAM1) in addition to non-glycolytic genes known to drive 
hypoxia-mediated cancer pathology (CAIX, VEGFA, LDHA, LOX, P4HA1, P4HA2 and ANGPTL4). 
Full gene lists for each cluster can be seen in Appendix 2.1. 
 
4.3 The global transcriptional response to hypoxia in MCF7 
and MCF7-HER2 shows that HER2 primes cells for hypoxia.  
 Having determined that HER2 overexpression is able to increase the hypoxic 
response in terms of recognised hypoxia signatures, the effect of HER2 overexpression on 
the complete cellular transcriptional response to hypoxia was investigated. Rank product 
analysis of our microarray data was used to identify significantly changed genes across the 
entire transcriptome in MCF7 and MCF7-HER2 after acute or chronic hypoxic exposure. Lists 
of significantly upregulated genes were created by comparing each hypoxic condition to 
normoxia in each cell line (see Appendix 2.2). In addition a list of constitutively highly 
expressed genes was created for each cell line by directly comparing normoxic gene 
expression in MCF7 with MCF7-HER2. These gene lists were compared to assess the overlap 
of the hypoxic response from these cell lines and represented as Venn diagrams (Figure 4.2). 
In this figure genes significantly more highly expressed in either MCF7 or MCF7-HER2 are 
categorised based on whether they are significantly upregulated by hypoxia in MCF7 or 
MCF7-HER2 alone, in both cell lines, or are not increased by hypoxia in either. This gives a 
visual representation of transcriptional changes in response to hypoxia in these two cell lines, 
and has been shown independently for both acute and chronic hypoxia. This initial analysis 
demonstrates a large difference in the hypoxic response of these two cell lines, both after 
acute (24 hrs) or chronic (>10 weeks) hypoxic exposure. A small proportion of the total genes 
upregulated in hypoxia were seen to increase in both cell lines; this equates to just 13.8% of 
hypoxia responsive genes in acute hypoxia and 14.2% in chronic hypoxia (yellow region Figure 
4.2). In addition, it was found that some hypoxia responsive genes were more highly 
expressed in the MCF7-HER2 cell line than the MCF7 line in normoxia. 14.4% of genes 
upregulated in acute hypoxia and 18.6% in chronic hypoxia were also constitutively higher in 
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normoxia in MCF7-HER2 (red region in Figure 4.2), with only 1.2% (acute) and 7.6% (chronic) 
being constitutively higher in normoxic wild-type MCF7 cells (blue region). This suggests that 
a number of hypoxic response genes can be driven in normoxia by HER2 overexpression, and 
this may represent a mechanism by which HER2 primes cells for hypoxia. 
 The genes involved in the increased hypoxic response of MCF7-HER2 were 
investigated in more detail with a focus on genes which were specifically upregulated by 
hypoxia in MCF7-HER2 only (HER2-specific hypoxia genes) and those which were 
constitutively more highly expressed in MCF7-HER2 in normoxia (HER2-primed hypoxia 
genes). These genes, determined from the Venn analysis in Figure 4.2, were assessed for 
important drivers of breast cancer. Genes involved in glycolysis, invasion/metastasis, 
angiogenesis, tumour microenvironment regulation, and proliferation were identified in 
acute hypoxia, with an additional upregulation of DNA repair/maintenance and treatment 
resistance genes shown in chronic hypoxia. Interestingly, a large number of genes associated 
with notch signalling were also found in acute and chronic hypoxia, suggesting this may 
promote an epithelial to mesenchymal transition phenotype in these cells under hypoxia. A 
summary of these findings, including the pathways in which they are involved, can be seen 




Figure 4.2: Venn analysis of gene lists from rank product comparison of upregulated genes in hypoxia or 
normoxia in MCF7 and MCF7-HER2 
Venn diagram showing the rank product-determined genes upregulated in hypoxia (determined as a 
comparison between normoxia and hypoxia done individually for each cell line and for acute (AH) or chronic 
(CH) hypoxia), or genes more highly expressed under normoxia in comparison to the other cell line. Venn 
diagrams are shown separately for acute hypoxia (top) and chronic hypoxia (bottom). Colour-coding is used to 




4.4 The role of HIF1 and HIF2 target genes in the HER2-driven 
hypoxic response.  
Having established that HER2 overexpression in MCF7 can intensify the hypoxic 
response and prime genes for response to hypoxia, subsequent analysis focussed on the 
behaviour of HIF1 and HIF2 target genes in these two cell lines. HIF1 and HIF2 target gene 
sets were first established by combining published gene lists of HIF target genes designated 
through chromatin immunoprecipitation experiments in MCF7 cells [239, 240]. This provided 
a list of 370 HIF1 targets and 158 HIF2 targets, with 80 of these being assigned to both HIF1 
and HIF2. This HIF gene list is used when referring to ‘HIF genes’ in the following set of 
analyses; the specific strengths and weaknesses of how this list was defined and its 
applicability to this research will be discussed later (Section 4.6). Full gene lists can be found 
in Appendix 2.3.     
 
4.4.1 HER2 overexpression in MCF7 increases HIF target gene 
expression in normoxia and in response to hypoxia 
 An overview of HIF target behaviour in these two cell lines is provided by hierarchical 
clustering of these genes across hypoxia treated MCF7 and MCF7-HER2 cell lines (Figure 4.3). 
These analyses have been divided into acute and chronic hypoxia for HIF1 specific, HIF2 
specific and dual HIF1/HIF2 target genes. Clusters of similarly behaving genes have been 
colour-coded according to the Figure legend. In both acute and chronic hypoxia the majority 
of genes fell into one of three clusters: stronger hypoxic response in MCF7-HER2 (red), 
constitutively higher in MCF7-HER2 (green) or downregulated by hypoxia/constitutively 
lower in MCF7-HER2 (blue). Genes which behaved similarly in terms of overall expression and 
hypoxic induction formed relatively small clusters (pink), with additional small clusters 
showing higher induction by hypoxia in MCF7 (black). In general, the majority of HIF target 
genes for both HIF1, HIF2 or non-specific gene sets fall into categories equivalent to those 
seen with hypoxia metagenes in Figure 4.1 (red, green and blue clusters), suggesting a similar 
HER2-mediated modification in terms of hypoxic response (red) and the normoxic expression 




Figure 4.3: Hierarchical clustering of HIF target genes in normoxic and hypoxia treated MCF7 and MCF7-
HER2 
HIF target genes were compared by hierarchical clustering analysis in hypoxia treated MCF7 and MCF7-
HER2. This was done individually for HIF1 target genes, HIF2 target genes and target genes driven by both 
HIF transcription factors, as well as for a comparison of normoxia with acute and chronic hypoxia. Colour-
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4.4.2 HIF1 and HIF2 targets form part of the HER2-specific and HER2-
primed response to hypoxia and are involved in breast cancer 
pathology 
 HIF target genes were next identified in the rank product gene lists used in Figure 
4.2. This was done to see whether general differences in the hypoxic response between MCF7 
and MCF7-HER2 included differences in the expression of HIF1 and HIF2 target genes, and to 
determine whether there were differences in the roles of HIF1 and HIF2 in this effect. Figures 
4.4 and 4.5 show this analysis for acute and chronic hypoxia respectively. The proportion of 
HIF1, HIF2 and non-specific HIF target genes has been shown in each section of the Venn 
diagrams used in Figure 4.2. In addition, the number of HIF genes is shown as a percentage 
of the total number in each section. The proportion of HIF target genes in the HER2-mediated 
response to hypoxia increased. This involved a higher number of both HIF1 and HIF2 targets 
being increased by hypoxia in MCF7-HER2 only (HER2-specific response), as well as a greater 
proportion of HIF target genes constitutively expressed in MCF7-HER2 when compared to 
wild-type MCF7. Importantly, this includes an increase in constitutively overexpressed genes 
shown to respond to hypoxia (HER2-primed genes). Once again, these effects were seen for 
both acute and chronic hypoxia.  
  Within these HER2-modified HIF target genes a number of disease drivers were 
found in both HER2-specific and the HER2-primed hypoxic response, supporting the 
suggestion that HER2-overexpression may drive cancer progression in the context of tumour 
hypoxia. The most interesting HIF target genes from this analysis are shown in Figures 4.6 
(acute hypoxia) and 4.7 (chronic hypoxia) and full gene lists can be found in Appendix 2.2. In 
accordance with hypoxia metagenes in Figure 4.1, we saw a large number of glycolytic genes 
which behaved as either HER2-specific responders or were primed for hypoxic response in 
the context of acute and chronic hypoxia (GLUT1, ALDOA, ALDOC, ENO1, ENO2 etc.). In 
addition, a number of genes which facilitate cell survival and cancer progression in hypoxia 
were noted; these included microenvironmental regulators (CAIX, PDGFB, PXDN), cell 






























Figure 4.4: Analysis of HIF gene representation in Venn analysis of genes induced by acute hypoxia 
Mole and Schödel HIF gene sets were used to determine the representation of HIF target genes in the Venn analysis 
from Figure 4.2. (Top) A square representation of the Venn diagram from Figure 4.2. Pie charts have been included 
to display the total number of genes in that sections, as well as the proportion of that section that is represented by 
HIF target genes. A legend for the pie charts is shown at the lower centre of the image, whilst the percentage of HIF 




























Figure 4.5: Analysis of HIF gene representation in Venn analysis of genes induced by chronic hypoxia 
Mole and Schödel HIF gene sets were used to determine the representation of HIF target genes in the Venn analysis from 
Figure 4.2. (Top) A square representation of the Venn diagram from Figure 4.2. Pie charts have been included to display 
the total number of genes in that sections, as well as the proportion of that section that is represented by HIF target genes. 
A legend for the pie charts is shown at the lower centre of the image, whilst the percentage of HIF target genes in each 

































Figure 4.6: HIF1 and HIF2 target genes modified by HER2 overexpression in acute hypoxia 
ChIP determined gene lists for HIF1 and HIF2 target genes in MCF7 (from Mole and Schӧdel) were used to identify HIF1 and 
HIF2 target genes which were either specifically upregulated by acute hypoxia in MCF7-HER2 and not MCF7 (green box), or 
were constitutively overexpressed in MCF7-HER2 and part of the acute hypoxic response in either cell line (red box). This was 
done using rank product gene list from the Venn diagram in Figure 4.2. (Top) A representation of the Venn diagram from 
Figure 4.4 showing the total number of genes in each category and the proportion of HIF genes represented as pie charts. 
(Bottom) A list of HIF target genes from ‘HER2-specific’ (green box) or ‘HER2-primed’ (red box) categories with important 
cellular functions. Gene/protein name, whether the gene is described as a HIF1 or a HIF2 target and the general function of 

































Figure 4.7: HIF1 and HIF2 target genes modified by HER2 overexpression in chronic hypoxia 
ChIP determined gene lists for HIF1 and HIF2 target genes in MCF7 (from Mole and Schӧdel) were used to identify HIF1 and 
HIF2 target genes which were either specifically upregulated by chronic hypoxia in MCF7-HER2 and not MCF7 (green box), or 
were constitutively overexpressed in MCF7-HER2 and part of the chronic hypoxic response in either cell line (red box). This was 
done using rank product gene list from the Venn diagram in Figure 4.2. (Top) A representation of the Venn diagram from 
Figure 4.5 showing the total number of genes in each category and the proportion of HIF genes represented as pie charts. 
(Bottom) A list of HIF target genes from ‘HER2-specific’ (green box) or ‘HER2-primed’ (red box) categories with important 
cellular functions. Gene/protein name, whether the gene is described as a HIF1 or a HIF2 target and the general function of 
































Figure 4.8: Pathologically important genes which form part of the ‘HER2-specific’ or ‘HER2-primed’ response to acute and/or 
chronic hypoxia 
Rank product tested gene lists from chronic or acute hypoxia were assessed for important genes which form part of the ‘HER2-
specific’ or ‘HER2-primed’ hypoxic response in MCF7-HER2 cells. Top left) A representation of the Venn diagrams shown in 
figures 4.4 and 4.5 comparing genes which are significantly upregulated only in MCF7 in hypoxia, in both cell lines in hypoxia 
or only in MCF7-HER2 in hypoxia, with genes constitutively more highly expressed in MCF7 or MCF7-HER2  when compared to 
the other cell line. Top right) A demonstrative deconstruction of the Venn diagram showing which sections constitute the ‘HER2-
specific’ (black dotted box) and the ‘HER2-primed’ (red dotted box) hypoxic responses. (bottom) Important genes in each of 
these categories for both acute and chronic hypoxia are shown. Colour-coding is used to show the cellular functions of these 




4.5 The expression of primed hypoxic response genes 
correlates with HER2 expression across breast cancer cell 
lines 
 Whether HER2 expression could prime cells and increase response to hypoxia across 
breast cancer cell lines was next assessed. To do this we took the genes determined to be 
primed for hypoxia in MCF7-HER2 from our microarray data (n=85 in acute hypoxia and n=96 
in chronic hypoxia) and compared their expression with that of HER2 using publically 
available microarray gene expression data from 172 samples representing 77 different breast 
cancer cell lines [489]. This produced a reduced list (n=25 acute hypoxia, n=33 chronic 
hypoxia) of genes with significant (P<0.05) Pearson’s correlation to HER2 in this dataset. The 
expression of these genes in the cell line dataset and their correlation with HER2 expression 
can be seen in Figure 4.9. The top 5 correlating genes specifically primed in acute hypoxia or 
chronic hypoxia and the top 5 correlators primed in both conditions were determined and 
their expression in MCF7 and MCF7-HER2 in response to hypoxia is also shown in Figure 4.9. 
Notably, these included a number of genes with poor implications for breast cancer such as 
EFNA1 (angiogenesis), NUPR1 (metastasis), S100P (tumour aggression), TRIB3, WSB1 (poor 
prognosis) and RBCK1 (cellular proliferation). 
 
4.6 Discussion 
 The aim of this chapter was to assess the consequence of HER2 overexpression on 
the transcriptional response to hypoxia in the MCF7 and MCF7-HER2 breast cancer cell lines. 
These cell lines provide a model to study the effect of HER2 overexpression without the high 
variation normally seen between cell lines of differing origins, and have been used in Chapter 
3 to demonstrate a HER2-mediated increase in the hypoxic upregulation of HIF2α, CAIX and 
LDHA. Here we were able to compare the hypoxic response of these cell lines in more detail 
by measuring the expression levels of the entire transcriptome using an Illumina beadchip 
array.  
This microarray experiment was first used to compare the regulation of pre-
determined hypoxia response genes in acute and chronic hypoxia using a series of hypoxia 
metagenes. The aim of this approach was to broadly assess how the expression of predefined 
and verified hypoxia response genes differed in the context of wild-type MCF7 and HER2 
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Figure 4.9: Hypoxia response genes primed for hypoxia correlate with HER2 expression across breast cancer 
cell lines 
Genes which were primed for either acute or chronic hypoxia by HER2 overexpression in MCF7-HER2 were 
compared to HER2 expression in a dataset containing gene expression data from 172 samples representing 77 
different breast cancer cell lines. This resulted in 25 genes upregulated by acute hypoxia and 33 upregulated by 
chronic hypoxia which correlated with HER2 expression (p<0.005), with 16 genes represented in both acute and 
chronic hypoxia. Top) The expression of these genes is shown in a heat map with cell lines ordered by HER2 
expression to demonstrate concordance of gene expression. Top right) The top 5 correlating genes primed for 
acute, chronic or both types of hypoxia are shown along with Pearson’s correlation to HER2 across cell lines and 
the p-value. Bottom) The log2 expression values of top correlating genes in MCF7 and MCF7-HER2 from our 
HT12v4 beadchip array show the hypoxic regulation of these genes (error bars represent the SEM). A full list of 




overexpression after acute and chronic hypoxia. Three different hypoxia metagenes were 
used, each of which offered various strengths and weaknesses. 
The Winter et al. metagene was determined by hierarchical clustering of Affymetrix 
gene expression data with known hypoxic response genes in 59 head and neck squamous-
cell carcinoma biopsies. This was deemed an appropriate metagene for two reasons. Firstly, 
it was derived from clustering with key hypoxia response genes, many of which are known to 
be regulated by hypoxia in a number of cancers including breast cancer. These genes included 
CAIX, which was shown to be more strongly induced by hypoxic in MCF7-HER2 (Chapter 3).  
Secondly, this metagene was shown by Winter et al. to be a significant prognostic indicator 
for overall survival in a published breast cancer dataset, demonstrating the relevance of the 
expression of this metagene to breast cancer progression. 
 The metagene derived by Buffa et al. was included in this analysis as a robust 
metagene designed to detect hypoxia in various cancer types. This metagene was 
determined in silico through the assessment of co-expression with known hypoxia response 
genes (including both CAIX and LDHA, investigated in Chapter 3). Importantly this meta-
analysis was performed in 8 datasets including 5 from breast cancer patients, and was 
validated in independent breast, lung and head and neck cancer datasets. The use of breast 
cancer datasets in the creation and validation of this metagene make it highly applicable to 
this work, and a preference for metagenes designed for breast cancer is clearly required in 
this study. However, choosing metagenes recognised for their robustness and applicability 
to multiple cancer types provides broader coverage for investigating the role of HER2 in 
hypoxic response, especially considering that breast cancer samples used to determine 
hypoxia response genes would likely have had a larger proportion of HER2-negative samples 
than HER2-overexpressed samples (if they represent the standard frequencies of HER2 
overexpression in breast cancer), and thus may bias themselves against recognising hypoxic 
gene upregulation which only occurs in the context of HER2 overexpression. With this in 
mind, a combination of metagenes from various sources, not just those designed specifically 
for breast cancer, is clearly preferable.  
The Toustrup signature was included in this analysis as it was designed to be stringent 
for hypoxia response genes. Whilst not verified prognostically in breast cancer, a couple of 
different approaches were used, giving it a potential advantage over the other signatures; 
thus it was included. Firstly, genes were chosen specifically to be pH-independent. In the 
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tumour microenvironment hypoxia and acidosis often occur in parallel; there is an intrinsic 
link between the cellular response to hypoxia and to reduced pH, and thus pH level has been 
shown to affect the expression level of genes previously thought to be hypoxia responsive 
[490, 491]. The use of pH-independent genes in the creation of this metagene was considered 
to provide higher specificity for hypoxia and allowed a more stringent gene set to be 
developed.  Secondly, rather than discovering genes through the co-expression with known 
hypoxia responsive ‘seed’ genes, Toustrup et al. determined an optimum gene set able to 
differentiate between high and low oxygen tumours. Tumour oxygen levels were measured 
using an oxygen electrode and so the final gene expression signature is based on gene 
expression in hypoxia directly, as opposed to through what would be expected from the 
literature.   
Additional hypoxia metagenes are available [484-487], but the three chosen here 
were selected to provide a suitably robust overview of hypoxic response. This meant that 
hypoxic response could be assessed broadly, whilst also focussing on stringently determined 
hypoxia response genes. For these reasons the use of these three metagenes was deemed 
to be an appropriate way of robustly analysing hypoxic gene expression in MCF7 and MCF7-
HER2. 
 This analysis clearly demonstrated a modified hypoxic response in MCF7-HER2. 
Hierarchical clustering showed three predominant patterns of expression, with the vast 
majority showing an increased response to hypoxia in the HER2-overexpressing cell line. This 
included the majority of genes being more vigorously upregulated by both acute and chronic 
hypoxia, and these clusters were shown to be enriched for genes involved in glucose 
regulation and glycolysis. This demonstrates a clear role for HER2 in driving an increased 
hypoxic response in MCF7-HER2 cells and shows that this effect is not limited to the target 
genes shown in Chapter 3, but instead represents a broad change to the hypoxic response. 
In addition, this analysis showed that the HER2-enhanced response to hypoxia also includes 
genes which are downregulated by hypoxia, and in these metagenes such genes appear to 
be constitutively lower in MCF7-HER2. This suggests that in some cases HER2 overexpression 
in these cell lines might not only increase the response to hypoxia, but prime cells with gene 
expression changes normally associated with hypoxia being present even in normoxia. 
Finally, the presence of a small cluster in the Winter gene set showed that some genes were 
not responsive to hypoxia in MCF7. Whilst this is not in itself particularly surprising, it is 
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interesting to note that these genes were also more highly expressed in MCF7-HER2, despite 
no visible response to hypoxia in either cell line. This suggests that the role of HER2 in hypoxic 
gene expression is not limited to genes which are hypoxia inducible in MCF7.  
Having shown a broad modification of hypoxic gene expression in MCF7-HER2, the 
transcriptional response of these cell lines was assessed by comparison of the entire 
transcriptome (Figure 4.2). This work validated the vast difference in response to acute and 
chronic hypoxia seen when HER2 is overexpressed. The most striking difference between 
these cell lines was the disparity in the number of genes constitutively higher in each cell line 
that were also responsive to hypoxia. This occurred in both acute and chronic hypoxia but 
the difference was greatest in acute hypoxia. The expression of hypoxia responsive genes in 
normoxia suggests that cells may be primed to respond to hypoxia and may play a role in the 
exacerbated hypoxic response of MCF7-HER2 cells. Additionally, this suggests once again that 
HER2 overexpression may lead to the expression of genes associated with hypoxia even in 
normoxia, potentially increasing traits such as metastasis and angiogenesis, which are 
associated with tumour hypoxia. 
 Using this data we were also able to directly assess the role of HIFs in this increased 
response to hypoxia. This was achieved using a set of HIF target genes taken from the 
literature. The finalised list used was a combined gene set from two papers, these being the 
full set of identified HIF1 and HIF2 target genes from Mole et al. 2009 supplemented with the 
top 30 binding sites identified by Schödel et al. 2011. Both these papers used ChIP-seq of 
HIF1α or HIF2α to determine binding sites for these transcription factors in MCF7 cells 
treated with 2 mM dimethyloxalylglycine (DMOG), a prolyl-4-hydroxylase inhibitor which 
leads to the upregulation of HIFα subunits. The fact that these binding sites were determined 
in MCF7 means there should be a high level of concordance with our dataset. Being sequence 
dependent, HIFα binding sites would be largely expected to remain similar across cell types, 
however it should be acknowledged that the HIF targets are likely to vary to some extent in 
the context of HER2 overexpression. HER2-driven changes in cofactor expression and 
chromatin structure could play important roles in determining novel binding sites for HIFα 
subunits, and these would naturally not be included in the gene list used in this dataset. More 
importantly, it should be recognised that HER2-driven changes in HIF2α expression discussed 
in Chapter 3 are likely to have profound effects on HIF1 vs HIF2 target binding, and thus the 
categorisation of these genes as HIF1, HIF2 or HIF1/HIF2 target genes (based solely on ChIP 
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data in wild-type MCF7s) may not represent the transcription factor responsible for the 
expression of the gene in MCF7-HER2. With this in mind, HIF2 may play a more vital role in 
the increase of HIF target genes, as this is the isoform whose expression and hypoxic 
upregulation was markedly increased by HER2 expression. However, to determine this would 
require further work looking into how the transcriptional response to hypoxia in MCF7-HER2, 
either by ChIP-seq in this cell line or further expression experiments in the context of HIF1α 
or HIF2α inhibition. Despite this limitation, we were able to show a significant increase in HIF 
target gene expression in the MCF7-HER2 cell line. This was shown by both hierarchical 
clustering of HIF genes and by the assessment of HIF target genes in rank product gene lists 
via Venn analysis. In general, a large number of HIF targets were shown to be specifically or 
more intensely upregulated by hypoxia in the context of HER2 overexpression. This was most 
notable in the contrast between HIF genes which were not shown to be constitutively higher 
in either cell line but were upregulated specifically in acute hypoxia in MCF7 (1.6% n=3) or in 
MCF7-HER2 (19%, n=45). This pattern was repeated in chronic hypoxia (MCF7= 5.6% n= 7, 
MCF7-HER2=14.1% n=28). This, combined with the finding that the increased number of 
hypoxia responsive genes seen in the MCF7-HER2 constitutively overexpressed group 
contained a high proportion of HIF genes, allowed us to conclude that HER2 overexpression 
modified the hypoxic response in at least two key ways: firstly, by increasing the activity of 
HIF transcription factors in response to hypoxia, and secondly, by driving the constitutive 
expression of hypoxia response genes. This appeared to have no specificity for HIF1 or HIF2 
target genes, but a role for HIF2α is presumed due to its increased expression in this cell line.  
Our investigation into the genes involved in the modified hypoxic response of MCF7-
HER2 demonstrated a strong role for glycolysis. This was the case both when HIF target genes 
were analysed as well as when a non-HIF-centric approach was taken. With the non-HIF-
centric approach a wide variety of pathologically important genes were shown to be HER2 
regulated, with a number of important pathways represented. The majority of these are 
known to drive pathways associated with hypoxia-mediated pathology, including 
angiogenesis, metastasis/invasion and treatment resistance. This strongly suggests that the 
HER2-mediated increase in hypoxia response may be a strong driver of tumour progression 
and may contribute to the increased aggression of HER2-positive tumours. In addition to 
expected pathways, a number of notch signalling genes were noted in the HER2-specific 
response to hypoxia. Jagged1 and Jagged2 are both notch ligands associated with driving 
metastasis (especially to the bone) in breast cancer [492, 493]. Jagged1 has previously been 
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shown to be associated with worse tumour grade, vascular invasion as well as HER2 
expression when assessed by IHC in breast cancer [493], whilst Jagged2 has been shown to 
contribute to stem cell self-renewal and epithelial-to-mesenchymal transition (EMT) in breast 
cancer [494]. As well as notch ligands, the Notch3 receptor was also included in these genes. 
HES-1, HEY-1, HEY-2, SLUG and SOX4 are all known downstream targets of notch signalling. 
The HES/HEY transcription factors have been shown to promote the transcription of a 
number of genes in response to notch pathway activation. These include important cell cycle 
regulators (P21, CCND1), transcription factors (Myc and NFKB2), angiogenic factors (VEGFR1 
and VEGFR2) as well as the HER2 receptor [495]. Slug and Sox4 are both recognised drivers 
of EMT and metastasis in breast cancer [496-498]. In general, hypoxia is recognised as a driver 
of notch signalling [328], and notch signalling has also been recognised as an important driver 
of hypoxia mediated metastasis [499]. Notch signalling appears to be a predominant pathway 
in the HER2-enhanced transcriptional response to hypoxia in MCF7, suggesting that HER2 
expression and hypoxia may cooperate in breast cancer to drive EMT and metastasis through 
notch signalling. This may contribute to the increased cellular motility of MCF7-HER2 cells 
and their greater potential for migration in hypoxia when compared to wild-type MCF7 
(Chapter 3). 
 Having demonstrated a significant role for HER2 in driving an increased hypoxic 
response in MCF7-HER2 cells, we next used a cell line dataset to see whether genes primed 
for hypoxia in MCF7-HER2 correlated with HER2 expression across breast cancer cell lines. 
Whilst this publically available dataset provided gene expression data for a large number of 
breast cancer cell lines, samples were all collected under normoxic culture conditions, 
meaning the direct comparison of gene upregulation in hypoxia was not possible. Instead, 
genes shown to be primed for hypoxia were tested, as these genes were, by definition, more 
highly expressed in normoxia when HER2 was overexpressed. This allowed a set of genes 
which are hypoxia-inducible in our microarray data and which correlate to HER2 expression 
across breast cancer cell lines to be established, suggesting that such genes may form part of 
a HER2-driven hypoxic response which is generally applicable to a large number of breast 
cancer cell lines. Whilst similar experiments in patient tumour samples would have provided 
more clinical relevance to this work, cell line work was favoured as it would not have been 
possible to accurately determine the extent of hypoxia in clinical datasets. This would have 
meant that larger, poorly vascularised tumours might have been present with a stronger 
expression of hypoxia response genes and it would be impossible to form accurate 
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conclusions on whether this is driven by HER2 expression or simply variations in hypoxic 
intensity. For this reason, the combined analysis in breast cancer cell lines and discovery of 
numerous important drivers of cancer pathogenesis, which are involved in the increased 
response in MCF7-HER2, was used to propose a significant role for HER2-driven hypoxic 
activation in breast cancer.  
 In summary this chapter has investigated the role of HER2-expression in modifying 
the transcriptional response to hypoxia in breast cancer cell lines. Multiple approaches to 
analyse this data all demonstrate the increased hypoxic expression of HIF and non-HIF 
hypoxia response genes and an increased expression of hypoxia response genes under 
normoxia, suggesting a HER2-mediated priming of cells for hypoxia. Whilst a role for HIF1 
and HIF2 is suggested, this is with the understanding that the definition of HIF1 or HIF2 target 
genes is context dependent. This work supports the data shown in Chapter 3, with an 
increased hypoxic response in HER2 overexpressing MCF7 cells demonstrated at both protein 
and transcription levels, with a likely role for HER2-driven HIF2α expression. One caveat of 
these findings is that care must be taken with the direct comparison of MCF7 and MCF7-HER2 
cell lines. Whilst isogenic, these are from disparate clones which may have accumulated 
some differences. This issue has been partially addressed by the comparison of HER2-primed 
hypoxic response genes in a panel of breast cancer cell lines, providing some evidence that 
these changes in gene expression are more broadly attributable to HER2 expression and not 
just unrelated differences between MCF7 and MCF7-HER2 cell lines. However, future work 
assessing the effect of HER2 expression on hypoxic response in additional breast cancer 
models would be valuable.  The next chapters will investigate more directly the relationship 
of HER2 and HIF2α expression. 
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Chapter 5: Investigating the normoxic 




Neuregulin-1β (NRG) is a ligand for HER3 and HER4 receptors [500, 501]. It drives 
growth factor signalling by binding to either one of these receptors and permitting the 
formation and subsequent activation of HER receptor dimers (discussed in Chapter 1). 
Previous research has demonstrated that NRG treatment of MCF7 cells can increase the 
levels of HIF1α in normoxia through the PI3K/AKT/mTOR signalling pathway, leading to 
increased protein translation, and also by reducing the protein degradation rate caused by 
increased binding of HIF1α to HIF1β [220, 421]. These findings show that the HIF pathway is 
relevant to tumour cell signalling in normoxia if HER growth factor signalling is activated. 
Despite this, there is still little understanding of how HER2 receptor overexpression (found in 
20% of breast cancers), might drive HIFα levels in normoxic conditions, or whether the 
overexpression of this receptor modifies the way in which cells respond to NRG in terms of 
HIFα pathway activation.    
 In this chapter, I describe studies investigating the effect of growth factor receptor 
signalling on the normoxic regulation of HIF1α and HIF2α and explore the effect of HER2 
overexpression on HIFα levels with and without NRG-driven pathway activation. Using 
molecular inhibitors of various signalling pathways, I investigated possible mechanisms 
involved in growth factor driven HIFα regulation and obtained evidence of important 






5.2 Investigating the growth factor-mediated upregulation of 
HIF1α and HIF2α in breast cancer cell lines 
The first aim of this chapter was to evaluate how NRG stimulation modified HIF1α 
and HIF2α levels in normoxia in MCF7 and MCF7-HER2 cells. This was to provide further 
understanding on two important aspects of growth factor-HIF interactions in breast cancer; 
firstly, to assess the differential capability of growth factors to drive HIF1α vs HIF2α, which 
has not previously been investigated but is important to consider in the light of our increased 
understanding of their differential roles in cancer biology, and secondly, to establish whether 
HER2 overexpression is sufficient to drive HIFα in normoxia or to intensify upregulation in 
response to NRG, as this may have important implications for the role of normoxic HIF activity 
in HER2-positive breast cancers. 
 
5.2.1 Growth factor-mediated HIF1α upregulation is not affected by 
HER2 overexpression in MCF7 cells  
To assess the potential for HIF1α upregulation by NRG in MCF7 and MCF7-HER2 cells, 
cells were treated with 25-400 ng/ml of NRG EGF domain (the HER receptor activating 
domain of the NRG protein) for 1 – 24 hrs. This was initiated after 20 hrs growth in low serum 
media to allow the addition of NRG to elicit a strong signalling response. Western blotting of 
whole cell lysates collected from these cells showed that HIF1α was upregulated by NRG 
addition (Figure 5.1a), even with low concentrations (25 ng/ml) across the time course in 
both cell lines. Whilst this demonstrates the potential for NRG-driven upregulation of HIF1α, 
a quantitative comparison was difficult as levels of HIF1α protein were highly variable. To 
provide a model for comparison, the upregulation of nuclear HIF1α over a 6 hr time course 
was assessed (Figure 5.1b). As a transcription factor, nuclear levels of HIF1α are more 
representative of the active protein, and the isolation of the nuclear fraction where relative 
levels of transcription factors will be higher allows for better signal to noise ratio when 
immunoblotting to reduce variability. Figure 5.1b shows HIF1α levels in the nuclear and 
cytoplasmic compartments after treatment with 200 ng/ml NRG EGF-domain. This 
experiment clearly indicated upregulation of the protein, with levels steadily increasing over 
time in both cell lines. This result agrees with previously published examples for MCF7 cells 
[220]. Surprisingly, HER2 overexpression in this cell line had no apparent effect on the 






Figure 5.1: HIF1α can be upregulated by neuregulin-1β (NRG) and is similarly induced when HER2 is 
overexpressed 
 
A) Western blotting of NRG treated MCF7 and MCF7-HER2 whole cell lysates showing the expression of HIF1α and 
β-actin (loading control). Cells were first serum starved (0% FCS) in phenol red-free media for 20 hrs before the 
addition of 0, 25, 100, 200 or 400 ng/ml of NRG.  Cells were grown in treatment conditions for 1-24 hrs before 
protein lysates were collected. Probing for HIF1α in 40 µg of these lysates shows that NRG treatment is able to 
induce normoxic HIF1α levels in both cell lines with no clear indication of a modified effect in the context of HER2 
overexpression. B) Similarly, nuclear and cytoplasmic cellular lysates were collected for MCF7 and MCF7-HER2 cells 
treated with 200 ng/ml of NRG for 1-6 hrs (also after 20 hrs in 0% FCS phenol red-free serum). This demonstrated 
the nuclear upregulation of HIF1α by NRG in both cell lines. Both figures A and B show representative western 




5.2.2 HIF2α is not upregulated by neuregulin-1β but is constitutively 
higher in the context of HER2 overexpression  
 Next, we assessed the effects of NRG treatment on HIF2α levels in normoxia in these 
two cell lines (Figure 5.2a). Whole cell lysates from MCF7 and MCF7-HER2 cells treated with 
200 ng/ml NRG over a 6 hr time course were used for western blotting of HIF2α. In contrast 
to HIF1α, we saw no change in HIF2α levels in either cell lines over the time course. 
Interestingly however, we saw constitutively higher expression of HIF2α in the MCF7-HER2 
cell line. This suggests that HER2 overexpression may be sufficient to drive HIF2α 
upregulation in normoxia despite no apparent NRG driven differences. This constitutively 
higher HIF2α level in MCF7-HER2 was confirmed in further western blotting experiments of 
whole cell lysates, and combined densitometry values were used to quantitatively compare 
HIF2α protein in these two cell lines (Figure 5.2b). HIF2α was approximately 7-fold higher in 
normoxic MCF7-HER2 cells than in wild-type MCF7 cells.  In MDA-MB-361, BT474 and SKBR3 
cell lines varying basal levels of HIF2α expression were seen, and in concordance with MCF7 
and MCF7-HER2 cell lines, no changes in response to NRG were seen. 
 This work demonstrates that ligand driven HIF1α upregulation is robust and may be 
independent of HER2 expression. The expression of HIF2α however, appears unaffected by 
NRG stimulation, whilst HER2 expression is sufficient to drive its upregulation in MCF7 cells, 
even in normoxia. These findings highlight once again the importance of taking differences 
between HIF1α and HIF2α into account when considering their implications in breast cancer. 
The importance of HIF1α vs HIF2α in growth factor-driven HIF regulation appears to be 
dependent on cellular context, and may have important implications for HER2-positive breast 
cancers. Importantly, there appears to be more than one mechanism by which HER signalling 
can drive HIFα upregulation and in this cell line model HIF1α and HIF2α are independently 
modulated by these different mechanisms. The rest of this chapter will focus on 





Figure 5.2: HIF2α protein is upregulated by HER2 expression despite no effect from NRG 
treatment 
 
A) Western blotting of HIF2α and α-tubulin in MCF7 and MCF7-HER2 cell lines treated with 200 
ng/ml NRG for 1-6 hrs after 20 hrs serum starvation (0% FCS in phenol red-free media). Whilst HIF2α 
is constitutively more highly expressed in the MCF7-HER2 there is no visible effect from NRG 
treatment in either cell line. B) Bar graph representation of HIF2α protein levels as determined by 
densitometry readings normalised to tubulin control values in untreated cell lines. This was done 
in n=5 experiments with the mean value shown for each cell line (error bars represent the SEM) 
(p=0.0041, unpaired t-test). C) Similar western blotting experiments were performed in breast 
cancer cell lines MDA.MB.361, SKBR3 and BT474, showing that despite differences in the levels of 

















5.3 Increased HIF2α levels in MCF7-HER2 are reduced by 
HER2 inhibition  
 To establish the role of HER2 driven signalling in the overexpression of HIF2α in 
MCF7-HER2 cells, we used a selection of receptor tyrosine kinase (RTK) inhibitors to assess 
how inhibition of HER signalling would affect the constitutive levels of HIF2α in this cell line. 
In these experiments small molecular inhibitors lapatinib, gefitinib and mubritinib were used. 
Lapatinib is a dual inhibitor of both HER2 and EGFR. By binding the ATP-binding pocket of 
these receptors lapatinib is able to prevent autophosphorylation by the receptor kinase 
domain, inhibiting signal initiation from these receptors [502, 503]. Gefitinib is a reversible 
inhibitor EGFR which, similar to lapatinib, inhibits kinase activity by binding to the ATP-
binding pocket of this receptor. Whilst, reportedly an EGFR inhibitor, gefitinib can also bind 
other HER family receptors, although the binding affinity of gefitinib to HER2 has been shown 
to be 200-fold lower than to EGFR [503-505]. Mubritinib (TAK-165) is a HER2 specific kinase 
inhibitor showing >4000-fold selectivity over other RTKs, and has been shown to have 
antiproliferative effects on HER2 overexpressing cells in vitro and in vivo [506, 507]. 
Initial experiments using lapatinib (a dual HER1/HER2 kinase inhibitor) demonstrated 
a significant reduction (approximately 50%) in normoxic HIF2α levels when treated with 
lapatinib when compared to a vehicle control (DMSO) (Figure 5.3) and this effect was similar 
over 8, 24 and 48 hr treatment durations. As lapatinib is an inhibitor of both HER1 (EGFR) and 
HER2 activity, we next performed equivalent experiments to compare the effects of lapatinib 
with EGFR-specific inhibitor gefitinib (Figure 5.4), as well as with a HER2-specific inhibitor 
mubritinib (Figure 5.5). Whole cell lysates of MCF7-HER2 cells treated with lapatinib (10 μM), 
gefitinib (2 μM) or a vehicle control (0.1% DMSO) for 8, 24 or 48 hrs were immunoblotted for 
HIF2α as well as for overall and phosphorylated HER2 and EGFR. This demonstrated a 
consistent reduction of HIF2α by lapatinib and gefitinib over the 48 hrs. This effect is 
consistent with the inhibition of HER2 phosphorylation (tyr1221/1222) in these experiments. 
Phospho-HER2 levels were reduced below detectable levels for cells treated with lapatinib 
or gefitinib. Additionally, phosphorylated EGFR (tyr1148) appeared reduced by lapatinib and 
gefitinib. As such, a role for EGFR in HIF2α regulation cannot be ruled out. To demonstrate a 
specific role for HER2 in HIF2α upregulation, we used a mubritinib, a highly HER2 specific RTK 




Figure 5.3: Inhibition of RTK signalling with lapatinib reduces the normoxic expression of 
HIF2α in MCF7-HER2 
 
A) Representative western blot from n=4 experiments showing HIF2α and α-tubulin levels in 
whole cell lysates of MCF7-HER2 cells treated with 10 µM of lapatinib or vehicle control (0.1% 
DMSO) for 8, 24 or 48 hrs after 24 hrs growth in 2.5% DCSS in phenol red-free media. B) Mean 
densitometry values for HIF2α normalised to α-tubulin for each condition (error bars 
represent the SEM). Ratio paired t-tests of individual time points shows a significant reduction 
in HIF2α levels at 8 and 24 hrs (p=0.0314 and p=0.0148 respectively). C) Each experiment 
(n=4) was normalised to its own DMSO control to remove the inter-experimental variability, 
which resulted in high standard error. This demonstrates a consistent reduction 




Figure 5.4: Normoxic HIF2α protein level in MCF7-HER2 is reduced after lapatinib or gefitinib treatment 
 
A) Western blotting experiment of whole cell lysates of MCF7-HER2 cells treated with 0.1% DMSO (Dm), 10 µM lapatinib (lap) 
or 2 µM gefitinib (gef) for 8, 24 or 48 hrs after 24 hrs in reduced serum conditions (2.5% DCSS with phenol red-free media). 
The same lysates were probed for HIF2α, α-tubulin (loading control, HER2, EGFR as well as phosphorylated forms of the HER2 
(tyrosine 1221/1222) and EGFR (tyrosine 1148) receptors. The ratio of these phosphorylated receptors to the overall level of 
the receptor was used as a surrogate for receptor activation and compared to HIF2α levels. B) The densitometry values for 
HIF2α (normalised to tubulin), phospho-HER2 (normalised to total HER2) and phosphor-EGFR (normalised to total EGFR) are 
shown relative to DMSO for each time point. The downregulation of HIF2α coincides with a reduction in both HER2 and EGFR 




Figure 5.5: HER2-specific tyrosine kinase inhibitor mubritinib reduces HIF2α levels in MCF7-HER2 in normoxia 
 
A) Western blotting of MCF7-HER2 whole cell lysates treated for 8, 24 or 48 hrs with 0.1% DMSO or 0.1 – 100 nM 
mubritinib. B) Densitometry values for HIF2α (normalised to α-tubulin) and phospho-HER2 (normalised to total HER2) 





vehicle control (DMSO) (treated for 8, 24 or 48 hrs) were immunoblotted for HIF2α, HER2 
and p-HER2 (Figure 5.5a). Mubritinib was effective at reducing normoxic HIF2α levels in 
MCF7-HER2 even at the lowest concentration tested across the time course. This effect was 
partially dose-dependent and correlated to reduced phosphorylation of HER2 (Figure 5.5b). 
Some concentrations at later time points were excluded due to visible cytotoxicity.       
  
5.4 High HIF2α levels in MCF7-HER2 are driven at the 
transcriptional level  
 The NRG-mediated upregulation of HIF1α has previously been established as a post-
transcriptional effect, with increased translation of the protein through PI3K/AKT/mTOR 
signalling and increased heterodimer stability being demonstrated as the mechanisms driving 
the increased protein levels in normoxia. In Section 5.2 we demonstrated that differential 
mechanisms exist for HIF1α and HIF2α upregulation by growth factor signalling in MCF7 and 
MCF7-HER2 cell lines; therefore, we next wanted to assess whether the upregulation of 
HIF2α by HER2 overexpression was also mediated at the transcriptional or post-
transcriptional level. Having obtained gene expression microarray data for MCF7 and MCF7-
HER2 in normoxia and hypoxia (Chapter 4), we used this to compare transcript levels of HIF2α 
between these cell lines. HIF1α was also included in this comparison so that the differences 
in regulatory mechanisms of these two factors could be confirmed. Figure 5.6 shows gene 
expression values (n=3) for HIF1α and HIF2α in MCF7 (blue) and MCF7-HER2 (red) in 
normoxia, acute and chronic hypoxia as well as after 24 hrs cobalt chloride treated (400 μM). 
Treatment with cobalt chloride leads to the stabilisation of HIFα subunits even in the 
presence of oxygen. This is achieved as cobalt ions are able to bind to the iron binding domain 
of HIF hydroxylases, preventing HIF hydroxylation and subsequent ubiquitination and 
degradation. Additionally, cobalt is able to bind directly to hydroxylated HIFα proteins and 
prevent their interaction with VHL [508]. In this way cobalt chloride offers a mechanism of 
inducing HIF activity without the requirement of hypoxia. Both the treatment of cells in 
hypoxia and the use of cobalt chloride will induce some HIF-independent effects. By showing 
gene expression changes occur both in response to hypoxia and cobalt chloride treatment, 
more evidence is provided that these effects are HIF driven, and not a HIF-independent 















































































































































































































































































































































































































Figure 5.6: Microarray analysis of HIF1α and HIF2α gene expression in response to hypoxia in MCF7 and 
MCF-HER2 
 
Log2 expression values from HT-12v4 Illumina beadchip array for HIF1α and HIF2α in MCF7 (blue) and MCF7-
HER2 (red) cell lines grown in normoxia, acute hypoxia (0.5% oxygen for 24 hrs), chronic hypoxia (0.5% oxygen 
for 10 weeks) or treated with 400 μM cobalt chloride (CoCl2). Panels A and B show mean and standard deviation 
of HIF1α or HIF2α in MCF7 (A) and MCF7-HER2 (B) cell lines individually, with individual data points shown n=3. 
One-way ANOVA with Dunnett’s multiple comparison to the normoxic group was used to assess any significant 
effects of hypoxia on expression level. C shows the mean expression (with standard deviation) of HIF1α or HIF2α 
with the two cell lines plotted on the same axis for comparison. A two-tailed T-test was performed to compare 
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Figure 5.7: RT-PCR analysis of HIF1α and HIF2α gene expression in response to hypoxia in MCF7 and 
MCF7-HER2 
 
Real-time-PCR quantification of HIF1α and HIF2α expression in MCF7 and MCF7-HER2 cells in normoxia and 
8, 24, 48 and 72 hours hypoxia. Panels A and B show the mean expression values with standard deviation 
of individual cell lines over the hypoxic time course with individual data points also shown. Statistically 
significant differences are indicated by asterisks (one-way ANOVA with Dunnett’s multiple comparison). 
Panel C shows a comparison of expression levels in the two cell lines on the same axis to demonstrate cell 
line differences in expression level, with mean and standard deviation shown. T-test was performed to 
compare normoxic expression values between cell lines. For both types of statistical test *= p< 0.05, **= p< 






This gene expression analysis provided evidence for important differences in the 
regulation of HIF1α and HIF2α in these cell lines. Transcript levels of both proteins in MCF7 
cells were comparable and stable. HIF1α and HIF2α had similar basal levels of expression and 
no changes were seen in hypoxia or after cobalt chloride treatment. In MCF7-HER2 cells, 
HIF1α expression was comparable to MCF7 cells. However, HIF2α expression was 
significantly higher in normoxia when compared to MCF7 cells, and was significantly 
increased in hypoxia. This included increases in acute and chronic hypoxia, as well as by 
cobalt chloride treatment.  
 To validate these findings, quantitative RT-PCR was used to assess the mRNA levels 
of HIF1α and HIF2α in MCF7 and MCF7-HER2 cells over a 72 hr hypoxia time course. RT-PCR 
experiments were able to validate a significant increase in mRNA levels of HIF2α in MCF7-
HER2 cells when compared to wild-type MCF7, with a > 10-fold increase in transcript levels 
which remained across the hypoxic time course (Figure 5.7). Differences in the hypoxic 
upregulation of HIF2α were modest but increased in both cell lines, with a greater effect in 
MCF7 cells when assessed by RT-PCR. A significant change in HIF1α expression after 24 hrs 
hypoxia was noted in MCF7-HER2 cells, however this was not apparent in later hypoxic time 
points or in microarray data. Thus, the key results from assessing transcript levels of HIF1α 
and HIF2α in these RT-PCR experiments are that HIF2α is more highly expressed in MCF7-
HER2 when compared to MCF7 cells, and that HIF2α but not HIF1α transcription is induced 
by hypoxia.  
 
5.5 Investigation of the signalling pathways involved in the 
HER2-mediated increase of HIF2α 
 In Section 5.2 we were able to characterise differences in growth-factor mediated 
regulation of HIF1α and HIF2α through a comparison of NRG stimulation and HER2 
overexpression, showing a HIF1α-specific upregulation in response to NRG stimulation and a 
HIF2α-specific effect in the context of HER2 overexpression. To understand the mechanisms 
driving these responses we considered the differences between these two modes of HER 
signal activation. NRG is a HER3 ligand and so promotes growth factor signalling through 
HER3 heterodimers, whilst HER2 overexpression drives signalling down stream of HER2 [509]. 
Whilst both receptors are capable of driving both pathways, we hypothesised that higher 
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levels of PI3K/AKT/mTOR activation as a result of NRG binding to HER3 may be responsible 
for its upregulation of HIF1α, whilst the increased activation of Ras/MEK/ERK signalling 
through HER2 activation may result in a transcriptional response which drives HIF2α gene 
expression. As the role of PI3K/AKT/mTOR in driving NRG-induced HIF1α upregulation has 
been published previously [220, 421], we aimed to test whether HIF2α upregulation was 
driven specifically by the PI3K or the MEK/ERK pathway. This was achieved by inhibiting these 
pathways using compounds LY294002 and PD98059 in normoxic MCF7-HER2 cells and testing 
whole cell lysates for levels of HIF2α. LY294002 is a specific inhibitor of PI3K, and as such is a 
potent inhibitor of PI3K-mediated AKT and mTOR activation. PD98059 is an inhibitor of both 
MEK1 and MEK2 and so prevents the activation of ERK1/2 by the MAPK signalling cascade. 
In order to understand differences in signal activation which may be responsible for 
HIF2α upregulation in the context of HER2 overexpression, we next decided to assess 
differences in ERK and AKT activation in MCF7 and MCF7-HER2 cells. To do this, MCF7 and 
MCF7-HER2 whole cell lysates were collected after 1-6 hr stimulation with 200 ng/ml NRG 
and assessed for differences in ERK and AKT phosphorylation by western blotting (Figure 
5.8a). Whole cell lysates were probed for phospho-ERK1/2 (T202/Y204) and phospho-AKT 
(S473), these were compared to the levels of total ERK1/2 or total AKT to demonstrate 
changes in pathway activation and not just protein abundance. All targets showed clear 
bands at the expected molecular weights, whilst total AKT showed an unexpected doublet 
this could be due to the pan AKT antibody picking up multiple members of the AKT family or 
phosphorylated version of the protein (other than S473). Phosphorylation of ERK was shown 
to be constitutively higher in MCF7-HER2 whilst AKT phosphorylation was comparable 
between cell lines. The upregulation of phosphorylated forms of both signalling molecules by 
NRG treatment was equivalent between cell lines. Next MCF7-HER2 cells treated with 
LY294002 (10 μM) or PD98059 (50 μM) or equivalent concentrations of vehicle control 
(DMSO) were collected as whole cell lysates and used for western blotting to compare HIF2α 
expression with these two pathway inhibitors over a 48 hr time course. A representative 
western blot (Figure 5.8b) and quantitative analysis of densitometry values for HIF2α from 
n=4 experiments are shown (Figure 5.8c-d). Both compounds were effective in specifically 
inhibiting downstream phosphorylation; PD98059 showed specific inhibition of ERK 
phosphorylation whilst LY294002 showed the specific inhibition of AKT phosphorylation. 
Whilst HIF2α appeared to be inhibited by both compounds at 8 hrs, this inhibition was only 
stable and reproducible in the context of PI3K inhibition. Combined experiments showed no 
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significant inhibition of HIF2α after MEK inhibition, whilst PI3K inhibition was shown to 
produce a significant reduction in HIF2α protein levels. This effect was modest however, 
reducing protein expression by less than a third of the DMSO control.   
  
Figure 5.8: Investigating the role of PI3K and ERK downstream signalling on HIF2α expression 
 
A) Western blotting of whole cell lysates from NRG treated MCF7 and MCF7-HER2 cells. Cells were serum 
starved for 24 hrs (2.5% DCSS, phenol red-free media) prior to treatment with 200 ng/ml NRG for 1-6 hrs. 
Lysates were probed for ERK1/2, phospho-ERK1/2 (T202/Y204), AKT and phospho-AKT (S473). This is a 
representative blot of n=4 experimental repeats. B) Western blotting of MCF7-HER2 cells treated with 
DMSO (<1%), 10 µM PI3K inhibitor LY294002 (LY) or 50 µM MEK inhibitor PD98059. MCF7-HER2 cells were 
serum starved (2.5% DCSS, phenol red-free media) for 24 hrs before treatment with DMSO, LY294002 or 
PD98059 for 8, 24 or 48 hrs. Whole cell lysates were collected and probed for HIF2α, ERK1/2, phospho-
ERK1/2 (T202/Y204), AKT, phospho-AKT (S473) and α-tubulin. This is a representative western blot from 
n=4 experimental repeats. Panels C and D show the densitometric quantification of HIF2α protein in these 
western blots. With individual experimental repeats in each treatment category shown in different colours 
and mean expression values relative to DMSO controls represented by the bars. Ratio paired t-tests were 
used to compare the expression of each treatment with DMSO. Here only LY294002 after 8 hrs showed a 





 In this chapter, I aimed to investigate how HIF1α and HIF2α subunits might be 
differentially regulated by growth factor signalling in normoxia. Using our isogenic cell line 
model for HER2 overexpression in MCF7, I was able to demonstrate a HER2-driven 
upregulation of HIF2α, which differs mechanistically to the ligand-driven HIF1α upregulation 
previously described [220, 421]. Using western blotting of NRG treated whole cell lysates, I 
was able to confirm the NRG-driven effects on HIF1α in both our cell lines, whilst 
demonstrating no equivalent response in HIF2α levels. This is in contrast to the constitutive 
differences seen in HIFα expression between HER2 overexpressing and wild-type MCF7 cells, 
where I showed an increased level of HIF2α protein only in the context of highly expressed 
HER2 receptor. One limitation of this work is it does not address the full complexity of HER 
signalling, whilst interesting differences between the effects of NRG1β stimulation and HER2 
overexpression were seen, the potential for other HER ligands to differentially stimulate 
HIF1α and HIF2α has not been investigated. Further experiments to assess the possible 
effects of EGFR signalling, perhaps through stimulation with EGF or other EGFR specific 
ligands could provide more information on how differences in HIF1α and HIF2α upregulation 
are governed. Despite this limitation, the differences seen between NRG treatment and HER2 
overexpression are of particular interest when considering the HER2-positive subtype of 
breast cancer. To further understand these differences the mechanisms surrounding 
constitutive HIF2α expression in MCF7-HER2 were investigated.  
 The use of small molecular inhibitors which target RTK activity provide a simple 
means by which specific RTKs can be inhibited to assess downstream functional 
consequences. Here I used lapatinib, an inhibitor of EGFR/HER2 lapatinib, EGFR-specific 
inhibitor gefitinib, and HER2 specific inhibitor mubritinib to assess a role for EGFR and HER2 
in driving HIF2α in MCF7-HER2. HIF2α was inhibited by lapatinib, gefitinib and mubritinib. 
Whilst this is not consistent with a specific and independent role for HER2 in this process 
based on the understood mechanisms of these inhibitors, a strong concordance was seen 
between HER2 phosphorylation and inhibition of HIF2α in these experiments. Inhibition of 
EGFR phosphorylation by these molecules was generally weaker but also showed 
downregulation with lapatinib and gefitinib. Unfortunately, we were unable to provide 
evidence on whether specific EGFR inhibition would be sufficient to reduce normoxic HIF2α 
levels, as gefitinib and lapatinib both inhibited HER2 phosphorylation. Nevertheless, the 
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correlation of HIF2α levels with HER2 phosphorylation, as well as the successful inhibition of 
HIF2α with the HER2-specific inhibitor mubritinib, provides convincing evidence that HER2 
activation is directly responsible for the increases in HIF2α seen in MCF7-HER2 cells. Due to 
mubritinib’s reported specificity for the HER2 receptor, phosphorylation of EGFR was not 
assessed in experiments using this compound. However, considering the possibility of direct 
interplay between different members of the HER receptor family, EGFR activation after 
mubritinib treatment needs to be measured to be sure that a reduction in EGFR signalling is 
not responsible for reduced HIF2α in these experiments.   
 Using gene expression data from our microarray experiment (described in Chapter 
2) and real-time PCR experiments, I was able to compare the transcriptional regulation of 
HIF1α and HIF2α in wild-type and HER2 overexpressing MCF7 cells. This provided further 
evidence that HER2-driven HIF2α upregulation differs from NRG-driven control, which has 
been shown in the literature to be post-transcriptional [220, 421], relying on a perturbation 
of protein synthesis and degradation equilibrium to drive the increased protein level. Here 
we have demonstrated that HIF2α transcript levels are higher in MCF7-HER2, and whilst 
transcript levels were also significantly increased by hypoxia, this change was small compared 
to the difference caused by HER2 overexpression. Initially, we had hypothesised that this 
difference may reflect disparities in downstream pathway activation from NRG stimulation 
and HER2. However, a comparison of inhibition of the PI3K/AKT and Ras/MEK/ERK pathways 
suggests that PI3K plays a greater role in HIF2α upregulation, the same pathway 
demonstrated to drive HIF1α upregulation in response to NRG [220, 421]. Due to the lack of 
constitutive HIF1α expression in MCF7-HER2 cells and the failure of HIF2α to be stimulated 
by NRG, it seems unlikely that the same pathway is directly driving expression of these 
transcription factors. Instead we suggest that the HER2-mediated upregulation of HIF2α is 
not directly driven by either MEK/ERK or PI3K signalling, and instead may be perturbed as an 
indirect consequence of PI3K inhibition.  
  In summary, I have demonstrated a HER2-specific effect on HIF2α levels in normoxia 
which is likely to contribute to the increased hypoxic response of MCF7-HER2 cells discussed 
in chapters 3 and 4. The increased transcription of HIF2α drives the higher level of HIF2α 
protein in normoxia, which in turn provides a larger pool of protein which, when the cells are 
subjected to hypoxic conditions, allows the normal hypoxic accumulation of protein to be 
accelerated. This seems a plausible mechanism as parallel differences between HIF1α and 
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HIF2α are seen in normoxia and hypoxia. HIF1α is similarly expressed in normoxia in both cell 
lines and similarly upregulated by NRG, as well as showing a similar increase in response to 
hypoxia. HIF2α however is more highly expressed in the context of HER2 expression and also 
more vigorously upregulated in hypoxia in this cellular context. The HIF2α specific differences 
seen when HER2 is overexpressed suggest that alterations in the severity of the hypoxic 
response (shown in chapters 3 and 4) may be a direct result of HER2-mediated increases in 
HIF2α transcription.   
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Chapter 6: Investigating HIF2α as a potential 
target in breast cancer 
 
6.1 Introduction 
 As discussed in Chapter 1, research into the role of hypoxia-inducible factors in breast 
cancer has focussed predominantly on HIF1. The absence of HIF2-focussed research 
pertaining to breast cancer has extended into investigations of HIF-inhibition as a possible 
therapeutic strategy for breast cancer. Whilst the apparent benefits of targeting HIFs in 
breast cancer have resulted in the development of numerous inhibitors which target HIF1 
either directly or indirectly [170], the development and investigation of HIF2-specific 
inhibitors has only progressed due to the recognised role of HIF in other cancer types [510]. 
In this study, I have demonstrated both the potential for HER2-overexpressing cells to drive 
HIF2α expression in normoxia (Chapter 5) as well as the increased hypoxic upregulation of a 
number of pathologically important genes in the context of HER2 overexpression which 
coincides with HER2-mediated changes to HIF2α but not HIF1α (Chapters 3 and 4). This 
suggested that HIF2 may be an important driver of breast cancer pathogenesis in the context 
of HER2 overexpression.  
 HIF2 inhibitors have been most extensively investigated in ccRCC [511]. Most recent 
success with HIF2 antagonists has come in the form of small molecule inhibitors designed to 
inhibit HIF2 dimer formation through binding to the HIF2α PAS domain, which results in the 
inability of HIF2α to form active dimers with HIFβ subunits [389-391]. These allosteric 
inhibitors of HIF2 have shown a high level of efficacy in renal cell carcinomas, with PT2399 
and its close analogue PT2385 showing great potential in pre-clinical research and phase-1 
clinical trials respectively [393, 396, 512]. PT2385 is also currently the subject of a phase II 
clinical trial for ccRCC [395]. Two such inhibitors were used in this study to investigate their 
efficacy on breast cancer cell lines, these being the aforementioned PT2385 and HIF2 
inhibitory compound 2 [391] (a well-characterised first-generation inhibitor of HIF2 
dimerization). In addition to these, compound 76, a specific inhibitor of HIF2α translation 
[283], was used as an alternative means of HIF2 inhibition. Compound 76 works by promoting 
the binding of the IRP1 protein to an iron-response element (IRE) in the 5’-UTR of HIF2α 
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mRNA. Binding of IRP1 to HIF2α mRNA represses basal translation until hypoxic conditions 
mediate its release through post-translational changes, permitting the translational 
upregulation of HIF2α in response to hypoxia. Thus compound 76 is a useful tool to assess 
the effects of HIF2α inhibition in breast cancer through reducing protein levels. 
With the potential of HIF2 inhibition in breast cancer being poorly understood, I 
aimed to assess the efficacy of HIF2-specific inhibition by siRNA and the use of three small 
molecular inhibitors of HIF2 (PT2385, compound 2 and compound 76) in breast cancer cell 
lines and investigated whether HER2-positive cell lines showed an increased sensitivity to 
such treatment. 
 
6.2 Inhibition of HIF2α using siRNA 
 In initial experiments, I used HIF2α knockdown by siRNA transfection to assess the 
effects on cell line growth through SRB assays and hypoxic response through western blotting 
of whole cell lysates. This included some preliminary experiments to establish successful and 
specific knockdown of HIF2α post-transfection and also to establish an appropriate time 
frame for HIF2α knockdown.  
 
6.2.1 Preliminary experiments to assess the effectiveness of siRNA 
transfection in inhibiting HIF2α 
 As stated above, preliminary experiments were set up to evaluate the specific activity 
of HIF2α targeting siRNAs. MCF7-HER2 cells were transfected with a panel of siRNA 
oligonucleotides to assess their ability to knockdown HIF2α. Four unique siRNAs (targeted 
against HIF2α) at a recommended concentration of 25 μM as well as a SMARTpool siRNA mix 
(a 1:1:1:1 mix of the four individual siRNAs) at a range of concentrations between 5 and 100 
μM were used. To act as controls, additional cells were transfected with either 25 μM non-
targeting siRNA (NT), without any siRNA, or left untransfected (unt). Whole cell lysates were 
collected 96 hrs after transfection and after 24 hrs treatment with 400 μM cobalt chloride. 
Immunoblotting for HIF1α and HIF2α was performed and is shown in Figure 6.1. This 
experiment demonstrated that all targeted siRNAs tested were effective at reducing HIF2α 
levels in this cell line. This effect was weaker at the lowest concentration of SMARTpool siRNA 




Figure 6.1: Western blotting of a panel of HIF2α siRNAs to determine target specificity 
 
Whole cell lysates were collected after treatment of MCF7-HER2 cells with various HIF2α siRNAs for 
a total of 96 hrs with 24 hrs cobalt chloride treatment (400 µM) in normoxia. This included 4 siRNAs 
of various sequences (#1, #2, #3 and #4) all used at a final concentration of 25 μM. As well as 
SMARTpool siRNA used at concentrations ranging from 5 µM to 100 µM. This was done alongside 
untransfected cells (Unt), cells transfected with no siRNA (Mock) and cells transfected with a non-
targeting siRNA (NT) used at 25 µM. Immunoblotting for HIF2α, HIF1α and loading controls α-tubulin 
and β-actin (n=1).  
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reduction in HIF2α levels was seen in mock or NT treatment groups when compared to 
untransfected cells. In most instances, siRNAs appeared highly specific, as defined by no 
effect on HIF1α, α-tubulin or β-actin. The main exception to this was siRNA #2 which showed 
a marked reduction in HIF1α. From this experiment, siRNA #4 and the SMARTpool siRNA used 
at 10 μM (SP10) were selected for further work, providing two examples of effective yet 
specific HIF2α knockdown in these cells. SP10 was selected as this was the lowest 
concentration of SMARTpool siRNA to provide the maximum observed reduction of HIF2α, 
with the intention of having minimum siRNA induced cellular toxicity. 
 Having shown that these siRNAs are able to inhibit cobalt chloride stabilised HIF2α 
in MCF7-HER2 cells, our next experiment aimed to determine whether HIF2α siRNA #4 and 
SP10 were able to inhibit the hypoxic upregulation of HIF2α. Hypoxic time courses of 0-72 
hrs were performed with 96 hrs siRNA treatment to see whether this was sufficient to inhibit 
the hypoxic upregulation of HIF2α MCF7-HER2. Western blotting of this experiment is shown 
in Figure 6.2, which demonstrates the expected hypoxic upregulation of HIF2α in 
untransfected, mock and NT treated samples, but a complete absence of hypoxia 
upregulated HIF2α after transfection with both #4 and SP10.   
 Our last preliminary experiment assessed the time frame over which siRNA-mediated 
inhibition of HIF2α was effective. To do this, MCF7-HER2 cells were treated with #4 or SP10 
HIF2a targeting siRNAs alongside mock, NT and untransfected controls. Transfections were 
performed 24-96 hrs prior to lysate collection and treatment with 400 μM cobalt chloride 
24hrs before collection. In this experiment HIF2α levels were particularly low, especially at 
shorter siRNA time points; despite this HIF2α was reduced at all time points in HIF2α 
targeting siRNA treated samples, being below the detection limit in these samples (Figure 
6.3). 
 Together these preliminary experiments show that two HIF2α targeting siRNA 
treatments (#4 and SP10) are effective at reducing HIF2α protein levels with no discernible 
effects on HIF1α. This knockdown resulted in HIF2α protein levels being reduced by 
approximately 90% and knockdown was shown to prevent the accumulation of HIF2α protein 
through cobalt chloride or hypoxia over a 72 hr time course. Knockdown reduced HIF2α levels 
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Figure 6.2: Western blotting of siRNA-mediated HIF2α knockdown in MCF7-HER2 in hypoxia 
 
Whole cell lysates were collected after treatment of MCF7-HER2 cells with two HIF2α-specific siRNAs #4 (25 
µM) and SMARTpool (10 µM) as well as Untransfected, Mock (no siRNA) and Non-targeting siRNA (25 µM). 
Cells were treated with siRNAs for a total of 96 hrs, and were either grown in normoxia or in hypoxia for 24, 
48 or 72 hrs prior to lysate collection. Immunoblotting for HIF2α or α-tubulin protein (loading control) is 
shown. Representative repeat of n=2 experiments. 
Figure 6.3: Testing the temporal effects of siRNA-mediated HIF2α inhibition 
 
Whole cell lysates were collected from MCF7-HER2 cells untreated or treated with either HIF2α targeting 
siRNA #4 (25 µM), HIF2α siRNA SMARTpool (10 µM), non-targeting siRNA (25 µM) or transfection reagent 
without siRNA for 24-96 hrs. All samples were treated with 400 µM cobalt chloride for 24 hrs. 
Immunoblotting was performed for HIF2α and α-tubulin (loading control) (n=1). 
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6.2.2 siRNA-mediated HIF2α inhibition reduces cellular growth in 
normoxia and hypoxia with higher sensitivity in MCF7-HER2 cells 
 Next, siRNA-mediated knockdown of HIF2α was used to assess the potential for 
HIF2α inhibition in reducing cellular growth rate as measured by the SRB assay. Relative cell 
growth was assessed after 5 days treatment with non-targeting, or HIF2α targeting siRNAs 
#4 and SP10 in normoxia and hypoxia. This was performed with four cell lines, MCF7, MCF7-
HER2, MDA-MB-231 and HBL100. HER2 overexpressing and wild-type MCF7 cell lines were 
used to assess whether HER2 overexpression, which has been associated with increased 
HIF2α, sensitizes cells to HIF2α inhibition. Triple negative cell lines MDA-MB-231 and HBL100 
were used to assess whether cell lines shown to have higher constitutive expression of HIF2α 
are sensitive to HIF2α inhibition (Figure 3.1). Data from these experiments is shown in Figure 
6.4. 
A comparison of MCF7 and MCF7-HER2 cells shows that siRNA-mediated HIF2α 
knockdown had a greater effect on cellular growth in the HER2 overexpressing cell line. In 
normoxia, MCF7 growth was significantly inhibited by treatment with siRNA #4 (p<0.0001) 
but this was not replicated with the SMARTpool siRNA (SP10). MCF7-HER2 growth was 
significantly inhibited by both siRNAs (p<0.0001) and the level relative growth inhibition was 
significantly greater in MCF7-HER2 for both siRNAs when compared to wild-type MCF7. 
Whilst growth was generally inhibited to a lesser extent in hypoxia when compared to 
normoxia, increased sensitivity of MCF7-HER2 cells when compared to wild-type cells was 
still observed. No significant inhibition of MCF7 cells was achieved in hypoxia, whilst in MCF7-
HER2 both siRNA treatments were once again able to significantly inhibit cellular growth over 
5 days  (p<0.0001 in both cases). Triple-negative cell lines MDA-MB-231 and HBL100 also 
displayed reduced growth rates with HIF2α siRNA treatment compared to non-targeting 
controls. In all cases this effect was greater in normoxia. Overall, siRNA #4 was effective at 
reducing cellular growth in both triple-negative cell lines in normoxia and hypoxia, whilst 
SP10 transfection was only effective in reducing growth in HBL100 and only in normoxia. 
Generally, this demonstrates that only MCF7-HER2 cells had a robust sensitivity to HIF2α 
knockdown. Triple negative cell lines (especially HBL100) did demonstrate higher sensitivity 
than wild-type MCF7 cells but in these experiments it is unclear whether that is due to being 





Figure 6.4: The effect of siRNA-mediated HIF2α inhibition on cellular growth 
 
Sulforhodamine B growth assays performed on MCF7 (blue), MCF7-HER2 (red), MDA-MB-231 (green) and HBL100 
(purple) cells after 5 days growth in normoxia or hypoxia (0.5% oxygen), following treatment with non-targeting 
or two HIF2α targeting siRNAs (#4 (25 μM) and SMARTpool (10 μM)). Bars represent mean cell density 5 days 
after treatment, with standard deviation represented by the error bars (n=12). P-values from all statistically 
significant results as determined by one-way ANOVA with Dunnett’s multiple comparisons are shown. 
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6.3 Investigating the potential of HIF2 inhibitory compounds 
in breast cancer cell lines 
  
As discussed in Chapter 1 and the introduction to this chapter, a few HIF2 specific 
molecular inhibitors have recently become available, and three of these were selected to test 
whether inhibition of HIF2 through small molecule drugs may be more effective than an 
siRNA-based strategy at eliciting a cellular response in terms of growth inhibition and 
inhibition of the upregulation of hypoxic response genes in hypoxia. In the next set of 
experiments, a HIF2α specific translation inhibitor compound 76 (C76) [283] and two specific 
inhibitors of HIF2 heterodimer formation, compound 2 (C2) [391] and PT2385 (PT) [393], 
were used to assess to assess the potential for HIF2 inhibition in breast cancer cell lines. First, 
these compounds were tested on a range of breast cancer cell lines in SRB growth assays to 
determine their relative potential for growth inhibition in various subtypes of breast cancer. 
Compounds were then tested in MCF7-HER2 to assess their potential to inhibit exacerbated 
hypoxic response in these cells, and finally the potential of these compounds to inhibit cell 
motility in a selection of cell lines in 2D wound healing assays and 3D collagen invasion assays 
was examined.   
 
 
6.3.1 A comparison of cell line sensitivity to HIF2 compounds using 
SRB growth assays 
 To assess the effect of these compounds on the growth rate of breast cancer cell 
lines, two sets of SRB experiments were performed. Firstly, cellular growth over 7 days was 
assessed using a range of compound concentrations in normoxia and hypoxia in MCF7, MCF7-
HER2, MDA-MB-231 and HBL100 cells. Following this, additional experiments were 
performed on a larger set of cell lines to determine IC50 concentrations for each compound 
in normoxia using cell density measures taken 5 days after treatment.  
 Figure 6.5 shows SRB growth assay data for MCF7, MCF7-HER2 (6.5a), MDA-MB-231 
and HBL100 cells (6.5b) treated with C2, C76 or PT in normoxia or hypoxia over 7 days. A 
comparison of MCF7 and MCF7-HER2 shows no differences in sensitivity to these compounds 
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in normoxia or hypoxia. In addition, no clear differences in the effectiveness of compounds 
were seen between normoxic and hypoxic conditions when compared within cell lines. 
Treatment with 10 µM C76 did show a stronger relative reduction in growth by 3 days in 
hypoxia when compared to normoxic equivalents in each cell line, however this was limited 
to this concentration and results were difficult to interpret due to general reduced 
proliferation in hypoxia. Whilst no differences between cell lines or oxygen conditions were 
observed, all three compounds did inhibit cellular growth relative to vehicle (DMSO) controls. 
With C2 and C76, a clear concentration-dependent effect was seen in both cell lines, with 
C76 being effective over the range of concentrations tested. PT2385 was generally less 
effective with a reduction in cellular growth rate only seen at 100 µM (the highest 
concentration tested). Similar experiments in triple-negative cell lines MDA-MB-231 and 
HBL100 (Figure 6.5b) suggest that these cell lines may be less amenable to HIF2 inhibition as 
a strategy for reducing growth rate. Once again, no significant differences were observed 
between these two cell lines and no differences were observed between normoxia and 
hypoxia. In contrast to MCF7-derived cell lines however, triple-negative cell lines 
demonstrated minimal response to C2 and PT treatment. In comparison to DMSO, these cell 
lines actually showed increased growth rate. However, a dose-dependent reduction in 
growth rate was still apparent, suggesting that these compounds did not induce cellular 
growth but rather were less damaging to growth at low concentration than the relatively high 
concentration of DMSO used as a control in these experiments. This is reflected by the 
concordance of DMSO controls with 100 µM treatments with both C2 and PT treatment, 
which represent treatments of the same DMSO concentration. Despite the lack of effects 
seen using C2 and PT, treatment with the translational inhibitor of HIF2α C76 was still 
effective at reducing cellular growth in both cell lines in a dose-dependent manner relative 
to DMSO. This suggests that inhibition of HIF2α protein translation may be a more generally 
applicable approach than inhibition of HIF2 activity (although non-specific cellular toxicity 
may reduce its effectiveness as a potential therapeutic).  
 To further investigate the question of cell line specificity for these compounds, I 
performed a larger scale experiment in 9 breast cancer cell lines (Figure 6.6). ER-driven cell 
lines MCF7, T47D and ZR751, HER2-driven cell lines MCF7-HER2, BT474, SKBR3 and 
MDA.MB.361, and triple-negative cell lines MDA-MB-231 and HBL100 were used. This was 
done using compound concentrations ranging from 10 nM to 100 µM in normoxia over 5 
days, and where possible IC50 values were determined for each compound in each cell line 
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(Figure 6.7 C). In this experiment each compound concentration was compared directly to a 
DMSO control of equivalent concentration so that compound specific effects could be more 
easily differentiated from DMSO-mediated toxicity. Graphs for each cell line show the change 
in cell density over 5 days as a percentage of 5-day growth in the DMSO controls. Across all 
cell lines C76 had the greatest effect of the three compounds tested. A comparison of C76’s 
effect on each cell line is shown in Figure 6.7 A. This demonstrates that, with the exception 
of MCF7-HER2, all HER2-overexpressing cell lines (red lines) have increased sensitivity to this 
compound when compared to ER-positive/HER2-negative (blue) and triple-negative cell lines 
(green). A comparison of 10 μM C76 treatment after 5 days shows reduced growth in all cell 
lines tested. However, HER2-overexpressing cell lines BT474, MDA.MB.361 and SKBR3 all 
showed a significantly greater reduction in growth when compared to ER-driven or triple-
negative cell lines (p<0.0001 in all cases, one-way ANOVA with Tukey’s multiple comparison). 
The increased sensitivity of these cell lines is also apparent from the reduced IC50 values 
compared to other cell lines (Figure 6.7 C). Compound 2 and PT2385 were both less effective 
at reducing cellular growth over 5 days and did not show consistently increased activity in 
HER2-overexpressing cells over the range of concentrations tested (demonstrated by the IC50 
values shown in Figure 6.7 C). Despite this, C2 did demonstrate significantly greater effects 
on BT474 (p<0.0001), MDA.MB.361 (p≤0.0002) and SKBR3 (p≤0.0188) (one-way ANOVA, 
Tukey’s multiple comparison) compared to HER2-negative cell lines when treated with 50 μM 

































Figure 6.5a: A comparison of cell growth in breast cancer cell lines treated with HIF2 inhibitory compounds 
MCF7 and MCF7-HER2 cells were seeded 1000 cells per well in 96-well plates. These were left for 48 hrs 
before being treated with 0.1-100 μM of compound 2 (C2), compound 76 (C76), PT2385 (PT) or 1% DMSO 
(vehicle). Cells were grown in normoxia or hypoxia (0.5% oxygen) for 7 days after treatment. Plates were 
fixed and SRB assays performed to assess cell density at 3, 5 and 7 days post treatment. Graphs showing the 
absorbance of 540 NM wavelength light as a measure of relative cell density. Error bars show the standard 
























































Figure 6.5b: A comparison of cell growth in breast cancer cell lines treated with HIF2 inhibitory compounds 
MDA-MB-231 and HBL100 cells were seeded 1000 cells per well in 96-well plates. These were left for 48 hrs before 
being treated with 0.1-100 μM of compound 2 (C2), compound 76 (C76), PT2385 (PT) or 1% DMSO (vehicle). Cells 
were grown in normoxia or hypoxia (0.5% oxygen) for 7 days after treatment. Plates were fixed and SRB assays 
performed to assess cell density at 3, 5 and 7 days post treatment. Graphs showing the absorbance of 540 NM 
















































Figure 6.6: Determining IC50 values for HIF2 inhibitors in breast cancer cell lines 
An expanded panel of breast cancer cell lines was used to determine IC50 values for compound 2 (C2), compound 
76 (C76) and PT2385 (PT). Cells were seeded into 96 well plates and left for 48 hrs before being treated with 10 
nM-100 µM of C2, C76, PT or a range of equivalent concentrations of DMSO (vehicle). Cellular density was 
assessed after 5 days by SRB assay, and growth curves were normalised to DMSO controls for each cell line. 
Normalised data was plotted as a percentage of DMSO treated cells. Where possible a non-linear regression 
model was used to fit curves and determine the value at which cellular growth was reduced by 50%. Error bars 
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Figure 6.7: Summary of IC50 growth data for HIF2 inhibitory compounds 
A) Five-day cellular growth as a percentage of DMSO control shown for each cell line over a range of 
concentrations of compound 76 (10 nM-100 μM). All cell lines have been plotted on a single axis for 
direct comparison. ER-positive/HER2-negative (blue), HER2-positive (red) and triple-negative (green) 
cell lines are colour coded. Error bars represent the standard deviation of n=6 repeats. B) Bar graphs 
showing 5-day growth relative to DMSO control for chosen concentrations of each compound, error 
bars represent the standard deviation from n=6 repeats. C) Table of IC50 concentrations of each 









6.3.2 Inhibition of hypoxic protein upregulation in MCF7-HER2 by HIF2 
inhibitory compounds 
 Western blotting of whole cell lysates was used to assess the effect of HIF2-targeting 
inhibitors on the hypoxic upregulation of HIF1α, HIF2α, CAIX and LDHA. MCF7-HER2 cells 
were treated with 50 μM compound 2 (C2), 20 μM compound 76 (C76), 10 μM PT2385 (PT) 
or vehicle control DMSO (0.5%) for 1 hr before being transferred to and grown in hypoxia for 
24, 48 or 72 hrs. The concentrations used were based on previous published research as well 
as SRB data shown above; both compound 2 [391] and PT2385 [393] have been shown to 
maximally inhibit HIF2 dimerisation in co-immunoprecipitation experiments in cell line 
models at concentrations as low as 0.1 and 0.01 μM respectively, with no additional effects 
seen after 10 μM for compound 2 or 1 μM for PT2385. In addition, PT2385 was shown to 
reduce the expression of HIF2 target genes in 786-0 cells at concentrations as low as 0.01 
μM, with maximal effects seen at 1 μM [393]. The concentration of C76 was chosen as this 
was the highest concentration which could be used without complete inhibition of cell 
growth (Figure 6.5a). Western blotting results for this experiment are shown in Figure 6.8. Of 
the three compounds tested only C76 appeared to have an inhibitory effect on the 
upregulation of hypoxic response proteins. After treatment with 20 μM C76, the hypoxic 
upregulation of CAIX was reduced when compared to DMSO control (n=2). This occurred 
despite no visible reduction in the upregulation of LDHA or HIF2α and an observed increase 
in the levels of HIF1α in hypoxia when compared to DMSO controls. Treatment with 50 μM 
C2 had no visible effect on any of the proteins tested, whilst 10 μM PT treatment visibly 
reduced HIF2α after 72 hrs in hypoxia (n=1) with no concomitant effects on either CAIX or 





Figure 6.8: Inhibition of hypoxic upregulation with specific inhibitors of HIF2 
Immunoblotting of HIF1α, HIF2α, CAIX and LDHA in whole cell lysates of MCF7-HER2 cells treated 
with HIF2-specific inhibitors (n=2). A) MCF7-HER2 cells were treated with 50 μM compound 2 (C2), 
20 μM compound 76 (C76), 10 μM PT2385 (PT) or 0.5% DMSO for 1 hr before being grown in 
normoxia for 48 hrs or transferred to hypoxia for 24, 48 or 72 hrs before collection. B) Similarly 





6.3.3 Investigating the effect of HIF2 inhibitory compounds on cell 
motility in 2D and 3D models 
 Next I wanted to establish whether HIF2α inhibition through treatment with various 
HIF2 inhibitory compounds could affect the motility of breast cancer cell lines. Initially, cell 
motility was assessed by 2D wound healing assays in MCF7, MCF7-HER2 as well as in triple-
negative cell lines MDA-MB-231 and HBL100, which are both highly motile/invasive cell lines. 
Cell lines were grown in dishes containing removable inserts. Cells were allowed to reach 
confluence before inserts were removed and media was changed to low serum media 
containing either 50 μM C2, 20 μM C76, 10 μM PT or 0.5% DMSO (vehicle control). The 
removal of the insert produced a uniform 500 μm cell-free gap which closes as cells migrate 
to occupy the space. By measuring the area of this gap, cell motility was assessed after 24 
(MDA-MB-231 and HBL100) or 48 hrs (MCF7 and MCF7-HER2); this was also done with MCF7 
and MCF7-HER2 cells cultured in hypoxia for 48 hrs to compare to cell motility in normoxia. 
Quantitative analysis and representative images from these experiments are shown in figures 
6.9 and 6.10. 
In normoxia in MCF7 and MCF7-HER2 there was a relatively slow rate of wound 
closure, whilst no effect was seen in terms of wound closure after C2 or PT (only performed 
in MCF7-HER2) treatment. However, a significant increase in wound closure rate was seen 
for both cell lines (MCF7 p=0.0153, MCF7-HER2 p=0.0001, ANOVA with Dunnett’s multiple 
comparison to DMSO) after treatment with C76. This effect was most pronounced in 
normoxia, but for MCF7 cells was also noted in hypoxia (p=0.0002). In contrast, MDA-MB-
231 and HBL100 demonstrated a reduction of wound closure rate when treated with HIF2 
inhibitory compounds. MDA-MB-231 wound closure was significantly reduced after 
treatment with C2 only (p=0.0033), whilst HBL100 demonstrated reduced wound closure 
after treatment with both C76 (p=0.0037) and PT (p=0.0205), but not C2.   




Figure 6.9: 2D wound healing assays for MCF7 and MCF7-HER2 cell lines treated with HIF2 inhibitory 
compounds 
MCF7 (A) and MCF7-HER2 (B) cells were seeded on wound healing plates containing a removable 
insert. Upon reaching confluence, inserts were removed and media was changed to low serum media 
containing 0.5% DMSO, 50 μM compound 2 (C2), 20 μM compound 76 (C76) or 10 μM PT2385 (PT) 
and cultured in normoxia or hypoxia. Plates were imaged and wound area measured at 0 and 48 hrs. 
(LHS) Quantitative analysis of wound size for each treatment category shown as a percentage of 
wound size at 0 hrs. Differences were assessed by one-way ANOVA with Dunnett’s multiple 
comparison to the DMSO control (MCF7 n=3, MCF7-HER2 n=6), p-values for significant results are 
shown (error bars represent the SEM). (RHS) representative images of wound size at 0 hrs and after 





   
Figure 6.10: 2D wound healing assays for MDA-MB-231 and HBL100 cell lines treated with HIF2 
inhibitory compounds 
MDA-MB-231 (green) and HBL100 (purple) cells were seeded on wound healing plates containing a 
removable insert. Upon reaching confluence, inserts were removed and media was changed to low 
serum media containing 0.5% DMSO, 50 μM compound 2 (C2), 20 μM compound 76 (C76) or 10 μM 
PT2385 (PT) and cultured in normoxia for 24 hrs. Wound size at 24 hrs was compared to 0 hr wound 
size for each plate. (LHS) Quantitative analysis of wound size for each treatment category shown as a 
percentage of wound size at 0 hrs. Differences were assessed by one-way ANOVA with Dunnett’s 
multiple comparison to DMSO control, all significant p-values are shown (error bars represent the SEM) 
(n=6). (RHS) Representative images of wound size at 0 hrs and 24 hrs for each treatment.  
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Figure 6.11: Comparison of MCF7 and MCF7-HER2 spheroid invasion with HIF2 inhibitory 
compounds 
 
A) A representative example of MCF7, MCF7-HER2 and HBL100 spheroids grown for 1 week before 
being embedded in collagen for 72 hrs. The area of the spheroid (blue lines) and the area covered by 
invasive cells after 72 hrs (red lines) are shown. B) A comparison of untreated spheroid invasive area 
relative to spheroid size after 3 days in collagen. MCF7 (blue, n=13), MCF7-HER2 (red, n=6), error 
bars represent the SEM (p<0.0001, Mann-Whitney unpaired t-test). C & D) Comparison of invasive 
area from MCF7 (C) or MCF7-HER2 (D) spheroids grown in collagen for 3 days and treated with DMSO 
(0.5%), HIF2 dimerization inhibitor compound 2 (50 μM) or HIF2α translation inhibitor compound 76 
(20 μM). Whisker plots represent mean values with standard deviations. Kruskal-Wallis test with 
Dunn’s multiple comparisons was used to determine significance, p-values for all significant results 
are shown.  
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Figure 6.12: Normoxic vs hypoxic invasion in MCF7 and MCF7-HER2 spheroids 
 
MCF7 (blue) and MCF7-HER2 (red) were grown as spheroids for 1 week before being embedded into 
collagen and left for 3 days in either normoxia (atmospheric oxygen) or hypoxia (0.5% oxygen). Spheroids 
were treated for the duration with either DMSO (0.5%), HIF2 dimerization inhibitor compound 2 (50 μM) 
or HIF2α translation inhibitor compound 76 (20 μM). A & B) Comparison of MCF7 (A) or MCF7-HER2 (B) 
invasion in normoxia and hypoxia. Whisker plots represent mean and standard deviations of multiple 
spheroid measurements. Kruskal-Wallis non-parametric ANOVA was used to determine significance, the 
p-values of all significant results are shown. C & D) A comparison of spheroid invasion after 3 days in 
hypoxia MCF7 (C) and MCF7-HER2 (D) spheroids treated with either DMSO, compound 2 or compound 76. 
No significant results differences were found using a Kruskal-Wallis non-parametric ANOVA with Dunn’s 
multiple comparisons.  
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  The potential for HIF2 inhibition in reducing cell invasion was assessed using 3D 
multicellular spheroids for MCF7 and MCF7-HER2 cell lines. Spheroids were grown for one 
week before being embedded in collagen type-1A. The collagen and surrounding media was 
treated with 50 μM C2 or 20 μM C76 and spheroids were left for 72 hrs in normoxia or 
hypoxia. After 72 hrs spheroids were imaged and cellular invasion was assessed by measuring 
the area covered by cells moving out of the spheroids mass. The invasive area was compared 
between cell lines and treatment categories to determine the effect of HIF2 inhibition in 
MCF7 and MCF7-HER2 cells.  
 MCF7 and MCF7-HER2 spheroids both showed relatively low invasive potential after 
72 hrs when compared to HBL100 (used as a positive control for invasion) (Figure 6.11 A). 
However, MCF7-HER2 did show significantly higher invasion than MCF7 spheroids (p<0.0001) 
(Figure 6.11 B). Despite low invasion, a significant reduction in invasion was seen in MCF7 
cells when treated with C76 (p=0.0159) when compared to the DMSO control; no effect was 
seen after C2 treatment (Figure 6.12 C). In MCF7-HER2 a significant reduction in invasion was 
seen in C2 treated spheroids (p=0.0391), but no significant effect was seen after C76 
treatment (Figure 6.11 D). Hypoxic experiments demonstrated that spheroid invasion was 
reduced by growth in hypoxia (Figure 6.12 A and B). In MCF7-HER2, invasion in hypoxic 
spheroids treated with DMSO (p=0.0002), C2 (p<0.0001) or C76 (p=0.0048) was significantly 
lower than in normoxic spheroids treated with DMSO. Under hypoxic conditions compound 
treatment with C2 or C76 was unable to further reduce the invasive potential of either MCF7 
or MCF7-HER2 spheroids (Figure 6.12 C and D).  
  
6.4 Discussion 
 In this chapter, I assessed the potential for HIF2 as a therapeutic target in breast 
cancer by investigating the effects of HIF2 inhibition through siRNA or treatment with HIF2-
specific inhibitory compounds on cellular growth and motility in a panel of breast cancer cell 
lines. 
 Using two different siRNAs which were able to specifically reduce HIF2α protein 
levels in normoxia and hypoxia, I was able to demonstrate an increased sensitivity of HER2-
overexpressing cells when compared to their wild-type counterparts. Similar growth assays 
were able to demonstrate an increased sensitivity of 3 HER2-positive cell lines (SKBR3, BT474 
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and MDA.MB.361) to C76 and (at 50 μM concentrations only) C2 treatment in normoxia. 
Together this provides compelling evidence that these cell lines are more sensitive to HIF2-
specific inhibition. This would be consistent with the increased sensitivity of HER2-
overexpressing cell lines to HIF inhibition being causally linked to the HER2-mediated 
upregulation of HIF2α demonstrated in Chapter 5. Interestingly, the sensitivity of these cells 
to both siRNA and small compound-mediated HIF2 inhibition was higher in normoxia than 
hypoxia. This suggests that the sensitivity to HIF2 inhibition is not due to an inability to 
respond to hypoxic stress, but instead represents an important non-canonical role for 
normoxic HIF2α in these cells. Whilst SRB assays were in this way able to demonstrate 
important differences in cell line growth after HIF2α inhibition, it is important to note that 
the measurement of total cellular protein by SRB binding does not directly provide 
information on whether these effects are due to a reduction in proliferation or an increase 
in cell death. Further work including the use of BrdU incorporation as a measure of DNA 
synthesis or apoptosis assays (such as the TUNEL assay) would offer more insight into how 
HIF2α inhibition perturbs cell line growth in vitro.  
In western blotting experiments treatment with HIF2α-specific translation inhibitor 
C76 was able to reduce the hypoxic upregulation of CAIX in MCF7-HER2 cells. This was despite 
an increase in the levels of HIF1α. This effect was limited to 24 hrs, the earliest time point 
tested, which is likely a result of HIF2α build up in hypoxia. Whilst C76 inhibits translation of 
HIF2α by promoting binding of IRP1 to the iron response element in the HIF2α 5’ UTR, this 
effect is reduced in hypoxia where binding of IRP is inhibited [283]. This means that C76 was 
able to reduce normoxic levels of HIF2α, but under hypoxia the re-enabling of HIF2α 
translation allowed levels to quickly reach those seen in untreated cells. The effect of C76 on 
CAIX after 24 hrs in hypoxia may be due to a reduced pool of HIF2α at the initiation of hypoxia 
and a delayed response in terms of CAIX transcription and translation. The inhibition of CAIX 
upregulation was only seen with C76 and not with either C2 or PT (which are both inhibitors 
of HIF2 dimerisation with HIFβ). This suggests that canonical HIF2 transcription with HIFβ may 
not be responsible for CAIX transcription in hypoxia. With this in mind it is likely that HIF2α-
mediated upregulation of CAIX in hypoxia occurs through transcriptional actions of HIF2α 
with other co-factors, or through events which are not reliant on the direct transcriptional 
activity of HIF2. However, this is only preliminary data as these experiments were only 
repeated twice, therefore no statistical analysis was possible and more experimental repeats 
are required to verify these findings. 
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 We also investigated the role of HIF2 inhibitory compounds on cell motility in 2D and 
cell invasion in 3D spheroids of breast cancer cell lines. In 2D wound healing experiments I 
was able to demonstrate the inhibition of cell motility by C2 (MDA-MB-231) and both C76 
and PT (HBL100) in normoxia, broadly demonstrating the ability of HIF2 inhibition to inhibit 
motility in highly invasive triple-negative cell lines. Equivalent experiments in MCF7 and 
MCF7-HER2 were unable to demonstrate a positive effect (presumably due to the low basal 
level of motility in these cell lines), and contradictory to findings in triple-negative cell lines, 
motility was increased in both MCF7 and MCF7-HER2 after treatment with C76. This may be 
due to the effect of C76 on HIF1α, which was shown to be increased even in normoxia by 
treatment with C76 (Figure 6.9). Despite these findings in 2D, collagen invasion assays using 
3D spheroids were able to demonstrate a small inhibition of invasion by HIF2 inhibitory 
compounds in these cell lines. In MCF7 spheroids, C76 treatment reduced the invasive area 
after 3 days, however due to the low basal invasiveness of MCF7 spheroids in collagen and 
the demonstrated cytotoxic effects of C76 in this chapter, it is not currently clear whether 
this effect is a result of specific inhibition of cell invasion or due to a broader detrimental 
effect on these cells. In MCF7-HER2 the significant reduction of invasion was seen only after 
treatment with compound 2. Due to the higher invasive potential of this cell line and the less 
cytotoxic effect of C2 treatment on these cells, this result provides more convincing evidence 
that HIF2 inhibition is able to reduce cellular invasion in breast cancer cell lines. 3D spheroids 
grown in hypoxia showed reduced invasive potential, especially in the case of MCF7-HER2 
where normoxic invasive potential was higher. No inhibition of 3D spheroid invasion in 
hypoxia was seen after treatment with HIF2 inhibitory compounds, but this is probably 
attributable to the minimal invasive potential seen under these growth conditions.     
 This investigation of HIF2 inhibition in breast cancer cell lines has demonstrated the 
possibility that targeting HIF2 may be a therapeutic approach in a subset of breast cancers. 
SiRNA and compound work demonstrates an increased sensitivity of HER2-overexpressing 
cells to perturbation of HIF2α, which in concordance with results from chapters 3-5 suggest 
that the HER2-HIF2 axis may be an important driver of breast cancer pathogenesis and a 
targetable pathway. That these effects were limited to HER2-overexpressing cells highlights 
the importance of considering the molecular subtype when investigating potential 
therapeutic targets in breast cancer. As well as cellular growth, HIF2 inhibition was shown to 
perturb cell motility and invasion in breast cancer, suggesting that HIF2 contributes to these 
characteristics in breast cancer. Effects on cell motility in triple-negative cell lines raises the 
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question of whether HIF2 inhibition would also be an effective strategy in this particularly 
aggressive subtype of breast cancer, which currently has limited treatment options. Whilst 
HER2 expression is definitively low in these cell lines, their frequent reliance on EGFR (HER1) 
driven growth also begs the question of whether EGFR may also result in HIF2α-dependent 
pathology under certain conditions. Finally, whilst this chapter has provided evidence for 
HIF2α as an effective means of inhibiting breast cancer cell growth and motility, the fact that 
C76 can increase cellular motility in MCF7 and MCF7-HER2 cell lines, possibly through the 
increased levels of HIF1α, demonstrates the importance of considering the role and effect of 




Chapter 7: Investigating the role of HIF2α 
expression in breast cancer survival 
 
7.1 Introduction 
  The association of HIF1α expression with poor outcome in breast cancer has 
been demonstrated in a number of studies [284-293, 513, 514]. Despite this the impact of 
HIF2α in breast cancer is still poorly understood. Whilst a correlation between HIF2α 
expression and poor prognosis has been shown in various cancer types, including head & 
neck [515, 516], lung [517], colorectal [518] and bladder [519] cancers, few studies have been 
conducted in breast cancer and these appear to have conflicting results, with HIF2α 
expression being associated with both a better [427] and worse [261] prognosis. Having 
shown that HIF2α is associated with HER2 expression in breast cancer cell lines (chapters 3 
and 5), and that HER2 overexpressing cell lines may have increased sensitivity to HIF2α 
inhibition (chapter 6), we next wanted to ask whether stratifying patients based on HER2 
expression may help define the role for HIF2α in breast cancer prognosis.  
In this chapter I assessed the relationship between HIF2α expression and patient 
survival using two publically available datasets; the online tool and associated dataset Kmplot 
[438] and the METABRIC [437] gene expression dataset, each containing matched clinical and 
gene expression data. This approach has allowed the role of HIF1α and HIF2α expression in 
breast cancer survival to be assessed both on complete cohorts and on patients identified as 
either HER2-positive or HER2-negative in two independent datasets.  
 
7.2 A comparison of HIF1α and HIF2α expression and patient 
survival using Kmplot  
 Initially survival analysis for HIF1α and HIF2α was performed using Kmplot [438]. The 
impact of gene expression on overall survival, recurrence-free survival and distant 
metastasis-free survival was assessed for both HIF1α and HIF2α. Kaplan-Meier curves were 
produced to compare survival between patients stratified as having cancers with either high 
or low expression based on the optimum cut-point, with p-values and hazard ratios for each 
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analysis provided (Figure 7.1). A comparison of HIF1α and HIF2α shows a clear difference 
between the two genes; as expected based on previously published research high HIF1α 
expression was broadly associated with poor survival. Overall (p<0.0001), recurrence-free 
(p<0.0001) and distant metastasis-free (p=0.00012) survival were all significantly worse in 
high HIF1α expressing breast cancers. In contrast, high expression of HIF2α had either no 
significant association with survival (overall and distant metastasis-free survival p>0.1) or was 
weakly associated with an improvement in survival (recurrence-free survival p<0.05), 
showing a clearly differential role for these two factors in breast cancer survival. 
 The relationship between recurrence-free survival and HIF2α expression in breast 
cancer patients was shown to vary between high and low grade tumours (Figure 7.2). Survival 
analysis using Kmplot was performed on patients stratified based on tumour grade; this was 
only performed for recurrence-free survival as the availability of clinical data precluded a 
worthwhile analysis in alternative measures of disease progression. This demonstrated a 
clear difference in the role of HIF2α between low grade and high grade tumours. In grade 1 
tumours, high HIF2α expression was associated with an improvement in recurrence-free 
survival (p=0.011), whilst in grade 3 tumours an association with worse recurrence-free 

























Figure 7.1: HIF1α expression, but not HIF2α, is associated with worse prognosis in a large breast cancer 
dataset 
 
The online resource Kmplot was used to perform survival analysis for HIF1α and HIF2α expression in a large 
cohort of breast cancer samples. Kaplan-Meier plots for overall survival, recurrence-free survival and distant 
metastasis-free survival are shown for each gene. Samples were placed into high and low expression groups 
based on the optimum cut-point in each individual analysis. Each plot also shows its associated p-value, hazard 
ratio and the number of patients in the analysis. 
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Figure 7.2: HIF2α is associated with worse recurrence-free survival in higher grade tumours 
 
The online resource Kmplot was used to perform survival analysis based on HIF2α expression in a 
large cohort of breast cancer samples. Kaplan-Meier plots for recurrence-free survival in grade 1, 
grade 2 or grade 3 tumours. High and low gene expression groups were determined by the optimum 




7.3 HIF2α expression is associated with worse prognosis in 
HER2–positive breast cancer 
 Having demonstrated using Kmplot that HIF2α expression has no significant 
prognostic impact in the full cohort of breast cancer patients, we next stratified this dataset 
based on HER2 status determined by IHC or FISH, to investigate whether HIF2α was 
associated with worse survival in HER2-positive patients. A comparison of recurrence-free 
survival based on HIF1α and HIF2α expression was performed using HER2-positive (n=252) 
and HER2-negative (n=800) patients (Figure 7.3). Whilst HIF1α demonstrated an association 
with worse recurrence-free survival in both HER2-positive (HR=1.75, p= 0.011) and HER2-
negative samples (HR=1.74, p=<0.0001), HIF2α was only associated with worse survival in 
HER2-positive samples (HR=1.95, p=0.0023), with no significant association seen in HER2-
negative cases (HR=0.83, p=0.16).  
 To validate the association of HIF2α with poor prognosis in HER2-positive samples, 
survival analysis was performed using the METABRIC dataset. Patients in this dataset were 
once again stratified based on clinical HER2 status as determined by IHC and/or FISH analysis. 
A comparison of disease-specific survival was performed using optimum cut-point values for 
HIF2α expression in HER2-positive or HER2-negative cohorts (Figure 7.4). This analysis 
demonstrated, once again, a specific association of HIF2α expression with worse prognosis 
in HER2-positive patients (HR=6.81, p=0.0197), whilst no significant association was seen in 
HER2-negative samples (HR=0.46, p=0.0819). The optimum cut-points were determined 
using the SurvivALL package in R. SurvivALL is an analysis package developed by a 
collaborative laboratory (Andy Sims/Dominic Pierce) which performs survival analysis based 
on multiple cut-points to identify all which are significant for a gene of interest. This has 
allowed us not only to determine the optimum cut-point, but to show a robustness of this 
effect by demonstrating a range of significant cut-points which all show HIF2α to be 
associated with worse disease-specific survival in the HER2-positive samples in this dataset. 
Cut-points with p-values of less than 0.05 are shown by coloured points in SurvivALL graphs 




Figure 7.3: HIF2α expression is associated with worse survival specifically in HER2-positive breast 
cancers 
 
The online resource Kmplot was used to perform survival analysis in breast cancer cohorts divided 
into HER2-negative and HER2-positive (based on IHC scoring). Recurrence-free survival is shown for 
HIF1α and HIF2α, with cohorts divided into low and high expression groups by the optimum cut-point. 













Figure 7.4: Analysis of disease-specific survival (DSS) in the publically available METABRIC dataset 
demonstrates robust concordance with Kmplot, showing a HER2-specific effect for HIF2α expression 
 
A-C) METABRIC DSS data was assessed for the optimum cut-point in terms of HIF2α expression using the 
SurvivALL package. The hazard ratio is plotted for survival analysis based on each possible cut point. This is 
plotted against samples ordered by HIF2α expression (increasing left to right). Cut-points with p-values less 
than 0.05 are coloured according to the scale shown below for each plot. This analysis has been performed 
in all samples from the METABRIC dataset (A), HER2-positive samples only (B) and HER2-negative samples 
only (C). Whilst no significant cut-point was available for the complete sample set, optimum cut-points for 
HER2-positive and HER2-negative sets have been used to draw Kaplan-Meier curves (D and E). The number 
and position of significant cut-points according to SurvivALL analysis (grey bar) and how high and low 






7.4 A 10-gene signature for HIF2α activity is associated with 
worse survival in HER2-positive breast cancer 
 To further assess the role of HIF2α activity in HER2-specific breast cancer 
pathogenesis, we next investigated the association of HIF2-specific target gene expression 
with survival in breast cancer using the Kmplot and METABRIC datasets. A gene set 
comprising of HIF2α and 9 HIF2-driven genes shown to be HIF2-dependent in MCF7 cells was 
chosen [243]. These were determined by the siRNA-mediated knockdown of HIF2α followed 
by microarray expression analysis to find genes whose hypoxic upregulation was dependent 
on HIF2α expression. The genes included in this set are as follows: EPAS1, CITED2, WISP2, 
IGFBP3, LOXL2, HIST1H4H, TBC1D3, ILVBL, FAM13A1, and HEY1. Kmplot was used to assess 
overall, recurrence-free and distant metastasis-free survival based on the mean expression 
of these genes stratified into high and low expression categories based on the optimum cut-
point value (Figure 7.5). High expression of this HIF2 gene signature was associated with 
significantly worse overall (HR= 2.02 p= 0.049), recurrence-free (HR= 2.66, p<0.0001) and 
distant metastasis-free survival (HR=4.25, p<0.0001) in the HER2-positive group. Significantly 
worse prognosis was also seen in terms of recurrence-free (HR= 1.18, p=0.0043) and distant 
metastasis-free survival (HR= 1.28, p=0.016) in the complete dataset without stratification 
based on HER2 status, and in terms of recurrence-free survival only (HR=1.4, p=0.014) in the 
HER2-negative patients. All 3 measures of survival demonstrated the greatest association of 
these genes with poor prognosis when assessed in the HER2-positive group.   
 The METABRIC study was used as a second dataset to validate a role for HIF2 target 
genes in poor prognosis in HER2-positive breast cancers. The SurvivALL package was used to 
determine all significant (p<0.05) cut-points for disease-specific survival based on the mean 
expression of the 10-gene HIF2 signature. This was done in the complete cohort as well as 
HER2-positive and HER2-negative cohorts (Figure 7.6 A-C). Significant cut-points in the 
complete cohort were only seen at particularly high expression levels and so a meaningful 
comparison of high and low expression groups was not possible. There were no significant 
cut-points in the HER2-negative cohort, but in HER2-positive samples a robust set of 
significant cut-points were found. The optimum cut-point value for this group was 
determined and a Kaplan-Meier plot is shown in Figure 7.4E the expression of these genes is 
shown as a heat map in Figure 7.4D, and the optimum cut-point used for Kaplan-Meier 
analysis is shown. In this case, significantly worse disease-specific survival as associated with 





Figure 7.5: A 10-gene HIF2 signature also signifies a worse prognosis in HER2-positive breast cancer  
 
The online resource Kmplot was used to perform survival analysis in breast cancer cohorts divided into HER2-
negative and HER2-positive. Survival analysis based on the mean expression of HIF2α and 9 HIF2-specific 
target genes (CITED2, FAM13A1, HIST1H4H, HEY1, IGFBP3, ILVBL, LOXL2, TBC1D3 and WISP2) is shown in 
terms of overall survival, recurrence-free survival and distant metastasis-free survival, with cohorts divided 
into low and high expression groups by the optimum cut-point of mean gene expression. Each plot has its 






Figure 7.6: Disease-specific survival (DSS) using a 10-gene HIF2 signature in the METABRIC dataset 
demonstrates concordance with Kmplot, and an association of high HIF2 activity with worse survival in 
HER2-positive breast cancer  
 
A-C) METABRIC DSS data was assessed for the optimum cut-point in terms of the mean expression of HIF2α 
and 9 HIF2-specific target genes using the SurvivALL package. The hazard ratio is plotted for survival analysis 
based on each possible cut-point. This is plotted against samples ordered by the mean expression of genes 
(increasing left to right). Cut-points with p-values less than 0.05 are coloured according to the scale shown 
below for each plot. This analysis has been performed in all samples from the METABRIC dataset (A), HER2-
positive samples only (B) and HER2-negative samples only (C). The expression of each of the 10 genes ordered 
by the mean expression is shown for HER2-positive samples (D) with the position of significant cut-points 
according to SurvivALL analysis (grey bar) and how high and low categories are optimally divided (blue and 
red bar with n numbers below) both shown. The Kaplan-Meier plot with samples divided by the optimum cut-










 The role of HIF2α in breast cancer prognosis is poorly understood, and the limited 
studies which have aimed to address this issue have produced conflicting results [261, 427]. 
Results in chapters 3, 4 and 5 of this thesis have suggested an important relationship between 
HER2 and HIF2α expression and demonstrate the potential for HER2 overexpression to drive 
an increased response to hypoxia with the upregulation of a number of genes implicated in 
breast cancer progression and aggressiveness. With this in mind I have investigated the 
possibility that the role of HIF2α expression on survival may be directly linked to HER2 
expression. 
 It has been recognised that breast cancers can be broadly defined by their molecular 
subtype which is determined by the expression of growth factor or hormone receptors, and 
that molecular subtypes of breast cancer represent distinct diseases with different prognoses 
and treatment requirements. Here we were able to demonstrate that the role of HIF2α on 
breast cancer prognosis depends on the expression of HER2. This finding has been shown to 
be robust as the relationship between HIF2α and poor prognosis was found to be HER2-
dependent in two datasets. Whilst optimum cut-points were used for Kaplan-Meier analysis, 
it was also demonstrated that a range of cut-points are able to show this effect with p<0.05.  
The requirement for HER2 expression for HIF2α’s role in worse survival may offer an 
explanation for the contradictory findings of previous studies [261, 427]. These studies both 
used IHC of tissue microarrays containing 282 and 691 primary invasive breast cancer 
samples respectively. Unfortunately, data on HER2 status for these two cohorts has not been 
published so it is currently unclear whether this could have caused the contradictory 
outcomes of these studies.  
In addition, the role of HIF2 activity in prognosis was shown to be dependent on HER2 
expression; the association between the mean expression of a 10-gene HIF2 signature and 
poor outcome was seen to be greater in HER2-positive cohorts when compared to HER2-
negative or complete patient datasets. This was the case for overall survival, recurrence-free 
survival, and distant-metastasis-free survival, providing further evidence for the robustness 
of this relationship.    
This work once again demonstrates an important difference between HIFα proteins 
in breast cancer and highlights the need to consider both HIF1α and HIF2α when investigating 
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HIF-driven cancer pathophysiology. We provide evidence that HIF2α may be a useful 
prognostic indicator in the context of high HER2 expression and, considering the increased 
sensitivity of HER2 overexpressing cell lines to HIF2α inhibition discussed in chapter 6, 
highlight the possibility that HIF2-targeted therapies may be an effective approach for the 
treatment of HER2-positive breast cancers.  
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 Chapter 8: Final Discussion 
 
8.1 Summary of findings 
 This project aimed to investigate the role of HER2 and HIF interactions in breast 
cancer. Specifically, it sought to evaluate how HER2 overexpression may modulate the 
cellular response to hypoxia through HIFs, and whether any differences could be identified 
between the roles of HIF1 and HIF2 in growth factor mediated HIF signalling in breast cancer.  
 First of all, I assessed how HER2 overexpression in an MCF7 cell line model altered 
the response to hypoxia in terms of cellular growth, motility and the upregulation of hypoxic 
response proteins including HIF1α and HIF2α. In these experiments I was able to 
demonstrate an increased upregulation of HIF2α in response to hypoxia, as well as an 
increased upregulation of the canonical hypoxic response protein CAIX, in the context of 
HER2 overexpression, providing evidence that HER2 may be an important regulator of HIF2α 
expression in these cell lines. This coincided with increased motility in hypoxia and the 
ubiquitous upregulation of HIF2α and hypoxia response proteins VEGF, CAIX and LDHA in 3D 
spheroid models of these cell lines. I was able to demonstrate that HIF2α upregulation in 
these cells occurs in normoxia and is driven by HER2 at the level of HIF2α transcription as 
indicated by both microarray and RT-PCR experiments. In this model I was able to 
demonstrate that HER2 drives an increase in HIF2α and not HIF1α suggesting a potential role 
for HIF2α in the differential responses to hypoxia seen in these cell lines, and indicating that 
the regulation of HIF1α and HIF2α by growth factor signalling occurs through different 
mechanisms. 
 In concordance with western blotting and IHC results, Illumina beadchip microarray 
analysis of MCF7 and MCF7-HER2 cells cultured in both acute and chronic hypoxia was able 
to demonstrate an increased upregulation of hypoxic response genes when HER2 is 
overexpressed. When compared to wild-type cells, MCF7-HER2 demonstrated a stronger 
upregulation of genes known to respond to hypoxia and prognosis in breast cancer. This was 
seen under conditions of both acute and chronic hypoxia and included a large number of 
genes known to promote glycolysis and hypoxia-mediated breast cancer progression. An 
increased hypoxic response was also shown in terms of the upregulation of HIF target genes, 
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but no clear preference for HIF2 target genes was seen, suggesting that in the context of 
HER2 overexpression, increased levels of HIF2α can drive the expression of both HIF1 and 
HIF2 target genes. This highlights the fact that the definition of hypoxic response genes as 
being either HIF1 or HIF2-driven is malleable and dependent on cellular context, specifically, 
it appears that high levels of HIF2α might override this target specificity and allow more 
promiscuous HIF2 target selection. A genome wide analysis of transcripts upregulated by 
hypoxia in these cell lines demonstrated a role for HER2 overexpression in priming cells for 
hypoxia. A large proportion of hypoxia responsive genes were seen to be constitutively 
expressed at higher levels in the context of high HER2 expression. This suggests that the 
normoxic upregulation of HIF2α might result in an increase in the expression of a number of 
hypoxia response genes. In addition a larger number of HIF target genes were expressed 
specifically in the HER2 overexpressing cell line in acute and chronic hypoxia. This 
demonstrates that HER2 overexpression is able to exacerbate the hypoxic response of MCF7 
cells both in terms of HIF and non-HIF target genes and is thereby able to drive glycolysis, 
angiogenesis, metastasis and cellular proliferation in hypoxia. Having demonstrated that 
HIF2 and not HIF1 is upregulated and further increased in hypoxia when HER2 is 
overexpressed in these cells, HIF2 is presumed to play a predominant role in the increased 
hypoxic response of these cells. This was supported by the inhibition of CAIX upregulation in 
hypoxia when MCF7-HER2 cells were treated with the HIF2 specific translation inhibitor C76.  
 In a series of experiments I then demonstrated an increased sensitivity of HER2-
positive breast cancer cell lines to HIF2α inhibition. SiRNA-mediated knockdown of HIF2α was 
able to reduce the growth rate of MCF7-HER2 cells to a higher degree than their HER2-low 
counterparts, whilst triple-negative cell lines HBL100 and MDA-MB-231 showed 
intermediate sensitivity. An increased sensitivity of other HER2-positive cell lines was 
demonstrated using the HIF2α translation inhibitor C76, which was more effective at 
reducing cell growth in SKBR3, MDA-MB-361 and BT474 cell lines. In addition, HIF2α 
inhibitors were able to reduce the motility of the highly invasive cell lines MDA-MB-231 and 
HBL100 in 2D wound healing assays, and despite having a low invasive potential, a small 
inhibition of MCF7 and MCF7-HER2 invasion into collagen using a 3D spheroid model was 
also demonstrated. This showed that HIF2 inhibition may be effective at reducing the 
expression of motility genes, such as those upregulated by hypoxia. Interestingly, in all cell 
lines, the siRNA-mediated inhibition of cellular growth was greater in normoxia than hypoxia. 
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This indicates that the role of HIF2α upregulation in normoxia may be important for cell line 
growth, and targeting HIF2 may not only be applicable to highly hypoxic tumours.  
 Having demonstrated a HER2-driven mechanism for HIF2α upregulation, and an 
increased sensitivity of HER2-positive cell lines to HIF2 inhibition, it was hypothesised that 
HIF2 activity may be an efficacious target in HER2-positive breast cancers. To test whether 
this HER2-HIF2α relationship may be an important driver of breast cancer I used publically 
available gene expression and clinical datasets to perform survival analysis based on HIF2α 
expression and the expression of HIF2 target genes in two large breast cancer cohorts. Here 
I was able to demonstrate that high HIF2α expression is associated with worse prognosis in 
breast cancer when HER2 is overexpressed. This suggests that the relationship between HER2 
signalling and HIF2α expression demonstrated in this thesis is applicable to breast cancer 
more generally, and may be an important determinant of survival. In addition, the 
requirement of HER2 overexpression for the association between HIF2α and poor prognosis 
offers a potential explanation as to why previous studies [261, 427] have been ambiguous in 
terms of the relationship between HIF2α and clinical outcome, showing an association of high 
HIF2α with both worse [261] and with better [427] prognosis. This novel role for HIF2α in 
HER2-driven breast cancer differs from HIF1α, which was found to be associated with poor 
prognosis irrelevant of HER2 expression. This, in addition to the differential mechanisms of 
HIFα regulation by growth factors demonstrated in this thesis, suggests that growth factor 
regulated HIF1α and HIF2α have differential contributions to breast cancer pathogenesis, and 
that despite previous findings of HIF1α-growth factor interactions, it appears to be HIF2α 
which is directly associated with poor prognosis in the context of HER2 overexpression.  
   
8.2 Relevance of findings 
 Previous work has demonstrated an interplay between growth factor signalling and 
HIFα proteins. It has been shown, both through the stimulation of growth factor signalling 
with NRG ligand and the activation of intracellular signalling pathways through the 
expression of dominant-negative AKT, that these pathways have the capability to increase 
levels of HIF1α protein and can lead to the increased levels of HIF target VEGF [220, 421]. 
This work has highlighted a non-canonical relationship between growth factor signalling and 
HIFα protein regulation in breast cancer cell lines. These findings have important implications 
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as they demonstrate that the influence of HIF signalling on solid tumours may not be limited 
to areas of hypoxia, suggesting that HIF-targeted therapies may also be efficacious in solid 
tumours in the absence of developed hypoxic regions. However, previous work has not 
reported on how this interaction may contribute to HIF-driven gene expression changes in 
hypoxia. The work in this thesis has addressed this question by considering how gene 
expression changes driven by hypoxia are altered in breast cancer cell lines when HER2 is 
overexpressed. By demonstrating an increase in the expression of hypoxic response genes at 
low oxygen concentrations in a HER2-overexpressing cell line, we provide evidence that HER2 
can promote a more vigorous cellular response to hypoxia, driving a robust set of both HIF 
and non-HIF genes with a number known to contribute to breast cancer progression. 
Together with previous studies, this finding provides us with novel insight into how HIF 
targeted therapies may be best used. Specifically, such compounds may be more effective in 
the context of high growth factor signalling such as in HER2-positive breast cancers, because 
in these cancers HIF target genes may play a bigger role in progression and aggressive tumour 
characteristics due to their increased expression both in normoxia and in response to 
hypoxia. In these contexts the co-therapies with HIF and HER2 targeting compounds may also 
be effective as both these factors appear to work together to drive the expression of genes 
which contribute to disease progression.  
 One limitation in our understanding of how HIFs contribute to disease has been the 
different roles of HIF1α and HIF2α. Despite numerous publications on the differences 
between these two proteins [245, 249, 265], and the exemplar of renal carcinoma; where 
HIF2α has been shown to be a major contributor to disease progression, in the field of breast 
cancer much research has been conducted on the presumption that HIF1α is the 
predominant HIFα protein, or that differences between HIF1α and HIF2α are not important. 
However, it has now been shown by large scale ChIP experiments that the genes sets driven 
by HIF1 and HIF2 transcription factors are not the same [239, 240]. With this in mind, one 
aim of this thesis was to try and understand whether HIF1α and HIF2α are distinct in terms 
of their regulation by growth factor signalling, and we were able to shown that these two 
proteins are differentially upregulated by ligand-driven growth factor signalling vs HER2 
overexpression in breast cancer cell lines. Whilst the mechanisms governing these 
differences were not elucidated, this finding contributes to our growing understanding of the 
specific functions of HIF1α and HIF2α in breast cancer. With previous work already showing 
that HIF2α gene expression can be driven by EGFR [426], we suggest that EGFR and HER2 
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driven HIF2α may function through equivalent mechanisms as both result in upregulation at 
the gene expression level. In contrast, HIF1α upregulated in normoxia by NRG or dominant-
negative AKT has been shown to be driven by an increased rate of translation and increased 
stability of the protein [421]. Therefore the separate mechanisms for the specific 
upregulation of HIF1α or HIF2α by growth factor signalling shown both in the literature and 
in this thesis suggest that the context of growth factor signalling and the expression of HER 
receptors may be an important determinant of which HIFα proteins are highly expressed in 
breast cancer, and that HIF2α may be predominantly driven in HER2-positive and triple-
negative breast cancers.        
Most importantly, this thesis has demonstrated the potential for targeting HIF2α 
specifically in HER2-positive breast cancer. HIF2α targeted therapy has already proven 
effective in pre-clinical models of RCC [393, 396, 512], and the development of HIF2 
dimerisation inhibitors such as PT2385 and PT2399 mean that these compounds can be 
repurposed for breast cancer if effective. With the current literature having focussed heavily 
on HIF1α, the potential of specifically targeting HIF2α in breast cancer has not been widely 
considered. This may be due to HIF1α’s clear negative association with survival in breast 
cancer, which does not appear to be determined by molecular characteristics of the disease.  
However, by demonstrating that efficacy of targeting HIF2 in MCF7-HER2 and comparing this 
with survival data stratified by HER2 expression, we provide evidence that HIF2α may be a 
targetable determinant of disease progression only when HER2 is highly expressed. 
8.3 Future work 
 The findings presented in this thesis provide an exciting new insight into the role of 
HIF2α in breast cancer. Having demonstrated the pathological relevance of HIF2α expression 
in HER2-positive breast cancer and provided evidence for mechanistic differences between 
HIFα protein regulation by growth factors in normoxia and hypoxia, it is now important to 
further characterise the precise pathways which differentiate between HIF1α and HIF2α 
signalling in response to growth factor signalling and further assess the potential of targeting 
specific HIFα proteins in breast cancer. Cellular context seems to be important and 
understanding these mechanisms may help to stratify patients so that HIF-targeting 
therapies can be developed specifically for those who would benefit. 
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 HER2 overexpression was able to upregulate HIF2α expression in MCF7-HER2 cells 
when compared to wild-type MCF7, and this appears to have important implications for the 
hypoxic response in these cells. Whilst differences in mechanism between HIF1α and HIF2α 
upregulation by growth factor signalling were demonstrated, it is still unclear how signalling 
pathways which mediate HIF1α stabilisation in normoxia differ from the pathways driving 
increased expression of HIF2α. The possible roles of AKT and ERK signalling were investigated, 
and HIF2α upregulation was shown to rely, at least partially, on AKT signalling; the same 
pathway reported to promote increased translation and stability of HIF1α in response to the 
HER3 ligand NRG. A better understanding of these differences may provide important 
insights into the function of HIF1 versus HIF2 signalling in breast cancers with different forms 
of signalling dysregulation. 
Whilst CAIX upregulation by hypoxia was shown to be increased by HER2 
overexpression, there are still some unanswered questions as to the mechanisms 
responsible. Further work is required to establish how robust this effect is, i.e. can increases 
in HER2 drive CAIX and other hypoxic targets in other breast cancer cell lines, and whether 
this effect is driven exclusively by HIF2, or if increases in HIF1 transcriptional activity are also 
involved. I have demonstrated that the HIF2α translation inhibitor C76 is able to reduce the 
hypoxic upregulation of CAIX, but due to the nature of the inhibitor it was not particularly 
amenable to inhibition in hypoxia, and HIF2 transcriptional inhibitors were not able to 
produce this effect. Additional experiments including a comparison of HIF1α and HIF2α 
inhibition may be required to determine the contribution of these factors to this response. 
Similarly, the strong upregulation of hypoxic response genes demonstrated through 
microarray analysis is presumed to be a result of increased HIF2α in MCF7-HER2, however 
the relative contributions of HIFα proteins can only be confirmed through further 
experiments with HIF1α or HIF2α specific inhibition.  
 The mechanisms driving HIF transcriptional activity in the context of HER2 
overexpression also need clarification. The increased expression of HIF2α is likely to 
contribute but it is still not clear whether HER2-mediated changes in the expression of co-
factors may also play a role in HIF target selection. On this note, previous work to understand 
HIF target selection in breast cancer cell lines has focussed predominantly on MCF7 cells. It 
is clear from the results presented in this thesis that cellular characteristics such as growth 
factor expression can contribute to large differences in HIF targets. HIF targets should 
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therefore be understood as variable and understanding the mechanisms which determine 
target selection may be more valuable than the identification of HIF1 vs HIF2 targets in a 
particular context. A number of transcriptional co-factors are known to have specific 
associations with either HIF1α or HIF2α, thus it may be the expression of these factors as well 
as the absolute levels of different HIFα proteins which determine HIF gene transcription in 
normoxia and in response to hypoxia. 
 Given that HER2-HIF2α interactions have been shown to be associated with breast 
cancer progression, and HER2-positive cell lines seem to have a distinguishing sensitivity to 
HIF2 inhibition, further work into the efficacy of HIF2 inhibitors in HER2-positive breast 
cancers would be highly valuable. HIF2 inhibitors such as PT2385 and its close homologue 
PT2399 have been shown to be effective at treating ccRCC, with PT2399 currently enrolled 
on a phase II clinical trial. Whilst heterodimerisation inhibitors C2 and PT2385 did not 
perform well in growth or motility assays in breast cancer cell lines, it would be worthwhile 
to understand whether this is due to a failure of these compounds to inhibit HIF2 activity in 
these models or a failure of HIF2 inhibition to effectively reduce growth or motility. Given 
the clear relationship between HIF2α expression and poor prognosis in HER2-positive breast 
cancers, and the efficacy of C76 and HIF2α siRNA in reducing the growth rates of HER2-
positive cell lines, it seems sensible that inhibitors such as PT2385 and PT2399, which have 
been shown to be clinically effective in a different form of cancer, should be more deeply 
investigated with respect to HER2-positive breast cancer. 
 Finally, the importance of HIF2α in the context of high HER2 signalling in breast 
cancer is clear. However, it is still uncertain what role HIF2α may play in breast cancers where 
growth is promoted by other growth factor receptors such as EGFR (HER1). Triple-negative 
cell lines showed a moderate sensitivity to HIF2 inhibition in terms of both cell growth and 
cell motility. As mentioned above, a deeper understanding of the mechanisms governing 
growth factor-mediated HIF upregulation may provide insight into the relevance of HIF2 in 
EGFR-driven cancers, and further investigation into the relationship between EGFR and HIF2α 
expression in breast cancer may implicate HIF2 as a potential target for triple-negative breast 






8.4 Final remarks 
This project aimed to investigate the roles of HIF1α and HIF2α in growth factor driven 
HIF regulation. With the upregulation of HIF1α by NRG being previously described, I wanted 
to address the question of whether growth factor signalling is equally able to upregulate 
HIF1α and HIF2α levels in normoxia, and assess whether growth factor-driven upregulation 
of HIFα promoted an altered hypoxic response in the context of HER2 overexpression. I have 
been able to demonstrate that under different conditions growth factor signalling 
independently drives HIF1α or HIF2α in normoxia, depending on the nature of the signalling 
pathway. This finding provides a novel role for HIF2α in the non-canonical/normoxic role of 
HIFs in breast cancer, and demonstrates that differences in HIFα regulation may play an 
important role in determining their involvement in disease progression. This is reflective of 
the differences in HIF1α and HIF2α regulation which are already known to exist at the 
transcriptional, translational and post-translational levels, adding another level of complexity 
to the differential regulation of these factors.  
   
Whilst the roles of hypoxia and HIF signalling in driving breast cancer have been 
thoroughly investigated, we still have little understanding of the differential roles that each 
HIFα protein plays. Previous research has demonstrated an association of HIF1α expression 
and growth factor signalling both in cell lines and breast cancer samples. Despite this, it was 
not known to what extent growth factor signalling may affect the cellular response to hypoxia 
through HIF upregulation, or how different HIFα proteins may be modulated by growth factor 
signalling. With HER2 overexpression seen in approximately 20% of breast cancers, it is 
important to understand how HIF signalling in these patients may drive pathogenesis both in 
normoxic and hypoxic tumour environments. Together this work has shown important 
differences between HIF1α and HIF2α in terms of their response to growth factor signalling, 
with a specific role for HIF2α in HER2 overexpressing cells. HIF2α has been implicated as an 
important player in HER2-positive breast cancer in terms of prognosis, and the increased 
sensitivity of HER2-positive cells to HIF2 inhibition suggesting that HIF2 may be an effective 
target in the context of HER2 overexpression. Further work is required to develop these 
findings, but it is clear that the consideration of both HIF1α and HIF2α as well as the 
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molecular subtype of the breast cancer is important when contemplating HIF-targeting 
approaches for this disease. A number of HIF inhibitors are under investigation, and their 
efficacy in various cancer types has been shown. However, for the majority, little is known 
about their mechanism of action and their effect on HIF2α. Given the mechanistic differences 
in growth factor-driven regulation of HIF1α and HIF2α demonstrated in this thesis, I suggest 
that further work on HIF inhibitors in breast cancer should aim to understand their effects on 
both. The targeting of individual HIFα proteins such as HIF2α may increase the effectiveness 
of HIF-targeting therapies. Furthermore, the specific role of HIF2α in HER2-positive breast 
cancers suggests that HIF2 targeted therapies may be most effective in this subtype, and 
further work into HIF inhibition as a therapeutic strategy may benefit from the stratification 
of patients so that the effectiveness of HIF inhibitors can be tested in the context of breast 
cancers with high growth factor receptor expression. Finally, the role of growth factor 
signalling in driving HIFα expression raises the question of whether HIF inhibitors may be 
effective as a co-therapy alongside HER2-targeted therapies for breast cancer. The nature of 
this relationship suggests that this may be an effective strategy both in normoxic and hypoxic 
tumour regions. With a range of HIF inhibitory compounds available and the ongoing 
development of specific HIF2 inhibitors, these considerations may facilitate the use of HIF 
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Appendix 1: Assessment of microarray data  
  
Appendix 1.1: Multi-dimensional scaling of gene expression microarray data. 
Multidimensional scaling of samples from the gene expression microarray displays relative 
similarity between the samples. Cell line clusters are circled in individual colours, whilst samples 
are colour-coded for cell line (outside colour) and by treatment category (central colour). Red 
arrows indicate these samples which have not clustered with their biological repeats. These 







Appendix 1.2: Hierarchical clustering of significantly changed genes in normoxic vs hypoxic samples in MCF7. 
Hierarchical clustering of significantly changed genes (as determined by rank product testing FDR=0.05) used to assess 
the similarity of unsure samples to normoxic or hypoxic samples in MCF7 cells. Samples with ambiguous coordinates in 
MDS analysis were tested in this way to determine whether they clustered with normoxic or hypoxic samples. MCF7 AH 
(14) was found to cluster more closely to normoxic MCF7 samples than equivalent hypoxic samples and so was omitted 
from microarray analysis experiments unless otherwise stated. 
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Appendix 2: Gene lists  
Hypoxia metagene green cluster 
Winter 
MNAT1, BCAR1, SNX24, TPD52L2, PSMA7, CORO1C, PGF, RAN, EIF2S1, NUDT15, IMPA2, CNIH4, TPBG, HOMER1, 
C16orf74, PPP4R1, SLC16A1, TMEM30B, S100A3, COL4A5, GMFB 
 
Hypoxia metagene blue clusters 




METTL22, PVR, CA12, TFAP2C, GEMIN2, GSS, 
GPN3, B4GALT2, SLIRP, XPO5, PSMB7, ECE2, 
NTMT1, BMS1, ADORA2B, CDCA4, MTX1, 
PSMD2, MRPL14, RUVBL2, TEAD4, NME1, MIF 
 
  
  KIF4A, ACOT7, CDKN3, CHCHD2, KIF20A, 
CORO1C, TUBA1B, PSRC1, TUBA1C, PNP, 
MRPL15, SLC16A1, SLC25A32, 
SHCBP1, MRPL13, TUBB6, UTP11,MCTS1 
 
Hypoxia metagene red clusters 









 NDRG1, SLC2A1, P4HA1, 
ALDOA, BNIP3  
 
MRGBP, PGK1, CA9, GAPDH, TPI1, 
VEGFA, LDHA, HILPDA, PGAM1 
 
 MRGBP, PGK1, CA9, GAPDH, TPI1, 




  ADM, ANKRD37 
 
 
 ADM, ANKRD37 
 
  KCTD11      KCTD11 
 
    P4HA2, BNIP3L, LOX, 




  PFKP, ENO1, PSMA7, ESRP1, 
GPI, YKT6, LRRC42, MAD2L2, 
MAP7D1, SEC61G, CTSV, HK2 
AK4, DDIT4, MIF 
 
  
VEZT, HES2, MIR7855, PYGL,  
RNF24, LRP2BP, SLCO1B3, 
PPARD, PFKFB4, PDZD11,  
PLAU, VAPB, PLEKHG3, KRT17, 
MIR6886, SLC6A8, TNS4,  
PTGFRN, DPM2, TUBB2A, 
CREBZF, HAUS2, AK3, PPM1J, 
ANKRD9, ANGPTL4, CXCL8,  
TANC2, PAWR, NDUFA4L2,  
S100A10, RNPS1, SLC6A10P, 
TMEM189 
 
    
Appendix 2.1: Hypoxia metagenes arranged by clusters from Figure 4.3 
Tables show full gene lists from the metagenes used in Figure 4.3. Genes are organised by metagenes 
(columns) and which clusters they belong to (table titles). Genes which are found in multiple 






Acute hypoxia rank product gene lists 
Venn Location Gene names 
1 ZNF263, TRAPPC6A, MIR6511B1, AKAP8L, MIR6872, ZRANB1, PNKP, HSPA5, TNPO3, KLF6, MNT, 
ASNS, MYO3B, KDM5A, FERMT2, RBMS2, XAB2, JADE1, ZCWPW1, PPP1R13B, SPAG7, MFSD11, 
HDAC6, tspan15, PCNX1, CCNB1IP1, EMD, MAGT1, SLC38A7, HCFC1R1, CLASRP, ERCC2, SF3A2, 
MIR4750, CCDC130, PIAS4, RABAC1, LHPP, MIR6805, AATF, AIP, EPM2A, DBN1, GALNT3, CACYBP, 
ARHGEF2, ZBTB17, CTGF, FOXO3, SIL1, NFYB, TBC1D15, Hist1h1a, SPDEF, LRRFIP1, SYMPK, EDN2, 
krt17, MBD4, DOCK6, MAP1S, JUND, PNPLA7, RBBP8NL, ASS1, ZNF317, PLXNA3, ABCB7, dlg4, 
RNF122, ERCC5, LOC101927181, ABHD17C, USP8, MAPK8IP3, RNF165, ERBB2, Tmem91, FAM63A, 
RAB13, GMPPA, SLC25A38, ATG12, TIAM2, ITPRIP, TMEM219, NUBPL, VPS26B, DPYSL4, UBALD1, 
FLCN, MMS19, PDIA4, RNF20, FUT6, TSC22D3, RHPN1, ZYX, RNASEK-C17orf49, UBXN1, ALPP, 
ZNF148, PIGX, C1ORF50, CAMLG, USP49, PHAX, PPFIBP2, RNF169, WEE1, TEF, ACSF2, MVD, 
RAB3IL1, SLC3A2, ADAM9, THBS3, zrsr2, BRD3, IFFO2, CHD3, ADPRM, ZNF581, ZNF524, PTGER4, 
RAB33B, LAMB2, ZNF738, GOLGB1, NUDT18, NR1D2, ZNF408, c11orf68, WDR25, SGF29, MIR7-
3HG, FAM91A1, MIR6785, PCDHB9, DMAP1, ZNF223, KLHL28, GCC1, NLRP8, SSTR2, TMEM136, 
WASH6P, HIST2H2AA3, DUSP8, zbtb3, FAM83G, ZNF322P1, RPL14, ZNF600, SUPT5H, HIST3H2BB, 
PDLIM7, FLNA, ZNF433, SPTAN1, Mt1f, GPATCH3, ZNF358, SELENOM, PJA2, ENSG00000199298, 
ENSG00000199663, ENSG00000202364, RNU4-2, GDI1, ARHGEF35, TERF1P4, LOC285696, 
ENSG00000215719, LINC01567, DBT, SMCR5, WASH7P, DDAH2, LOC440704, ZDHHC20-IT1, cox19, 
ENSG00000240652, HIST2H2BB, RN7SL1, ENSG00000251701, ENSG00000255107, SLC5A8, 
ENSG00000257540, ENSG00000260043, PIR46900, GPS1M, SMG1P7 
 
2 SAMD4A, FOXJ2, PTPN21, EDN1, NFE2L1, MRGBP, RNF24, AVL9, RSRC2, BCL6, FAM162A, PFKFB4, 
KDM3A, RGS2, RLF, SERGEF, GADD45G, OSER1, DTNA, HILPDA, PHF21A, CIR1, CYR61, TUFT1, 
ppfia4, CSRNP1, TNIP1, NOCT, C10orf12, EYA3, CIART, DEDD2, ZNF653, ATF3, YEATS2, ARHGEF3, 
DAPK3, KRT80, ZNF212, KIF5B, BNIP3, VPS37D, PAWR, CLK3, PLD6, MB21D2, RIPK4, ANKRD37, 
HIST1H1C, FUT11, SERTAD1, Hist1h3d, PIM3, LRIG2, RNA5S9, RN7SKP80, rn7sk, HSPA1A, RNVU1-
18, ENSG00000207315, RNU1-3, ENSG00000209804, PPME1, ZNF579, PPP2R2A, EPB41L4A-AS1, 
LINC01715, ENSG00000248721, F5H5P2 
 
3 WDR54, MYLIP, CSDE1, DAPK2, ZZZ3, CDH10, RIOK2, DLX3, BCAS1, MSANTD3, PFKP, ARHGAP10, 
P4HA2, SCARB1, ENO1, FNDC3B, PGM1, STK17B, GSK3B, PLOD1, YTHDC1, ATG16L1, UIMC1, 
ZBTB25, ALKBH5, DSP, SIRT1, RASSF7, LRP5L, PIK3IP1, PACSIN2, PDGFB, PYGL, SUSD6, SLCO4A1, 
JAG1, RIOK3, PGK1, DHDH, PPP1R13L, SYDE1, GPI, stx1a, C1GALT1, CA9, SHB, DDX50, FBXL20, 
MANBA, GRPEL1, HSPA8, KMT5B, SLC35F2, LIN7A, LOC100507424, VEGFA, HBEGF, ARRDC3, PRLR, 
CRBN, HES1, BBX, GBE1, IGFBP5, COQ10B, ID2, DARS, atf2, ARID3A, qsox1, SMG7, GADD45A, CD2, 
ID3, SLC2A1, FKBP15, CTNNAL1, MXI1, AVPI1, PPP3CC, PAPD5, PSPC1, TMEM39B, CXCR4, HOXC13, 
KCNS1, ARFGEF2, TRERF1, FOSB, ZNF436, PLEKHG3, DNAJB9, GAD1, EGLN3, SAT1, DNAJB1, PER2, 
USPL1, SWAP70, PLEKHA8P1, LDHA, CABLES1, ddb2, UBQLN1, HEY2, EGLN1, cep350, c2orf49, 
WDR33, TEX10, PIM1, SORL1, INTS12, LNX2, VPS37B, USP3, CDR2, PRELID3A, GAREM1, NARF, 
WDR45B, NECTIN4, RGL1, MALL, OSBPL10, PAM, IGFBP3, PLIN2, ALDOA, VEGFC, FOXO1, NGLY1, 
CCL28, PELO, CCDC174, ELMSAN1, BRPF1, NCK1, HK2, CCDC107, CRTC2, ITGA5, AK4, DHRS3, RYBP, 
MEAF6, SAP30, CITED2, SLU7, RP9, SLC29A4, HEY1, GEM, UBAP1, RNF183, DPCD, ARIH1, CYB5A, 
ZNF143, nab2, patl1, c15orf39, vkorc1, ANGPTL4, FAM83B, ING2, TSPAN5, FEM1B, MAP2K1, 
SIN3A, GPR37L1, SLC30A1, RALGAPB, ZNF296, PPM1D, KBTBD2, NAIF1, MIR6510, KLF11, ISG20, 
HINFP, RND1, OVOL1, PPP1R3B, SLCO2A1, ZNF654, UBE2O, ANO6, RIMKLA, NIM1K, AQP11, 
ZFAND2A, MPI, MIR6883, SERTAD2, LOC284023, TMEM45A, SETD2, c3orf58, BACE2, SPNS2, 
Appendix 2.2: Gene lists for rank product 
analysis shown in chapter 4 (Figure 4.4) 
Full gene lists for rank product testing of MCF7 
and MCF7-HER2 cell lines. These are arranged in 
terms of their position on the Venn diagrams in 
Figure 4.4. Positions are labelled as shown in the 
key (LHS). Separate tables for acute and chronic 
hypoxia are shown. 
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DDX41, BCOR, ENSG00000183900, DENND5A, MAP7D2, FAM110C, JAG2, SEMA4B, IRS2, KPNA4, 
ZNF395, THSD4, fam47e, TSC22D2, MKL1, RPF2, ERO1A, HELZ, WWP2, FOXJ3, hspa1b, SMG1P2, 
ANG, LOC399715, CEBPD, HSPA7, PGAM4, TPI1P2, ENSG00000236575, ENSG00000238117, 
KCNMB3P1, C8orf58, ENSG00000249007, ENSG00000249590, MIR1204, ENSG00000256006 
4 SARS, PRSS8, FAM107B, LOC105376575, RGS17, TRIB3, TBL1X, GLTSCR2, RASD1, STC2, FHL2, 
KIAA1324, SIPA1L2, MYB, RRAS, MACROD1, HOOK1, FAM129A, SAT2, CDK19, VPS28, SPSB3, GBP2, 
S100P, RASEF, LARP6, KIFC2, ALCAM, NUPR1, CCDC154, NEU1, MIR424 
5 RRAGD, COBLL1, PPP1R15A, GADD45B, NDRG1, DBP, WSB1, ALDOC, ENO2, RRAGC, KDM5B, 
P4HA1, SOX4, GDF15, BHLHE40, HRK, DUSP5, ADM, SPRY1, CREBRF, DDIT4, PFKFB3, PHLDA3, 
DDIT3, PTRF, JUN, IER5L 
6 ZIC2, LIMCH1, RSBN1, BNIP3L, SASH1, ERRFI1, FLVCR2, PPP1R3C, DUSP1, TGFBI, RBCK1, ATG14, 
VLDLR, cnksr3, FAM46B, STC1, IER5, osr2, NFIL3, OTUD1, KIAA0355, EFNA1, SPSB1, AKAP17A, 
ENO1P1, ENSG00000257922 
7 CD99, SLC7A2, CALCR, PRSS22, TNFRSF12A, ARHGAP44, MIR614, PRKCH, GRN, FUT8, GAB2, AGA, 
NEDD4L, LIMA1, HERPUD1, HOMER3, HEBP2, ATP9A, MCOLN3, DCBLD2, CDH3, EIF4B, CTSA, IDI1, 
WIPI1, st6galnac2, TESK2, RPS6KA2, ZFYVE26, NUAK1, MOCOS, NT5C2, GPR137B, AMPH, OXCT1, 
WDFY1, IGBP1, SLC9A1, YPEL3, GNPTG, CERS4, NRCAM, SEL1L3, MAP3K1, MZF1, MKNK2, PRODH, 
SEPT3, DAAM1, SIX4, DHRS2, PYGB, ZMYND8, PABPC1L, SALL4, BMP7, ASB9, TIMP1, SGCG, CTSH, 
CERNIP, NCALD, DNASE2, ADAP1, CAV1, HIBADH, TAX1BP1, COBL, ANKMY2, AGR2, PTGR1, PHYH, 
ARHGAP21, DNAJC12, VAT1, PMP22, INPP4B, TRIM2, UGDH, SC5D, folr1, PPM1H, MGP, UST, 
ULBP1, CAP2, PERP, FAM46A, PCDHB2, HMGCS1, MRPS30, TARS, RBP1, KAT2B, c3orf52, SLC41A3, 
KLHL24, SLC30A3, KYNU, EPAS1, EPHA4, DHCR24, TMEM59, RPL22, RHOU, LGALS8, RSRP1, CTSD, 
RAB32, PPL, KLF9, CCDC92, c1orf198, MIR4709, YPEL5, MIR1287, SOCS2, ACO1, NECAB1, OPTN, 
RAB9A, FAM210B, PMEPA1, BCAS4, ATXN1, AHNAK, SOX9, INSIG2, IDUA, ATF4, MYO1B, PXDN, 
COL5A1, SH3BGRL, RFTN1, IL13RA1, LGALS3, EFR3A, prkaa1, aldh3b2, DCLK1, CDK7, MEIS2, 
SPIRE1, SLC38A2, LPIN1, EMP1, YARS, FAM189A2, TRAFD1, CD63, AHI1, GNS, KIAA0513, DRAM1, 
FLNB, GPNMB, RAC1, SYTL2, HECW2, ITGAV, CCNG2, SHROOM3, ANXA3, WARS, MAP1LC3B, 
TIGD7, SLC39A6, PTPRF, CELSR2, ATP1B1, SCCPDH, PSEN2, SOX13, ABCA12, DGKQ, MARCH6, 
MYO10, RPL37, LHFPL2, TNFRSF21, SHROOM2, SH3KBP1, SLC16A2, MAL2, EIF3H, SH3GLB2, LCN2, 
PAK1, LYPD6B, rilpl2, DIP2C, TMEM45B, ACSL1, PARP8, PTPRK, ZDHHC7, CEBPG, MCOLN2, PRKCA, 
ENSG00000155130, DEPTOR, EEF1A1, WDR19, CLSTN2, BTG2, EFCAB14, TFF3, ZG16B, zswim5, 
JAK1, CAMK2N1, CAPN13, KCNF1, SLC22A15, TGFBR2, PRICKLE2, SMIM14, FAM198B, NIPBL, 
CMBL, CMYA5, MIOS, TNFRSF11B, TP53INP1, DYNLT3, MID1IP1, SPTSSA, GPT2, CRABP1, NAV2, 
STX3, SMAD3, FAM102A, PRR15L, ANKRD33, IRF2BP2, RAB31, TMEM150A, IRS1, SLC25A6, CA5B, 
GUSB, FAXDC2, FOS, IRX2, TANC2, PLAC1, ZNF217, CYP4F22, CEBPB, MIR5572, STOX2, TRIB1, 
TOMM20, FZD4, YPEL2, SCUBE2, SIX5, ULK1, SVBP, OPLAH, MTURN, SHISA2, CUEDC1, HIST3H2A, 
CREB3L2, ATP6AP2, SGK223, VCX, znf721, FAM46C, KCNK12, TACSTD2, SLITRK6, HIST2H2BE, 
SLC24A3, SMYD3, MUC1, MIR1469, GLDN, SERPINA5, SERPINA3, SPATS2L, CD55, EVL, CACNA1H, 
SULF2, KIAA1211L, UAP1L1, ENPP1, PARVA, PSAP, ELOVL2, TMEM116, PAPSS2, 
ENSG00000199004, CAPN8, MAFB, CDSN, NBPF22P, C5orf51, FAM220CP, S1PR3, ZBED1, 
RPL13P12, ENSG00000224628, LOC101927745, MAPKAPK5-AS1, TMSB4XP1, Snord13, ACAD11, 
RPL37P6, SELENOP, ENSG00000255343, ENSG00000255990, ENSG00000256121, TUBB3, 
ENSG00000259537, ENSG00000260822, ENSG00000261452, ENSG00000261793 
8 LCP1, AGAP11, BRSK1 
9  
10 FAM83D, EFHD1, ID1, ENSG00000186076 
11 TSPAN6, c1orf112, SLC25A13, POLR2J, YBX2, SCIN, E2F2, UBR7, TACC3, POLA2, RPL26L1, hoxc8, 
SPDL1, LSG1, NOP16, RFC2, PPP1R3F, CYBA, THOC3, PKP2, POLD1, ISOC2, GSTO2, TP53BP1, 
COASY, PITX1, GAL, TRIP13, MCM2, CA12, WDR62, MLH1, UBE2T, HSPB11, MRPL22, GEMIN5, 
SLC27A5, MGST2, IPO11-LRRC70, EPDR1, MIR6875, SRRT, TPX2, RPL6, BIRC5, LAMB1, DLD, 
ZC3HC1, GEMIN2, TYRO3, CDC45, TMEM14A, CDC7, RANBP1, CENPM, MCM5, TSPO, FOXRED2, 
POLE2, CDKN3, ITPK1, VRK1, EFS, cinp, SUV39H1, PLS3, SLC25A15, ELMO3, fam173a, EARS2, FAH, 
OIP5, LAPTM4B, POP1, JPH1, GSDMD, RNASEH2A, ASF1B, TNNT1, ETFB, KDELR1, GRWD1, TFPT, 
ISYNA1, MPP6, PTCD1, TAF6, PLOD3, BCL7B, EXOSC3, CXCL12, ACTA2, KPNB1, LGALS3BP, KAT2A, 
NARR, FOXM1, RAD51AP1, SCNN1A, TIMELESS, CHPT1, CCND3, BYSL, KIF20A, LMNB1, PCCB, 
EIF4G1, RPS15, ABCB6, PASK, ODC1, SRM, TTF2, TXNIP, ARTN, DARS2, TGFB3, FAM98A, ZWINT, 
HJURP, PMS2P5, HMGB1P1, AARS2, c17orf53, ARMC7, SLC25A19, NKX2-2, XRCC3, PDCD2L, IFI6, 
FGD3, BCL11B, pkmyt1, LOC100506136, SDF2L1, KNSTRN, SGO1, GAMT, TOMM40, KIF1A, BST2, 
RTN4IP1, FCHO1, EXOSC2, GINS2, F12, HAUS8, TUBG1, TOP2A, SNRPA1, NUP210, RFC3, BEX1, 
EMC7, TMEM106C, CD36, ITM2C, TUBB2B, FGFBP2, THBS1, NUSAP1, NDUFAF1, CEP55, EFCAB11, 
FANCI, Uqcrc2, MYO19, P3H4, NT5C3B, PLK4, MIR3658, PIGM, ISG20L2, RGS16, ETNK2, TMEM177, 
POLR2D, RABL3, EIF2B5, LYAR, CCNA2, ADAMTS19, nhp2, FAM50B, CDCA5, MEPCE, NCAPG2, 
cxorf57, MRPS28, SIGMAR1, PDSS1, EML3, CDC42EP2, hirip3, HSPB8, gemin6, PFKM, GJA1, 
CARHSP1, MRPL39, CXXC1, PROM2, NUP205, FAM122B, UBE2L6, mapk13, SUSD3, CCNB2, 
SLC38A10, FAM213B, KRTCAP3, MRPL17, AUTS2, DUSP23, B4GALT3, MIR5187, pip, CCDC58, CBS, 
c21orf33, ZDHHC12, PKN3, RUSC1, PPP1R35, fgfr4, ALKBH4, MIR4467, PSMC2, AP2M1, POLR3K, 
c16orf59, CCNF, RPL29, IL20, ACTG2, MRPS18C, EOMES, CHCHD4, ELP6, POLR2H, RFC4, RPL39L, 
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POC1A, SFXN1, PTTG1, KIAA1324L, PEX2, VCP, STOML2, MELK, DDIAS, ZNF22, MOAP1, IFI27, 
RPUSD2, NOLC1, C11orf74, WDR72, CENPN, CLEC3A, BEX3, FAM96A, STAT6, ACAA2, RRM1, 
RAB8A, GPX4, GATAD2A, GGT6, CD320, MRPL58, TK1, ABCA3, COPS6, NT5DC2, DEGS2, lcmt2, 
CHST14, XPO6, PRELID1, GPRIN1, NFU1, CENPX, FASN, DUS1L, DCXR, TRIM56, YWHAG, MIR4444-
1, SLC16A5, GON7, CDCA4, LOC93622, LSM3, ATP6V0E2, CANT1, P2RY6, RRM2, RPS7, pop7, 
GNB2, COQ2, SYT12, PSMD1, ZWILCH, MRPL11, golt1a, PSMD2, FAM131A, DOLK, CCNE2, SWI5, 
SLC35A4, GPX2, C8orf59, RHOG, IRX3, AURKB, RRS1, MAGED1, GPC5, GEMIN4, fjx1, SLITRK4, 
DCTPP1, TSPYL5, S1PR5, hoxc9, D2HGDH, ANKRD34A, GINS3, MRPS11, CYB5D1, AP1S2, TEX19, 
FES, SLC25A10, CBX6, NPW, NIPSNAP1, HDDC3, BTBD6, SIVA1, C14orf80, PARPBP, MRPL40, 
C16orf53, HPDL, CMC1, ISG15, H2AFX, HBA2, C9orf152, HLA-DRB1, PLEKHG4, TUBB, RAD54B, 
HNRNPAB, SPANXA1, PRIM1, NUP62CL, TFDP1, HOXC4, BRINP2, PRC1, CCDC167, CENPW, 
MRPL38, CRHR1-IT1, FAM216A, c15orf59, POM121B, SNORD96, TRGV9, PTTG3P, 
ENSG00000213209, MRPL23, LINC00998, TUBBP2, CYCSP55, UBE2SP2, HSD17B8, CKS1BP2, 
MIR6873, TRGC2, SPANXB1, ENSG00000230195, ENSG00000230197, VARS, RPL7P21, CT45A3, 
KIFC1, ENSG00000233966, FABP5P7, ENSG00000235036, FABP5P1, CKMT1B, ATP5J2, PSMC1P1, 
ARPC1A, CT45A5, LINC00992, ENSG00000249762, I3L0E3, CHCHD10, SYS1-DBNDD2, PSMC1P9, 




Chronic hypoxia rank product gene lists 
Venn Location Gene names 
1 CX3CL1, TRAPPC6A, MYLIP, CSDE1, SH3YL1, CAPG, HSPA5, TTC17, SLC2A3, MIR21, ZCWPW1, 
MFSD11, NFKBIA, MAGT1, syt17, rhov, PCOLCE, TBC1D9, HMGCR, BCL6, KDM3A, GADD45A, 
ESYT2, IRF2BPL, SDC4, krt17, DNAJB9, MBD4, SERGEF, DOCK6, MIR6886, KIAA1683, PNPLA7, 
c14orf159, VTCN1, ELF5, TSPAN31, PAN2, IER3, CBX4, RNF165, lmtk3, SELENBP1, S100A8, DEGS1, 
ACKR3, AMT, PLK2, TNIP1, ZNF185, AK3, UGCG, STOM, notch1, FRG1BP, TMEM219, NOCT, 
MAT1A, DPYSL4, NR4A2, UBALD1, TSC22D3, IER2, UBXN1, AK4, CNST, S100A9, ANKZF1, RYBP, 
TIPARP, MIR6732, ARHGEF3, C4orf3, DLC1, GPER1, CKB, PEX11A, SLC3A2, UPF3A, AFAP1L2, 
ZBTB43, THBS3, BFSP2, JUNB, ISG20, MYO1D, IRX5, cracr2b, EGR3, SSTR2, TTC3, MST1P2, RXRA, 
rps23, INSIG1, FNBP1, RINL, C15orf52, NRARP, ZNF358, FICD, PJA2, RN7SKP80, rn7sk, RNU4-2, 
NYNRIN, UCA1, LINC00243, LINC00680, EPB41L4A-AS1, C14orf132, WASH7P, DDAH2, 
ENSG00000230572, PTMAP4, RPS3AP25, DICER1-AS1, ENSG00000235859, RP2PLP3, FOXP1-IT1, 
RN7SL1, ARPC4-TTLL3, ENSG00000255730, SLC5A8, ENSG00000260043, ENSG00000260789 
2 WDR54, BCAS1, P4HA2, FSCN1, DGKD, EDN1, PGM1, BAMBI, PGK1, ILVBL, GPI, CA9, EFNB3, 
ARHGDIB, FAM162A, PFKFB4, HES1, IGFBP5, ST3GAL5, ARID3A, CTGF, EGR1, EGR2, FOSB, ZFP36, 
SAT1, ZDHHC8P1, CYP1B1, CYP1A1, SIK1, TUFT1, ppfia4, CSRNP1, PAM, IGFBP3, nbl1, CIART, HK2, 
C19orf33, RAB26, CLIC3, TM4SF1, PTGER4, BNIP3, IRS2, ANKRD37, ZNF395, SBK1, S100A4, 
ENSG00000207315, PPME1, PPP1R3E, ENSG00000248721, ENSG00000256006 
3 ARHGAP33, TMEM132A, ALDH3B1, ST3GAL1, SNAI2, VIM, RAI14, CDH10, CYFIP2, SPAG4, PFKP, 
PKM, FGFR3, MIR8085, FSTL3, TCF3, SCARB1, NOTCH3, ENO1, LXN, DNM2, PLOD1, RAD54L, 
Ceacam6, MIR3198-2, ITPR3, DSP, RASSF7, DDT, LGALS1, PYGL, SLCO4A1, PCSK1N, HCFC1R1, 
CRISPLD2, NME4, METRN, EEF2K, BCKDK, SYDE1, CNFN, ZNF175, UPK1A, LHX2, PDLIM1, KMT5B, 
GALNT18, UPK2, LOC100507424, GAPDH, TPI1, GHR, GBE1, ID2, qsox1, IVNS1ABP, ID3, SLC2A1, 
NR4A3, SORBS3, CXCR4, FMOD, DNPEP, INHA, TOX2, TRERF1, BPIFB1, MIR4329, KLF2, CHTF18, 
GAD1, LRRC6, EGLN3, MIR675, thoc6, DNAJB1, PPARG, ITGB4, LDHA, DTNA, NREP, GOLM1, 
HILPDA, TROAP, SERPINE2, TNS3, GABBR2, FLOT1, BCAR3, PHLDA1, MFGE8, NUDT7, NOL3, NARF, 
FBXO15, CYR61, RGL1, MALL, PLAC8, PRPS1, DOCK5, ITPRIP, TENM4, MPZL2, ALDOA, VEGFC, 
PRSS53, SPOCK1, NTAN1, MUM1L1, RCAN1, CLDND2, DMKN, ITGA5, DHRS3, FCRLB, ATF3, INHBB, 
YEATS2, F2RL1, CITED2, SLC29A4, HEY1, RNF183, E2F7, DPCD, CYB5A, WEE1, CENPV, c15orf39, 
vkorc1, CACNB3, KRT80, ANGPTL4, SRRM2, ATOH8, PGAM1, RND1, MYEOV, NABP1, SLCO2A1, 
CSRP2, DMRTA1, VPS37D, TYMS, NIM1K, HNRNPA0, ENSG00000178550, RIIAD1, SELENOW, 
POLR2A, TMEM45A, IDH2, BACE2, PLCXD1, PCP4, DDX41, ALDH1A3, MAP7D2, JAG2, CD24P4, 
FAM174B, AHNAK2, VSIG10L, MT1X, THSD4, PLSCR3, SLX4, APOD, TSC22D2, TLE1, NMB, ERO1A, 
S100A6, MB, hspa1b, HSPA1A, TMEM256, CCDC183, ANG, LOC107985899, PPP2R2A, TPI1P1, 
PGAM4, TPI1P2, C12orf75, Dgcr5, ENSG00000240289, MIF, C8orf58, PEG10, TMEM141, NEAT1, 
DRAIC, ENSG00000249007, H7C4C6, RNF5P1, I3L3B4, ENSG00000257540 
4 RRAGD, GRN, CDH3, FAM107B, RSBN1, YPEL3, RGS17, MZF1, MKNK2, SALL4, GLTSCR2, DBP, MGP, 
HMGCS1, STC2, KYNU, KIAA1324, KDM5B, MYB, YPEL5, MIR1287, FAM210B, SOX4, GDF15, 
MACROD1, BHLHE40, SLC38A2, HOOK1, DRAM1, FLNB, DUSP5, CELSR2, ABCA12, MARCH6, VLDLR, 
SH3GLB2, CDK19, STC1, CAMK2N1, GBP2, CREBRF, TP53INP1, RASEF, SPTSSA, KIFC2, DDIT4, 
RAB31, TRIB1, PHLDA3, NUPR1, FAM46C, KCNK12, HIST2H2BE, IER5L, SERPINA3, EVL, MAFB, 
MIR424, Snord13, ENSG00000255343, ENSG00000255990, ENSG00000260822 
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5 PPP1R15A, ZMYND8, NDRG1, BNIP3L, RASD1, ALDOC, ENO2, ERRFI1, P4HA1, COL5A1, ATP1B1, 
ADM, TFF3, IER5, S100P, FOS, PFKFB3, MUC1 
6 LIMCH1, ASB9, EPAS1, DUSP1, TGFBI, RRAS, PXDN, EMP1, TMEM45B, MARCKS, SPRY1, CA5B, 
PTRF, CREB3L2, CACNA1H, ENO1P1-201 
7 CD99, SLC7A2, CALCR, PRSS22, TNFRSF12A, ARHGAP44, MIR614, PRKCH, SARS, FUT8, GAB2, AGA, 
ZIC2, NEDD4L, LIMA1, HERPUD1, HOMER3, HEBP2, PRSS8, ATP9A, MCOLN3, DCBLD2, EIF4B, CTSA, 
IDI1, LOC105376575, WIPI1, st6galnac2, TESK2, RPS6KA2, ZFYVE26, NUAK1, MOCOS, NT5C2, 
GPR137B, AMPH, COBLL1, OXCT1, WDFY1, IGBP1, SLC9A1, GNPTG, CERS4, NRCAM, SEL1L3, 
MAP3K1, GADD45B, PRODH, SEPT3, DAAM1, SIX4, DHRS2, PYGB, PABPC1L, BMP7, TRIB3, TBL1X, 
TIMP1, SGCG, CTSH, cemip, NCALD, dnase2, ADAP1, CAV1, HIBADH, TAX1BP1, COBL, ANKMY2, 
AGR2, PTGR1, PHYH, ARHGAP21, DNAJC12, VAT1, WSB1, PMP22, INPP4B, TRIM2, UGDH, SC5D, 
folr1, PPM1H, SASH1, UST, ULBP1, CAP2, PERP, FAM46A, PCDHB2, MRPS30, TARS, RBP1, KAT2B, 
c3orf52, SLC41A3, KLHL24, SLC30A3, FHL2, EPHA4, DHCR24, TMEM59, RPL22, RHOU, RRAGC, 
LGALS8, SIPA1L2, RSRP1, CTSD, RAB32, PPL, KLF9, CCDC92, c1orf198, MIR4709, FLVCR2, PPP1R3C, 
SOCS2, ACO1, NECAB1, OPTN, RAB9A, PMEPA1, BCAS4, ATXN1, AHNAK, SOX9, INSIG2, RBCK1, 
ATG14, IDUA, ATF4, MYO1B, SH3BGRL, RFTN1, IL13RA1, LGALS3, EFR3A, prkaa1, aldh3b2, DCLK1, 
CDK7, MEIS2, SPIRE1, LPIN1, YARS, FAM189A2, HRK, TRAFD1, CD63, AHI1, GNS, KIAA0513, 
FAM129A, GPNMB, RAC1, SYTL2, HECW2, ITGAV, CCNG2, SHROOM3, ANXA3, WARS, MAP1LC3B, 
TIGD7, SLC39A6, SAT2, PTPRF, SCCPDH, PSEN2, SOX13, DGKQ, MYO10, RPL37, LHFPL2, TNFRSF21, 
SHROOM2, SH3KBP1, SLC16A2, MAL2, EIF3H, LCN2, PAK1, LYPD6B, rilpl2, DIP2C, ACSL1, PARP8, 
PTPRK, cnksr3, ZDHHC7, CEBPG, MCOLN2, PRKCA, DEPTOR, EEF1A1, WDR19, FAM46B, CLSTN2, 
BTG2, EFCAB14, VPS28, SPSB3, ZG16B, zswim5, JAK1, CAPN13, KCNF1, SLC22A15, TGFBR2, 
PRICKLE2, SMIM14, FAM198B, NIPBL, CMBL, CMYA5, MIOS, TNFRSF11B, osr2, NFIL3, DYNLT3, 
MID1IP1, OTUD1, GPT2, LARP6, KIAA0355, CRABP1, NAV2, STX3, SMAD3, FAM102A, PRR15L, 
ANKRD33, IRF2BP2, TMEM150A, IRS1, SLC25A6, EFNA1, GUSB, ALCAM, FAXDC2, IRX2, TANC2, 
PLAC1, SPSB1, ZNF217, CYP4F22, CEBPB, MIR5572, STOX2, TOMM20, FZD4, YPEL2, DDIT3, 
SCUBE2, SIX5, ULK1, JUN, SVBP, OPLAH, MTURN, SHISA2, CUEDC1, HIST3H2A, ATP6AP2, SGK223, 
VCX, znf721, TACSTD2, SLITRK6, SLC24A3, SMYD3, MIR1469, GLDN, SERPINA5, SPATS2L, CD55, 
SULF2, KIAA1211L, UAP1L1, ENPP1, CCDC154, PARVA, PSAP, AKAP17A, ELOVL2, TMEM116, 
PAPSS2, ENSG00000199004, CAPN8, NEU1, CDSN, NBPF22P, C5orf51, FAM220CP, S1PR3, ZBED1, 
RPL13P12, ENSG00000224628, LOC101927745, MAPKAPK5-AS1, TMSB4XP1, ACAD11, RPL37P6, 
SELENOP, ENSG00000256121, ENSG00000257922, TUBB3, ENSG00000259537, 
ENSG00000261452, ENSG00000261793 
8 PIP, BRSK1, HOXC9 
9 AGAP11 
10 SCIN, TRIP13, MCM2, HSPB11, TSPO, FAM83D, RNASEH2A, ASF1B, ETFB, ACTA2, SCNN1A, 
TIMELESS, EFHD1, ABCB6, PASK, TXNIP, HJURP, ID1, KIF1A, GINS2, F12, THBS1, CEP55, GJA1, 
CARHSP1, ACAA2, TK1, ATP6V0E2, RRM2, D2HGDH, PGAM4, TUBB, PRC1, FAM216A, CKS1BP2 
11 TSPAN6, c1orf112, SLC25A13, POLR2J, YBX2, E2F2, UBR7, TACC3, POLA2, RPL26L1, hoxc8, SPDL1, 
LSG1, NOP16, RFC2, PPP1R3F, CYBA, THOC3, PKP2, POLD1, ISOC2, GSTO2, TP53BP1, COASY, PITX1, 
GAL, CA12, WDR62, MLH1, UBE2T, MRPL22, GEMIN5, SLC27A5, MGST2, IPO11-LRRC70, EPDR1, 
MIR6875, SRRT, TPX2, RPL6, BIRC5, LAMB1, DLD, ZC3HC1, GEMIN2, TYRO3, CDC45, TMEM14A, 
CDC7, RANBP1, CENPM, MCM5, FOXRED2, POLE2, CDKN3, ITPK1, VRK1, EFS, CINP, SUV39H1, 
PLS3, SLC25A15, ELMO3, fam173a, EARS2, FAH, OIP5, LAPTM4B, POP1, JPH1, GSDMD, TNNT1, 
KDELR1, GRWD1, TFPT, ISYNA1, MPP6, PTCD1, TAF6, PLOD3, BCL7B, EXOSC3, CXCL12, KPNB1, 
LGALS3BP, KAT2A, NARR, FOXM1, RAD51AP1, CHPT1, CCND3, BYSL, KIF20A, LMNB1, PCCB, 
EIF4G1, RPS15, ODC1, SRM, TTF2, ARTN, DARS2, TGFB3, FAM98A, ZWINT, PMS2P5, HMGB1P1, 
AARS2, c17orf53, ARMC7, SLC25A19, NKX2-2, XRCC3, PDCD2L, IFI6, FGD3, BCL11B, pkmyt1, 
LOC100506136, SDF2L1, KNSTRN, SGO1, GAMT, TOMM40, BST2, RTN4IP1, FCHO1, EXOSC2, 
HAUS8, TUBG1, TOP2A, SNRPA1, NUP210, RFC3, BEX1, EMC7, TMEM106C, CD36, ITM2C, LCP1, 
TUBB2B, FGFBP2, NUSAP1, NDUFAF1, EFCAB11, FANCI, Uqcrc2, MYO19, P3H4, NT5C3B, PLK4, 
MIR3658, PIGM, ISG20L2, RGS16, ETNK2, TMEM177, POLR2D, RABL3, EIF2B5, LYAR, CCNA2, 
ADAMTS19, nhp2, FAM50B, CDCA5, MEPCE, NCAPG2, cxorf57, MRPS28, SIGMAR1, PDSS1, EML3, 
CDC42EP2, hirip3, HSPB8, gemin6, PFKM, MRPL39, CXXC1, PROM2, NUP205, FAM122B, UBE2L6, 
mapk13, SUSD3, CCNB2, SLC38A10, FAM213B, KRTCAP3, MRPL17, AUTS2, DUSP23, B4GALT3, 
MIR5187, CCDC58, CBS, c21orf33, ZDHHC12, PKN3, RUSC1, PPP1R35, fgfr4, ALKBH4, MIR4467, 
PSMC2, AP2M1, POLR3K, c16orf59, CCNF, RPL29, IL20, ACTG2, MRPS18C, EOMES, CHCHD4, ELP6, 
POLR2H, RFC4, RPL39L, POC1A, SFXN1, PTTG1, KIAA1324L, PEX2, VCP, STOML2, MELK, DDIAS, 
ZNF22, MOAP1, IFI27, RPUSD2, NOLC1, C11orf74, WDR72, CENPN, CLEC3A, BEX3, FAM96A, 
STAT6, RRM1, RAB8A, GPX4, GATAD2A, GGT6, CD320, MRPL58, ABCA3, COPS6, NT5DC2, DEGS2, 
lcmt2, CHST14, XPO6, PRELID1, GPRIN1, NFU1, CENPX, FASN, DUS1L, DCXR, TRIM56, YWHAG, 
MIR4444-1, SLC16A5, GON7, CDCA4, LOC93622, LSM3, CANT1, P2RY6, RPS7, pop7, GNB2, COQ2, 
SYT12, PSMD1, ZWILCH, MRPL11, golt1a, PSMD2, FAM131A, DOLK, CCNE2, SWI5, SLC35A4, GPX2, 
C8orf59, RHOG, IRX3, AURKB, RRS1, MAGED1, GPC5, GEMIN4, fjx1, SLITRK4, DCTPP1, TSPYL5, 
S1PR5, ANKRD34A, GINS3, MRPS11, CYB5D1, AP1S2, TEX19, FES, SLC25A10, CBX6, NPW, 
NIPSNAP1, HDDC3, BTBD6, SIVA1, C14orf80, PARPBP, MRPL40, c16orf53, HPDL, CMC1, ISG15, 
H2AFX, HBA2, C9orf152, HLA-DRB1, PLEKHG4, RAD54B, HNRNPAB, SPANXA1, PRIM1, NUP62CL, 
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TFDP1, HOXC4, BRINP2, CCDC167, CENPW, MRPL38, CRHR1-IT1, c15orf59, POM121B, SNORD96, 
TRGV9, PTTG3P, ENSG00000213209, MRPL23, LINC00998, TUBBP2, CYCSP55, UBE2SP2, HSD17B8, 
MIR6873, TRGC2, SPANXB1, ENSG00000230195, ENSG00000230197, VARS, RPL7P21, CT45A3, 
KIFC1, UBE2S, FABP5P7, LOC100421490, FABP5P1, CKMT1B, ATP5J2, PSMC1P1, ARPC1A, CT45A5, 
LINC00992, ENSG00000249762, I3LOE3, CHCHD10, SYS1-DBNDD2, PSMC1P9, FBXO10, 







HIF target gene lists 
HIF1 specific WDR54, SPAG9, ANLN, PRICKLE3, MTMR11, cyp24a1, VIM, TFB1M, CASR, FBXO42, FOXN3, ATP9A, 
RELT, NDC1, TBXAS1, elmo2, BCAS1, gnai3, PKM, iars2, HEATR6, ATP11A, PLA2G10, TFRC, 
MAP3K13, CLASP1, ENO1, C1QTNF3, CHMP2B, SMAP2, MYNN, ERGIC2, ALKBH5, TRPM7, DSP, 
ENSG00000100010, DAAM1, NFATC4, PFDN4, DOK5, CSTF1, BMP7, PAK5, PGK1, DGKH, PSMD7, 
VAC14, nomo3, ATP8B4, SQLE, FBL, PPP2R1A, TTC26, PLOD3, CA9, RAD51C, TRIM37, DHX40, 
TUBD1, CCDC47, SMURF2, WSB1, ALDOC, SEPSECS, STIM2, MAGOHB, LOC100507424, CDK2AP1, 
GAPDH, ENO2, NCOA7, HSPA9, TARS, c5orf15, FAM162A, PFKFB4, C3orf14, BBX, IQCG, GBE1, 
SOS1, QSOX1, RLF, KDM5B, HSDL2, MXI1, TTLL2, PAIP2, TBX4, MIR6840, MTERF4, HJURP, NCOA5, 
PARD6B, CDH26, BCAS4, HIST1H4B, TREM1, ATXN1, MAX, PPAT, PODXL, NDUFA5, ACKR4, PSMA1, 
SERGEF, BCL2L2, EAPP, HSD17B3, PNISR, BTBD3, TPT1, EDEM1, SORT1, AP4B1, LDHA, CDC73, 
CABLES1, ddb2, AGO4, ENSG00000135180, PNPLA8, CGA, TEX2, BRIP1, CBWD2, SMC2, FAM129B, 
NCBP1, MYC, SYTL2, ENSG00000138041, TMOD3, WDR89, GOLGA6D, PARN, Uqcrc2, CDR2, 
ZFHX3, CLEC18B, CLTC, C17orf64, BCAS3, TP53, CARD14, NARF, Tmem91, ZFP14, RIT1, RABL2A, 
LNPK, PTPRG, ECE2, RNF145, TNIP1, PNRC1, TBC1D32, RGS20, NDUFB9, SAP18, IPMK, PLOD2, 
CARHSP1, RASSF3, FEZF2, RSPH10B, MOV10, MPV17L, SMG1, KRTCAP3, HIST1H2BD, SNX29P1, 
PPP1R15B, EMSY, C8orf58, RAPGEF6, CIART, CCDC107, NLRP4, PEX13, RPRD2, DAPL1, HIPK1, 
NBPF14, SRGAP2, AZI2, ANKZF1, THOC7, PSMD6, PRICKLE2, YEATS2, STARD4, ESM1, SNAPC3, 
RASEF, RNF183, R3HCC1L, OPN1MW, cox11, c15orf39, DHRS13, RBPJ, HFE2, FAM84B, HSPBAP1, 
RAB24, FAM103A1, UGP2, foxd4, SLN, PFKFB3, MIR7706, USP32, PPM1D, SOSTDC1, PGAM1, 
ZNF318, LKAAEAR1, KNDC1, ZNF217, ENSG00000172886, GLRX, ZBTB21, TUBB7P, 
ENSG00000175483, CLK2, OR4F17, BASP1, TGIF1, MIEF2, SLC35G3, GRB2, PDE4DIP, RPL10, 
TMEM107, CRIPAK, C11orf71, TMEM45A, SLX1A, OR2V2, ANXA2, RPS17, ENSG00000182945, 
RIPK4, gpr1, DENND5A, FOXD4L1, FAM110C, TMEM121, ENSG00000177799, OR7A17, AGAP4, 
CFAP126, RNFT1, ZNF250, GREB1, ZNF107, GTF2IRD2, pom121, ZNF33B, CLPSL2, 
ENSG00000196861, METTL9, ZNF398, TRIM33, ZNF323, TUBA3D, CCT8L2, ENSG00000068990, 
fank1, ENSG00000112727, HIST2H2BF, PPIAL4A, HLA-G, ENSG00000112448, CBWD5, OR4A47, 
SERF1A, ENSG00000212867, SLX1A-SULT1A3, LAT, FOXO3, C8orf44, DNASE1, ENSG00000214272, 
CBWD1, CBWD1, C3orf10, ENSG00000221897, PKM 
HIF1/HIF2 MIR614, CP, wisp2, MSANTD3, RSBN1, NFE2L1, DYNLL1, TF, BAMBI, CRKL, PDGFB, ZMYND8, 
DHX35, PLS3, BNIP3L, ILVBL, RAPGEF1, TRIM16L, TMEM97, CDKN1B, ARRDC3, STC2, UPK1B, 
KDM3A, ID2, DARS, IVNS1ABP, SLC2A1, PPP1R3C, TEX14, INHA, INSIG2, MIR3607, PAICS, CHD1L, 
SEC61G, LOXL2, DTNA, IER3, MYOF, FAM13A, HNRNPD, CCNG2, PIK3C2G, MINK1, SCYL1, 
NECTIN4, PLEKHA6, CSRNP1, UBC, OXSM, SLC45A3, LOC100506403, HK2, S100P, SPRY1, SAP30, 
CITED2, NFIL3, PCF11, TCP11L2, MS4A7, IRF2BP2, TCAF2, MAB21L3, gtf2ird2b, MIR6785, TMTC2, 
LINC01559, RAP2B, RAD51B, BACE2, FAM169B, CYP27C1, HIST1H1C, ASMT, S100A10, LEKR1, 
HILPDA, GPI 
HIF2 specific ITGA3, PFN2, CLUL1, CRYBG3, CPOX, KRT31, ASB2, MYL12A, ZNHIT1, AGR2, SFXN3, ODAM, KRT18, 
FAM65B, UNC93A, MFN2, KIAA1217, PDLIM2, WNT1, BMP4, MTUS1, PIK3C2B, KRT7, DRAM1, 
TRA2B, BLK, CTSV, IGF1R, USP3, OSBPL10, PLAC8, C4orf3, SNAPC1, UEVLD, LSS, IL6R, FSTL1, GNL3, 
KIAA0355, CXCL8, KRT8, CBX2, FAM174A, SLC35G5, GJC1, UPP1, S100A4, CXorf40B, ERO1A, HELZ, 
B3GNT6, eml6, ENSG00000215809, tff1, INHBA, PKP2, ELF3, PXDN, C8orf58, EGFR, FOS, ALDOA, 
DNAJB6, SCARB1, FAM65C, P2RY2, SLC2A3, KRT80, UBE2V1P2, TMEM189-UBE2V1, NDRG1, IRX1, 
BHLHE40, SEMA4B, DAPK2, EVL, GPR37L1, TNS1 
Appendix 2.3: HIF target gene lists 
Full HIF target genes for HIF1, HIF2 and both HIF1/HIF2 are shown. These lists were compiled from ChIP-seq 
analysis of MCF7 cells performed in Mole et al. 2009 and Schödel et al. 2011. These genes were used in the 






Genes primed for acute hypoxia in MCF7-HER2 and their correlation with HER2 
expression in breast cancer cell lines 
Gene name Pearson correlation P-value 
ERBB2 1 0 
PRSS8 0.615011 2.22E-19 
S100P 0.501738 2.04E-12 
EFNA1 0.489988 7.80E-12 
NUPR1 0.443018 1.04E-09 
KIAA1324 0.42151 7.68E-09 
TRIB3 0.414086 1.49E-08 
DBP 0.406198 2.94E-08 
SPRY1 0.386189 1.54E-07 
LIMCH1 0.380734 2.37E-07 
KDM5B 0.369369 5.70E-07 
P4HA1 0.344399 3.49E-06 
WSB1 0.339203 4.99E-06 
MACROD1 0.325755 1.22E-05 
ALDOC 0.319791 1.80E-05 
HOOK1 0.294937 8.18E-05 
RBCK1 0.285681 1.39E-04 
NDRG1 0.266116 4.02E-04 
SASH1 0.254177 7.39E-04 
SOX4 0.249483 9.32E-04 
DDIT4 0.241318 1.38E-03 
MYB 0.222011 3.33E-03 
VPS28 0.219645 3.69E-03 
AKAP17A 0.178319 1.89E-02 
LOC105376575 0.172109 2.36E-02 
Appendix 2.4: HER2-driven hypoxia response genes correlating with HER2 expression in cell 
lines 
Tables for acute and chronic hypoxia showing all genes which were found to be both 
overexpressed in HER2 and part of the hypoxic response in MCF7 and/or MCF7-HER2 cells, and 




Genes primed for chronic hypoxia in MCF7-HER2 and their correlation with HER2 
expression in breast cancer cell lines 
Gene Name Pearson correlation P-value 
ERBB2 1 0 
S100P 0.501738 2.04E-12 
SPTSSA 0.47189 5.61E-11 
NUPR1 0.443018 1.04E-09 
KIAA1324 0.42151 7.68E-09 
TFF3 0.418739 9.84E-09 
DBP 0.406198 2.94E-08 
SPRY1 0.386189 1.54E-07 
LIMCH1 0.380734 2.37E-07 
KDM5B 0.369369 5.70E-07 
ABCA12 0.36732 6.65E-07 
CAMK2N1 0.362676 9.41E-07 
P4HA1 0.344399 3.49E-06 
HMGCS1 0.340146 4.68E-06 
MUC1 0.339632 4.84E-06 
MKNK2 0.33716 5.73E-06 
MACROD1 0.325755 1.22E-05 
ALDOC 0.319791 1.80E-05 
ATP1B1 0.305257 4.43E-05 
TRIB1 0.296971 7.26E-05 
HOOK1 0.294937 8.18E-05 
CACNA1H 0.274835 0.000253 
HIST2H2BE 0.269225 0.000341 
NDRG1 0.266116 0.000402 
SOX4 0.249483 0.000932 
DDIT4 0.241318 0.001382 
CREB3L2 0.227049 0.002664 
FAM46C 0.224653 0.002963 
MYB 0.222011 0.003328 
MGP 0.221995 0.003331 
CA5B 0.183391 0.015728 
EPAS1 0.179395 0.018193 
MARCH6 0.152432 0.045273 
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